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Ndfip1 Regulates The Identity And Pathogenicity Of Th17 And Treg Cells
To Promote Normal Immune Homeostasis
Abstract
T helper 17 (Th17) and Foxp3+ T regulatory (Treg) cells are antagonistic in their development, function, and
abundance. Th17 cells protect against mucosal surface colonization by pathogenic organisms but are
important drivers of autoimmune disease, while Treg cells play key anti-inflammatory roles in suppressing
immune cell activation. Surprisingly, when mouse CD4 T cells lack Ndfip1, a co-activator of Nedd4-family E3
ubiquitin ligases, an increase in both Th17 and Treg cells is observed. This work investigates how Ndfip1
regulates these two cell types in order to promote immune homeostasis. We find that Ndfip1 opposes Th17
cell identity while enforcing Treg lineage stability in order to prevent spontaneous inflammatory disease.
Ndfip1 drives the degradation of RORγT, which is essential for Th17 identity and cytokine production.
Therefore, in Th17 cells, the absence of Ndfip1 results in reduced degradation and accumulation of RORγT.
Upon in vivo transfer, Ndfip1-deficient Th17 cells are more powerful inducers of colitis through increased
cytokine production and recruitment of inflammatory neutrophils, indicating that Ndfip1 dampens Th17 cell
function to limit pathogenicity. In contrast, Ndfip1 promotes Treg cell function by enforcing lineage stability
and preventing the expansion of IL-4-producing Treg cells. Thus the deletion of Ndfip1 in Treg cells leads to
inflammation in the skin, lungs, and spleen driven by activated Treg cells that are highly proliferative, IL-4
producers. These Treg cells more likely to lose Foxp3 and become IL-4-producing TH2 cells. Proteomic and
seahorse metabolic profiling indicated that these cells have altered metabolism marked by elevated glycolysis
and mTORC1 signaling pathways. Therefore, Treg cells require Ndfip1 to suppress mTORC1 activity, limit
glycolytic metabolism, and prevent IL-4 production to preserve lineage stability. Our data indicates that
Ndfip1 similarly limits the expansion and proliferation of both Th17 and Treg cells but antagonizes the
identity and function of proinflammatory Th17 cells while promoting Treg cell stability and function, with the
overarching aim of preventing spontaneous inflammatory disease.
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ABSTRACT		 NDFIP1	REGULATES	THE	IDENTITY	AND	PATHOGENICITY	OF	TH17	AND	TREG	CELLS	TO	PROMOTE	NORMAL	IMMUNE	HOMEOSTASIS	Awo	Akosua	Kesewa	Layman		Paula	M.	Oliver	T	helper	17	 (Th17)	and	Foxp3+	T	 regulatory	 (Treg)	 cells	 are	antagonistic	 in	 their	development,	 function,	and	abundance.	Th17	cells	protect	against	mucosal	surface	colonization	 by	 pathogenic	 organisms	 but	 are	 important	 drivers	 of	 autoimmune	disease,	while	Treg	 cells	 play	 key	 anti-inflammatory	 roles	 in	 suppressing	 immune	cell	activation.	Surprisingly,	when	mouse	CD4	T	cells	 lack	Ndfip1,	a	co-activator	of	Nedd4-family	 E3	 ubiquitin	 ligases,	 an	 increase	 in	 both	 Th17	 and	 Treg	 cells	 is	observed.	This	work	investigates	how	Ndfip1	regulates	these	two	cell	types	in	order	to	 promote	 immune	 homeostasis.	We	 find	 that	Ndfip1	 opposes	 Th17	 cell	 identity	while	enforcing	Treg	lineage	stability	in	order	to	prevent	spontaneous	inflammatory	disease.	 Ndfip1	 drives	 the	 degradation	 of	 RORγT,	 which	 is	 essential	 for	 Th17	identity	 and	 cytokine	 production.	 Therefore,	 in	 Th17	 cells,	 the	 absence	 of	 Ndfip1	results	 in	 reduced	degradation	and	accumulation	of	RORγT.	Upon	 in	 vivo	 transfer,	Ndfip1-deficient	Th17	cells	are	more	powerful	inducers	of	colitis	through	increased	cytokine	 production	 and	 recruitment	 of	 inflammatory	 neutrophils,	 indicating	 that	Ndfip1	 dampens	 Th17	 cell	 function	 to	 limit	 pathogenicity.	 In	 contrast,	 Ndfip1	promotes	 Treg	 cell	 function	 by	 enforcing	 lineage	 stability	 and	 preventing	 the	
viii	
expansion	 of	 IL-4-producing	 Treg	 cells.	 Thus	 the	 deletion	 of	 Ndfip1	 in	 Treg	 cells	leads	 to	 inflammation	 in	 the	 skin,	 lungs,	 and	spleen	driven	by	activated	Treg	cells	that	 are	 highly	 proliferative,	 IL-4	 producers.	 These	 Treg	 cells	 more	 likely	 to	 lose	Foxp3	 and	 become	 IL-4-producing	 TH2	 cells.	 Proteomic	 and	 seahorse	 metabolic	profiling	 indicated	 that	 these	 cells	 have	 altered	 metabolism	 marked	 by	 elevated	glycolysis	and	mTORC1	signaling	pathways.	Therefore,	Treg	cells	require	Ndfip1	to	suppress	mTORC1	activity,	limit	glycolytic	metabolism,	and	prevent	IL-4	production	to	 preserve	 lineage	 stability.	 Our	 data	 indicates	 that	 Ndfip1	 similarly	 limits	 the	expansion	and	proliferation	of	both	Th17	and	Treg	cells	but	antagonizes	the	identity	and	function	of	proinflammatory	Th17	cells	while	promoting	Treg	cell	stability	and	function,	with	the	overarching	aim	of	preventing	spontaneous	inflammatory	disease.		
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PREFACE	In	the	field	of	immunology,	the	golden	standard	for	determining	whether	a	protein	is	important	for	the	normal	functioning	of	the	human	body	often	involves	knocking	out	that	protein	of	 interest	 in	an	animal	model,	and	 investigating	whether	there	 is	evidence	 of	 dysfunction	 of	 one	 or	 several	 organ	 systems	 in	 the	 absence	 of	 that	protein.	This	 then	 lays	 the	 foundation	 for	 further	 investigation	 into	cell	 types	 that	express	the	protein,	timing	of	its	expression,	and	pathways	through	which	it	exerts	its	 functions.	 Thus,	 the	 discovery	 that	 mice	 which	 lack	 a	 protein	 called	 Ndfip1	(Nedd4-family	 interacting	 protein1)	 develop	 a	 severe,	 spontaneous,	autoinflammatory	disease	resulting	in	morbidity	and	eventual	mortality	after	12-16	weeks	 was	 the	 initial	 evidence	 that	 Ndfip1	 is	 important	 in	 enforcing	 immune	homeostasis.	 This	 discovery	 was	 followed	 by	 the	 development	 of	 mice	 that	 lack	Ndfip1	 only	 in	 CD4	 and	 CD8	 T	 cells,	 and	 the	 recognition	 that	 these	mice	 develop	disease	which	is	very	similar	to	the	global	Ndfip1	knockout	animals.	This	led	to	the	realization	that	Ndfip1	may	function	in	a	regulatory	capacity	in	one	or	several	T	cell	subsets	 to	 limit	 immune	 cell-mediated	 inflammation.	 In	 my	 thesis	 work,	 I	investigate	a	role	for	Ndfip1	in	two	subsets	of	CD4	T	cells:	Th17	cells	and	Regulatory	T	 (Treg)	 cells.	 This	 work	 identifies	 for	 the	 first	 time	 that	 Ndfip1	 represses	 Th17	identity	while	 promoting	Treg	 identity	 in	 order	 to	prevent	 pathogenic	 function	of	these	cells.		
	1	
CHAPTER	1:	Introduction1	The	 human	 body	 is	 exposed	 to	 potentially	 pathogenic	 microorganisms	 at	barrier	 sites	 such	 as	 the	 skin,	 lungs,	 and	GI	 tract.	 To	mount	 an	 effective	 response	against	 these	 pathogens,	 the	 immune	 system	 must	 recruit	 cells	 with	 effector	responses	 that	are	appropriate	 for	 the	 task	at	hand.	 Several	 types	of	CD4+	T	 cells	can	be	recruited,	including	T	helper	cells	known	as	Th1,	Th2,	and	Th17,	T	follicular	helper	 (Tfh)	 cells,	 and	 regulatory	 T	 cells	 (Tregs)	 (Fig.	 1a).	 These	 cells	 help	 to	maintain	normal	 immune	homeostasis	 in	the	 face	of	constantly	changing	microbes	in	 the	 environment.	 As	 these	 cells	 differentiate	 from	 a	 common	 progenitor,	 the	composition	of	their	intracellular	milieu	of	proteins	changes	to	appropriately	guide	their	effector	function.	One	underappreciated	process	that	 impacts	both	levels	and	functions	of	effector	fate-determining	factors	is	ubiquitylation.	
Ubiquitylation	and	deubiquitylation	Ubiquitylation	 is	 the	 post-translational	 addition	 of	 ubiquitin	 to	 a	 substrate	protein.	Ubiquitylation	of	a	substrate	requires	the	sequential	action	of	three	classes	of	enzymes:	the	E1	or	ubiquitin	activating	enzyme,	the	E2	or	ubiquitin	conjugating	enzyme,	 and	 the	 E3	 ubiquitin	 ligase.	 E1s	 activate	 ubiquitin	 by	 the	 formation	 of	 a	thiol	ester	with	the	carboxyl	group	of	glycine	76	on	ubiquitin1.	The	ubiquitin	is	then	transferred	 to	 a	 catalytic	 cysteine	 on	 an	 E22,	 which	 then	 associates	 with	 an	 E3	ubiquitin	ligase	that	is	in	a	complex	with	a	substrate.	The	E3	may	serve	as	a	scaffold																																									 																					1	This	chapter	has	previously	been	published	as:	Layman,	A.	A.	K.	&	Oliver,	P.	M.	Ubiquitin	Ligases	and	Deubiquitinating	Enzymes	in	CD4+	T	Cell	Effector	Fate	Choice	and	Function.	J.	Immunol.	196,	3975–3982	(2016).			
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to	facilitate	the	transfer	of	ubiquitin	from	the	E2	to	the	substrate,	as	is	the	case	for	RING	(Really	Interesting	New	Gene)	type	E3s3,4.	Alternatively,	HECT	(Homologous	to	E6AP	C-Terminus)5	and	the	RBR	(RING-between-RING)	type	E3s6,7	first	receive	the	ubiquitin	onto	a	 catalytic	 cysteine	 residue	before	 transferring	 it	 to	a	 lysine	on	 the	substrate.	E3	ligases	can	thus	identify	the	substrate	and	also	dictate	the	formation	of	ubiquitin	 linkages,	 driving	 the	 mono-,	 multi-mono-,	 or	 polyubiquitylation	 of	 the	substrate.		
Ubiquitin	has	seven	accessible	lysines	on	its	surface,	K6,	K11,	K27,	K29,	K33,	K48	 or	 K63,	 each	 of	 which	 can	 be	 a	 point	 of	 attachment	 for	 ubiquitin	 chains8–11.	Furthermore,	 the	amino	terminal	methionine	of	ubiquitin	(M1)	can	also	serve	as	a	point	 of	 attachment	 for	 linear	 chains	 in	 a	 reaction	 catalyzed	 by	 an	 E3	 ubiquitin	ligase	 complex	 called	 the	 linear	 ubiquitylation	 assembly	 complex	 (LUBAC)12.	Ubiquitin	 chains	 can	 alter	 the	 fate	 of	 a	 substrate	 by	 changing	 its	 cellular	 location,	promoting	 its	 interactions	 with	 other	 proteins,	 or	 driving	 degradation.	Ubiquitylation	of	protein	substrates	may	be	modified	or	reversed	by	enzymes	called	deubiquitinating	enzymes	(DUBs).	The	~100	DUBs	encoded	by	the	human	genome	are	 split	 into	 five	 main	 families	 based	 on	 their	 structural	 domains.	 These	 five	families	are	the	ubiquitin-specific	proteases	(USPs);	the	ubiquitin	carboxy-terminal	hydrolases	 (UCHs);	 the	 ovarian	 tumor-related	 proteases	 (OTUs);	 the	 Machado-Joseph	 disease	 domain	 proteases	 (MJDs)	 and	 the	 JAB1/MPN/Mov34	Metalloproteases	(JAMMs)13.		
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Ubiquitylation	affects	CD4+	T	cell	fate,	identity,	and	function.	When	a	naïve	T	cell	encounters	an	antigen	presenting	cell	(APC)	expressing	a	peptide	 antigen	 displayed	 on	 its	MHC	 (pMHC),	 the	 naïve	 T	 cell	 can	 get	 primed	 to	become	an	effector	T	cell14,15.	The	sequence	of	events	that	leads	to	the	formation	of	an	effector	requires	that	the	T	cell	receive	three	signals:	pMHC,	costimulation,	and	cytokine16,17.	 Ubiquitylation	 can	 influence	 each	 of	 these	 signals	within	 a	 T	 cell	 by	altering	 the	 levels	 and	 functions	 of	 signaling	 intermediates	 or	 by	 influencing	transcription	 factors	 that	drive	CD4+	T	cell	 identity	and	 function.	Many	E3	 ligases	have	known	roles	 in	 regulating	T	cell	 activation	and	co-stimulation.	These	 include	the	RING	E3	ligases:	Cbl-b18–22,	TRAC-123,	Peli124	and	the	HECT	E3	ligases:	Itch	and	Nedd425–29,	as	reviewed30–33.			
The	role	of	Ubiquitylation	in	the	generation	of	Th1	cells	
Th1	 cells	 are	 important	 for	 the	 clearance	 of	 intracellular	 pathogens.	 They	differentiate	 from	naïve	CD4+	T	 cells	 in	 response	 to	pMHC	and	 costimulation	 in	a	cytokine	 milieu	 containing	 IL-12	 and	 IFNγ.	 IL-12	 signaling	 induces	 the	phosphorylation	of	Jak2	and	Tyk2,	leading	to	STAT4	activation	which	in	turn	drives	IFNγ	production34.	IFNγ	receptor	signaling	through	STAT1	induces	expression	of	the	transcription	 factor	T-Box	Expressed	 In	T	Cells	 (T-bet)35.	 T-bet,	 transactivates	 the	IFNγ	 gene	 to	drive	 further	 IFNγ	 cytokine	production35	and	 increases	expression	of	the	IL-12Rβ2	to	promotes	more	IL-12	responsiveness36.	Thus,	STAT1,	STAT4	and	T-bet	help	to	promote	Th1	cell	identity.		 	 	 	 		 STAT1,	STAT4,	and	T-bet	are	degraded	via	ubiquitin-mediated	networks.	An	
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E3	 ligase	 enzyme	 called	 STAT-interacting	 LIM	 (SLIM)	 protein	 (also	 known	 as	PDLIM2	 or	 mystique)	 drives	 rapid	 nuclear	 degradation	 of	 STAT1	 and	 STAT4	 in	response	 to	 IFNα	 or	 IL-12	 signaling37.	 SLIM	 has	 been	 shown	 to	 aid	 in	polyubiquitylation	of	STAT4	in	vivo	and	in	vitro37,	and	STAT1	in	vitro38.	The	CD4+	T	cells	 in	 SLIM-/- mice	make	 increased	 IFNγ	 upon	 in	 vivo	 challenge	with	 heat-killed	Listeria	 monocytogenes37.	 It	 is	 however	 unclear	 whether	 the	 increased	 IFNγ	production	 by	 these	 cells	 leads	 to	 enhanced	 resistance	 to	 pathogen	 or	 rather,	enhanced	 immunopathology.	 Another	 E3	 ligase,	 Smad	 ubiquitylation	 regulating	factor	 1	 (Smurf1),	 mediates	 K48	 polyubiquitylation	 and	 degradation	 of	 STAT1	 in	transformed	cell	lines	but	it	remains	to	be	shown	whether	this	happens	in	T	cells	as	well39.	 STAT1	ubiquitylation	 is	 reversed	by	 the	DUB,	USP1340.	 Furthermore,	T-bet	can	 undergo	 ubiquitin-mediated	 degradation	 by	 a	 yet-unknown	 E3	 ligase41.	However,	 a	DUB,	USP10,	 reverses	 this	 ubiquitylation	 and	 stabilizes	T-bet42.	 These	findings	 raise	 the	 question	 of	 how	 else	 ubiquitylation	 influences	 both	 epigenetic	modifications	and	the	stability	of	proteins	that	result	in	the	decision	of	a	naïve	CD4	T	cell	to	differentiate	into	a		Th1	cell.	
The	role	of	Ubiquitylation	in	the	generation	of	Th2	cells	
Th2	cells	mediate	 immunity	against	extracellular	microbes,	 such	as	worms,	and	 facilitate	 clearance	 of	 allergens	 and	 toxins.	 Th2	 cells	 differentiate	 from	 naïve	CD4+	T	cells	in	response	to	pMHC	and	costimulation	in	the	presence	of	the	cytokine	IL-4.	Th2	cells	may	secrete	a	variety	of	cytokines	including	IL-4,	IL-5	and	IL-13.	IL-4	drives	 Th2	 cell	 generation	 in	 a	 positive	 feed-forward	 loop43.	 IL-4	 binds	 to	 its	
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receptor,	 resulting	 in	 the	 phosphorylation	 and	 activation	 of	 STAT6,	 which	translocates	 to	 the	 nucleus	 and	drives	 transcription	 of	 GATA3.	 GATA3	drives	Th2	cell	 identity	 via	 both	 Notch-dependent	 and	 Notch-independent	 mechanisms44–47.	While	 IL-4	 and	STAT6	may	be	dispensable	 for	 in	 vivo	 generation	of	Th2	 cells46–48,	GATA3	is	required	for	the	generation	of	Th2	cells44.		 	 	 		 IL-4,	 GATA3,	 and	 STAT6	 are	 regulated	 by	 ubiquitylation,	 either	 directly	 or	indirectly.	The	catalytic	ubiquitin	ligase,	Itch,	regulates	Th2	cell	differentiation	and	identity	 by	 regulating	 IL-4	 production.	 As	 with	 most	 catalytic	 E3	 ligases,	 Itch	enzymatic	 activity	 is	 restrained	 by	 a	 closed	 conformational	 state	 known	 as	autoinhibition49.	Upon	T	cell	activation,	a	small	membrane-bound	adaptor	known	as	Nedd4-family	 interacting	 protein	 1	 (Ndfip1)	 is	 expressed	 which	 activates	 Itch,	allowing	 it	 to	 polyubiquitylate	 targets	 including	 JunB25,50.	 This	 results	 in	 JunB	degradation	and	prevents	 its	 localization	 to	 the	nucleus	where	 it	would	otherwise	pair	 with	 c-Maf	 to	 drive	 IL-4	 transcription26,51,52.	 In	 mice	 lacking	 Ndfip1	 or	 Itch,	CD4+	T	cells	accumulate	high	levels	of	JunB	and	produce	excessive	quantities	of	IL-4	resulting	 in	 a	 preponderance	 of	 Th2	 cells25,26.	 Supporting	 this	 model,	 transgenic	mice	which	overexpress	JunB	to	levels	found	in	Th2	cells,	show	a	specific	increase	in	Th2	cytokines	such	as	IL-4	and	IL-551.	STAT	6	levels	are	regulated	by	two	different	E3	 ligases:	 gene	 related	 to	 anergy	 in	 lymphocytes	 (GRAIL)	 and	 Casitas	 B-lineage	lymphoma	 b	 (Cbl-b).	 GRAIL	 drives	 polyubiquitylation	 and	 degradation	 of	 STAT6,	and	 therefore	 limits	 the	generation	of	Th2	cells.	GRAIL	 is	highly	expressed	 in	Th2	cells	and	 its	knockdown	results	 in	an	 increase	 in	 IL-4,	 IL-5	and	IL-13	 from	T	cells.	GRAIL	 knockout	 animals	 are	 highly	 susceptible	 to	 allergic	 inflammation	 and	 their	
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naïve	 CD4+	 T	 cells	 fail	 to	 appropriately	 degrade	 STAT6	 after	 in	 vitro TCR	stimulation53.	Cbl-b	also	drives	STAT6	polyubiquitylation	and	degradation54.	Similar	to	 Grail-/- animals,	 Cbl-b-/- animals	 are	 highly	 susceptible	 to	 induced	 allergic	inflammation	due	to	a	Th2	and	Th9	bias	in	their	T	cells.		The	 E3	 ligase,	 murine	double	minute	2	(Mdm2),	drives	GATA3	polyubiquitylation.	Mdm2	is	well	known	for	its	role	in	ubiquitin-driven	degradation	of	the	tumor	suppressor	p5355,56,	but	Mdm2	has	 several	 other	 substrates	 including	 NFAT2c57,58	 and	 GATA359.	 Upon	 TCR	stimulation,	activation	of	the	ERK-MAPK	pathway	leads	to	the	association	of	Mdm2	with	 GATA3,	 and	 consequent	 polyubiquitylation	 and	 proteasomal	 degradation	 of	GATA359.	A	DUB	named	USP15	deubiquitinates	Mdm2	and	prevents	its	proteasomal	degradation57.	Therefore	ubiquitylation	of	GATA3	and	STAT6,	as	well	as	of	 factors	that	 regulate	 IL-4	production,	 influence	 the	generation	of	 	 a	Th2	cell	 from	a	naïve	CD4	T	cell.	
The	role	of	Ubiquitylation	in	the	generation	of	Th17	cells	
Th17	cells	are	important	for	the	clearance	of	extracellular	pathogens	such	as	fungi.	 Th17	 cells	 differentiate	 in	 the	 presence	 of	 a	 cytokine	 milieu	 containing	transforming	growth	 factor	β	 (TGF-β)	 and	 IL-660–62.	Other	 cytokines	 such	as	 IL-1β	and	IL-23	drive	differentiation	and	maintenance	of	Th17	cells	and	may	even	drive	Th17s	 in	 the	absence	of	TGF-β63.	STAT3	 is	 induced	downstream	of	 IL-6,	 IL-21	and	IL-23,	and	cooperates	with	 IRF4	(induced	downstream	of	 IL-1β)	 to	elevate	RORγT	levels64,65.	 RAR-related	 orphan	 receptor	 gamma	T	 (RORγT)	 and	 alpha	 (RORα)	 are	sufficient	to	drive	Th17	differentiation66,67.		 	
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Several	 enzymes	 in	 the	 ubiquitin	 conjugation	 pathway	 can	 influence	 the	differentiation	or	maintenance	of	Th17	cells.	For	example,	mice	lacking	Ndfip1	and	Itch	that,	as	discussed	in	the	prior	section,	have	increased	frequencies	of	Th2	cells,	also	have	increased	frequencies	of	Th17	cells.	While	this	may	be	partly	due	to	cell-extrinsic	effects	of	IL-4	mediated	inflammation	driving	increased	pro-inflammatory	cytokines	and	tissue	damage68,	there	are	also	more	direct	roles	for	other	factors	in	Th17	 generation	 or	 function	 as	 will	 be	 discussed	 in	 this	 thesis.	 Similarly,	 mice	lacking	 a	 RING	 E3	 ligase,	 Ro52/TRIM21,	 show	 increased	 production	 of	inflammatory	 cytokines	 such	 as	 IL-23,	 IL-6,	 and	 IL-21,	 and	 these	 mice	 have	increased	frequencies	of	Th17	cells69.	Crossing	the	Ro52-/- mice	to	IL-23p19-/- mice	abrogates	tissue	damage,	excessive	cytokine	production	and	lowers	the	frequencies	of	the	Th17	cells,	 indicating	that	the	increase	in	Th17	cells	 is	 indeed	driven	by	the	dysregulated	IL-23/IL-17	axis.	Ro52	acts	downstream	of	IFN	(predominantly	Type	II)	 signaling	 to	 polyubiquitylate	 IRF3,	 IRF5	 and	 IRF8	 and	 to	 target	 them	 for	degradation.	 This	 limits	 the	 production	 of	 cytokines	 including	 IL-6	 and	 IL-23	 that	would	otherwise	drive	Th17	generation.	A	 third	example	of	an	E3	ubiquitin	 ligase	that	influences	the	Th17	cell	fate	choice	is	SLIM.	As	described	above,	SLIM	can	drive	degradation	 of	 STAT4	 in	 Th1	 cells,	 but	 can	 also	 limit	 Th17	 differentiation	 by	promoting	 the	 proteasomal	 degradation	 of	 STAT370,71.	 Supporting	 this,	 SLIM-deficient	 animals	 show	 increased	 frequencies	 of	 Th17	 and	Th1	 cells	 and	 are	 very	susceptible	 to	 Experimental	 Autoimmune	 Encephalitis	 (EAE),	 a	 mouse	 model	 of	multiple	sclerosis71.	 	
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Several	DUBs	are	 important	 for	Th17	differentiation.	USP4	regulates	Th17s	in	 two	ways.	First,	USP4	deubiquitylates	Ro52	 in	transformed	cell	 lines72	and	thus	limits	the	expression	of	cytokines	needed	for	Th17	generation69.	Second,	it	directly	interacts	with	RORγT	 in	 primary	 human	Th17	 cells	 and	deubiquitylates	RORγT	 in	transformed	cell	lines73,	which	would	promote	Th17	cells	generation.	Further	work	is	 needed	 to	 understand	whether	 these	 two	 functions	 are	 performed	 by	 USP4	 in	primary	T	cells	and	if	these	opposing	actions	serve	to	regulate	Th17	cell	abundance	
in	 vivo.	 USP17	 (also	 known	 as	 DUB-3)	 is	 a	 second	 DUB	 that	 maintains	 RORγT	stability74.	 Knockdown	 of	 USP17	 in	 primary	 Th17	 cells	 results	 in	 a	 decrease	 of	endogenous	 RORγT	 levels74.	 Since	 IL-4	 and	 IL-6	 signaling	 can	 induce	 USP1775,	 it	appears	that	in	response	to	IL-6	signaling,	two	responses	occur:	first,	RORγT	levels	are	 increased	 downstream	 of	 STAT3	 and	 second,	 RORγT	 protein	 is	 stabilized	downstream	of	USP17.	How	USP17	integrates	these	two	events	downstream	of	IL-6	signaling	needs	further	evaluation	in	primary	CD4+	T	cells.		
A	 third	 DUB	 involved	 in	 Th17	 differentiation	 is	 DUBA	 (also	 known	 as	OTUD5),	 an	 OTU	 family	 DUB.	 DUBA	 facilitates	 the	 degradation	 of	 RORγT	 by	stabilizing	 a	 positive	 regulator	 of	 RORγT	 degradation	 known	 as	 UBR576.	 UBR5	polyubiquitylates	 and	 targets	 RORγT	 for	 proteasomal	 degradation.	 UBR5	 itself	 is	regulated	via	polyubiquitylation.	When	DUBA	deubiquitylates	UBR5	and	rescues	 it	from	degradation,	UBR5	 is	 free	 to	polyubiquitylate	RORγT,	driving	 its	degradation	and	 consequently	 limiting	 Th17	 differentiation.	 T-cell	 specific	 loss	 of	 DUBA	therefore	results	in	reduced	levels	of	UBR5,	stabilization	of	RORγT,	and	increased	IL-
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17A	production	in	response	to	TCR	stimulation76.		 	 	 		 Th17	cells	are	heterogeneous;	some	are	more	pathogenic	than	others63,77,78,	depending	on	how	the	Th17	cells	were	generated	and	upon	 their	gene	expression	profile.	GM-CSF	secretion,	for	example,	which	occurs	downstream	of	IL-23	signaling,	marks	pathogenic	Th17s	which	cause	EAE79–82.	IFNγ+	Th17	cells	are	also	thought	to	be	more	pathogenic	than	IL-17A	single	producers.	Further	work	needs	to	be	done	to	clarify	 the	 role	 of	 ubiquitylation	 in	 determining	 the	 pathogenic	 potential	 and	function	of	a	Th17	cell	both	during	and	after	differentiation,	and	how	this	influences	the	observed	heterogeneity	in	Th17	cells.	
The	role	of	Ubiquitylation	in	the	generation	of	T	follicular	helper	cells		
Tfh	(T	follicular	helper)	cells	are	CD4+	T	cells	that	provide	costimulatory	help	to	B	cells	 in	 germinal	 centers	 to	 enable	 B	 cell	 functions83–85.	 Tfh	 cells	 exist	 in	 an	interdependent	 relationship	 with	 B	 cells,	 wherein	 B	 cells	 are	 required	 for	appropriate	Tfh	differentiation	and	function,	and,	reciprocally,	Tfh	cells	promote	the	generation	 of	 high	 affinity	 antibody	 producing	B	 cells.	 Tfh	 cells	 differentiate	 from	naïve	 precursors	 in	 response	 to	 pMHC	 interactions	 and	 under	 the	 influence	 of	cytokines	 such	 as	 IL-6	 and	 IL-21,	 and	 ICOS	 signaling86–90.	 Tfh	 cells	 can	 secrete	cytokines	 such	 as	 IL-4,	 and	 IL-21	 as	 well	 as	 chemokines	 such	 as	 CXCL13,	 as	reviewed91.	The	differentiation	of	a	naïve	CD4+	T	cell	into	a	Tfh	cell	occurs	in	a	step-wise	 fashion	 and	 requires	 the	 transcription	 factor,	 achaete-scute	 homologue	 2	(Ascl2),	 to	 generate	 a	 Bcl6lo	 CXCR5+	 Tfh-intermediate	 cell.	 This	 intermediate	undergoes	 maturation	 and	 complete	 differentiation	 in	 the	 presence	 of	 Bcl6	 to	
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generate	a	Bcl6hi	CXCR5hi	Tfh	cell92.	Bcl6	is	thus	essential	for	Tfh	identity93–95.			 Several	E3	 ligases	affect	Tfh	differentiation	and	 function	by	 regulating	Bcl6	directly	 or	 indirectly.	 Four	of	 these	 are	RING	 type	E3	ubiquitin	 ligases.	 First,	Bcl6	may	be	repressed	by	 interaction	with	Cul3	E3	 ligase,	a	 ligase	known,	among	other	things,	to	ubiquitylate	histone	proteins.	In	thymocytes,	complexes	of	Cul3	and	Bcl6	directly	bind	and	lay	down	repressive	epigenetic	marks	on	two	genes	important	for	Tfh	 identity,	 namely	Batf	 and	Bcl696.	 Intriguingly,	 this	 repression	 is	 epigenetically	carried	 over	 into	 the	 periphery	when	 the	 T	 cells	 encounter	 antigen.	 Therefore,	 in	mice	 which	 lack	 Cul3	 in	 T	 cells,	 Tfh	 cells	 are	 increased	 in	 secondary	 lymphoid	tissues	 and	 these	 cells	 drive	 germinal	 center	 B	 cell	 expansion97.	 Exactly	 how	 the	Cul3	Ring	Ligase	complex	represses	Bcl6	expression	remains	unresolved.	Does	the	complex	directly	ubiquitylate	Bcl6	leading	to	its	degradation?	Or	does	the	complex	regulate	Bcl6	 indirectly	by	ubiquitylation	other	proteins	such	as	histone	modifiers	that	are	associated	with	Bcl6?	Second,	 the	E3	 ligase	Roquin	reduces	expression	of	ICOS,	upstream	of	Bcl6,	to	limit	Tfh	differentiation.	Roquin	is	a	RING	E3	ligase	with	an	RNA-binding	domain	that	binds	and	silences	target	genes,	including	ICOS	mRNA.	Supporting	this	model,	mice	that	bear	a	mutation	in	the	gene	encoding	Roquin,	(also	called	 sanroque	 mice),	 have	 increased	 ICOS	 levels	 in	 both	 naïve	 and	 activated	 T	cells.	This	leads	to	a	T-cell-intrinsic	increase	in	Tfh	differentiation,	large	numbers	of	germinal	 centers,	 and	 increased	 serum	 antibodies	 of	 various	 IgG	 isotypes,	 among	other	 defects98.	 Bcl6	 is	 regulated	 by	 two	 other	 E3	 ligases	 in	 diffuse	 large	 B	 cell	lymphomas	(DLBCLs)99,100.	Pellino1	E3	ligase	(PELI1)	directs	K63	(non-degradative)	chains	 on	 Bcl6	 leading	 to	 Bcl6	 stabilization	 in	 transgenic	 mice	 overexpressing	
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human	 PELI199.	 Furthermore,	 in	 these	 lymphoma	 cell	 lines,	 another	 E3	 ligase,	FBXO11,	 that	 normally	 marks	 Bcl6	 for	 degradation,	 is	 found	 to	 undergo	 loss	 of	function	mutations100.	 Follow	 up	 of	 these	 observations	 in	 primary	 T	 cells	 will	 be	crucial	in	determining	whether	PELI1	and	FBXO11	have	roles	in	regulating	Bcl6	and	consequently	in	Tfh	differentiation	in	vivo.	 	 	
	 The	HECT-type	E3	 ligase	 Itch	 also	 regulates	 the	differentiation	of	Tfh	 cells.	Mice	 lacking	 Itch	 globally	 or	 only	 in	 their	 T	 cells	 are	 unable	 to	 generate	 Tfh	 cells	following	 infection	 with	 vaccinia	 virus101.	 In	 Itch-deficient	 T	 cells,	 Foxo1	 is	 not	appropriately	 degraded	 and	 Tfh	 development	 can	 be	 rescued	 by	 knockdown	 of	Foxo1	 or	 by	 forced	 expression	 of	 Bcl6,	 suggesting	 that	 the	 defect	 is	 upstream	 of	Bcl6101.	ICOS	signaling	converges	on	this	pathway	by	transiently	inactivating	Foxo1	in	 order	 to	 relieve	 Foxo1	 repression	 of	 Bcl6	 and	 to	 allow	 Tfh	 differentiation	downstream	of	short-term	ICOS	signals102.	Surprisingly,	knockout	of	Foxo1	in	T	cells	does	 not	 lead	 to	 aberrantly	 increased	Tfh	 differentiation	 but,	 instead,	 to	 a	 lack	 of	formation	of	 germinal	 centers	 or	Tfh	 cells102.	 This	 suggests	 that	 the	 expression	of	proteins	such	as	Foxo1	is	precisely	modulated	to	allow	the	development	of	Tfh	cells	and	 the	 formation	 of	 germinal	 centers.	 Foxo1	 is	 important	 for	 regulatory	 T	 cell	generation	and	 function103	 and	 Itch-deficient	T	 cells	have	decreased	Tfh	 cells,	 and	defective	 Treg	 numbers	 and	 function101,104,	 therefore	 it	 will	 be	 important	 to	determine	whether	Foxo1	levels	are	changed	in	Itch-/- Treg	cells	and	how	defects	in	Itch-deficient	 Treg	 cells	 influence	 observed	 defects	 in	 Itch-deficient	 Tfh	 cells.	
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Further	work	is	needed	to	explore	the	role	of	other	ubiquitin-mediated	pathways	in	Tfh	identity.		
The	role	of	Ubiquitylation	in	the	generation	of	Regulatory	T	cells	
Tregs	are	a	subset	of	CD4+	T	cells	that	are	capable	of	suppressing	the	actions	and	functions	of	other	immune	cell	type	types105,106.	Several	distinct	subsets	of	Tregs	have	 been	 described	 including	 the	 Foxp3-	 Tr1	 cells	 (Type	 1	 regulatory	 T	 cells),	Foxp3+	Th3	cells,	and	the	Foxp3+	thymic-derived	Tregs.	Foxp3+	regulatory	T	cells	develop	in	the	thymus,	when	TCR/CD28	and	IL-2	signaling	drives	expression	of	the	transcription	factor	Foxp3107.	Foxp3	is	central	to	the	function	of	this	major	subset	of	Tregs	and	mutations	in	Foxp3	in	both	mice	and	men	leads	to	non-functional	Tregs	and	autoimmunity108.	Foxp3+	Tregs	may	also	be	 induced	in	the	periphery	through	the	 action	 of	 TGF-β	 and	 IL-2.	 TGF-β	 signals	 through	 the	 complementary	 proteins,	Smad2	 and	 Smad3,	 to	 drive	 Foxp3	 transcription109.	 IL-2	 binding	 to	 the	 IL-2R	complex	 leads	 to	 JAK1	 and	 JAK	 3	 recruitment	 and	 eventual	 recruitment	 and	activation	of	STAT5	which	in	turn	drives	expression	of	Foxp3110,111.		 	
Two	 E3	 ligases	 can	 regulate	 Foxp3	 stability:	 Stub1	 and	 Cbl-b.	 Stub1	 (also	known	as	CHIP	or	 carboxyl	 terminus	of	Hsc70-interacting	protein),	 interacts	with	both	Hsp70	and	Foxp3	to	drive	K48-linked	polyubiquitylation	of	Foxp3112.	Exposure	of	 the	 Jurkat	 T	 cell	 line	 to	 inflammatory	 cues	 such	 as	 LPS	 and	 IL-1β	 drives	 the	translocation	of	 Stub1	 into	 the	nucleus,	where	 it	 interacts	with	Hsp70,	 and	drives	the	ubiquitin-mediated	proteasomal	degradation	of	Foxp3.	Overexpression	of	Stub1	
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in	Tregs	and	subsequent	cotransfer	of	these	cells	together	with	naïve	T	cells	into	a	lymphoreplete	 host	 resulted	 in	 loss	 of	 Foxp3	 in	 the	 Tregs	 and	 subsequent	conversion	of	these	cells	into	IFNγ+	Th-1	like	effector	cells112.	Cbl-b,	has	been	shown	to	 ubiquitylate	 Foxp3	 by	 working	 together	 with	 Stub1.	 Specifically,	 Cbl-b	 binds	ubiquitylated	 Foxp3	downstream	of	 TCR/CD28	 signaling,	 and	 recruits	 it	 to	 Stub1,	allowing	 additional	 ubiquitylation	 of	 Foxp3	 and	 increased	 proteasomal	degradation113.	 	
E3	 ligases	 may	 also	 influence	 Tregs	 by	 affecting	 their	 function.	 One	 such	example	 is	 the	 regulation	 of	 Treg	 function	 by	 the	 E3	 ligase	 von	 Hippel-Lindau,	VHL114.	Under	normal	oxygen	levels	(normoxia),	an	oxygen	sensor	named	Hypoxia-inducible	 Factor	 alpha	 (HIF1α)	 is	 hydroxylated,	 recognized	 and	 then	polyubiquitylated	by	VHL.	This	results	in	proteasomal	degradation	of	HIF1α.	Under	conditions	of	low	oxygen	stress	(hypoxia),	HIF1α	is	not	degraded	by	VHL,	and	is	free	to	 drive	 the	 transcription	 of	 genes	 necessary	 for	 surviving	 hypoxia.	 HIF1α	 also	serves	 as	 a	 switch	 between	 Th17	 and	 Treg	 fates115,116.	 HIF1α	 can	 directly	 bind	RORγT	and	p300	to	drive	transcription	of	IL-17A	and	promote	Th17	identity	while	simultaneously	 binding	 and	 targeting	 Foxp3	 for	 degradation	 to	 repress	 Treg	differentiation115.	 Interestingly,	 mice	 lacking	 VHL	 only	 in	 their	 Tregs	 develop	 a	disease	 characterized	by	 large	numbers	of	 IFNγ+	Tregs	which	 infiltrate	 tissue	and	fail	 to	 suppress	 conventional	 T	 cells	 or	 prevent	 colitis114.	 In	 VHL-deficient	 Tregs,	stabilized	HIF1α	 drives	 the	 IFNγ	 promoter	 resulting	 in	 large	 amounts	 of	 secreted	IFNγ	and	poor	function	of	these	Tregs114.	 Why	 HIF1α	 specifically	 drives	 IFNγ	
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production	 is	 not	 understood.	 It	 would	 be	 interesting	 to	 explore	 the	 chromatin	landscape	to	understand	whether	the	IFNγ	promoter	is	accessible	while	promoters	for	other	cytokines	are	not.	
The	 HECT-type	 E3	 ubiquitin	 ligase	 Itch	 also	 regulates	 Treg	 differentiation	and	function.	Mice	encoding	a	Treg-specific	deletion	of	the	E3	ligase	Itch	develop	a	Th2-mediated	disease	characterized	by	infiltration	of	activated	T	cells	into	mucosal	sites	and	show	particularly	severe	 inflammation	 in	 the	airways104.	The	 inability	of	Itch-deficient	 Tregs	 to	 suppress	 Th2-mediated	 inflammation	 supports	 other	published	 studies	 showing	 that	mice	 that	 lack	Ndfip1	 express	 an	 inactive	 form	of	Itch	 that	 fails	 to	degrade	 JunB	and	 limit	 IL-4	production25.	Thus	T	cells	 from	mice	that	 lack	Ndfip1	are	defective	 in	 induced	Treg	 (iTreg)	generation	due	 to	high	 IL-4	production117.	Two	E3	 ligases,	Smurf2118	and	β-TrCP	(FBXW1)119,	ubiquitylate	and	degrade	 a	 protein	 called	 EZH2	 in	 neurons	 and	 transformed	 cells	 respectively.	Importantly,	EZH2-deficient	Foxp3+	Tregs	are	unable	 to	 suppress	 inflammation	 in	
vivo	 and	 show	 an	 increased	 loss	 of	 Foxp3120.	 EZH2	 forms	 part	 of	 the	 polycomb	repressive	complex	2	(PRC2)	that	trimethylates	histone	H3	in	order	to	repress	gene	transcription.	 Whether	 these	 E3	 ligases	 function	 to	 stabilize	 EZH2	 and	 reinforce	Treg	identity	in	primary	T	cells	will	be	interesting	to	explore	in	future	studies.		 	
Relatively	little	is	known	about	the	role	of	DUBs	in	Treg	differentiation.	The	USP	family	member	CYLD	(cylindromatosis)	plays	a	role	in	the	generation	of	Tregs.	In	 response	 to	TGF-β	 signaling,	K63-linked	polyubiquitylation	of	 Smad7	 results	 in	stabilized	 Smad7	 which	 activates	 TAK1,	 increases	 binding	 of	 AP-1	 to	 the	 Foxp3	
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promoter,	 and	 increases	 Foxp3	 transcription121.	 CYLD	 opposes	 this	 process	 by	removing	K63	 chains	 on	 Smad7.	 In	 CYLD-/- T	 cells,	 unopposed	K63	 ubiquitylation	upon	 TGF-β	 signaling	 stabilizes	 Smad7	 and	 drives	 increased	 differentiation	 of	Tregs121.	 These	 examples	 show	 that	 in	 addition	 to	 regulating	 Treg	 abundance	ubiquitin	enzymes	can	regulate	Treg	differentiation	and	function.	
Enforcing	 T	 effector	 and	 Treg	 cell	 identity	 is	 crucial	 for	 normal	 immune	
homeostasis.	
Maintaining	 CD4+	 T	 helper	 cell	 identity	 is	 important	 for	 proper	 immune	function.	On	one	hand,	the	flexibility	to	transition	from	an	initial	CD4+	T	effector	cell	into	a	more	relevant	effector	cell	may	be	important	for	quickly	tailoring	the	immune	response	as	infection	progresses.	However,	recent	work	suggests	that	CD4	effector	cells	 have	 the	 potential	 to	 lose	 stability	 and	 express	 transcription	 factors	 and	cytokines	that	are	typically	ascribed	to	other	lineages.	While	it	remains	possible	that	this	helps	to	promote	pathogen	clearance,	in	many	instances	this	is	associated	with	an	ineffective	immune	response	or	correlates	with	inappropriate	immune	responses	that	are	seen	in	autoimmune	diseases.	 	 	
Data	 from	patients	with	Crohn’s	 disease	 suggests	 that	 dual	Th1/Th17	 cells	may	play	a	pathogenic	role	in	disease122.	These	cells	appear	to	retain	aspects	of	both	Th1	and	Th17	identity,	expressing	T-bet	and	RORγT	and	secreting	both	IFNγ	and	IL-17A123,124.	This	co-expression	of	T-bet	and	RORγT	is	intriguing	since	T-bet	is	thought	to	repress	Th17	 identity	by	binding	Runx1,	 to	prevent	Runx1	from	transactivating	
16	
Rorc125–127.	 Runx1	 also	 represses	 the	 Th2	 fate	 by	 binding	 directly	 to	 GATA3128.	Runx1	 is	 ubiquitylated	 and	 degraded	 by	 the	 E3	 ligase	 Stub1129,	 placing	ubiquitylation	 of	 Runx1	 squarely	 at	 the	 center	 of	 decisions	 of	 CD4	 effector	 fate.	Furthermore,	in	vitro -derived	Th1	cells	bear	activating	H3K4me3	marks	at	the	gene	loci	for	IFNγ	and	T-bet,	as	expected,	but	also	unexpectedly	at	the	locus	for	GATA3130,	suggesting	 that	Th1	 cells	may	be	poised	 to	 take	on	other	T	helper	 identities.	This	corroborates	 data	 by	 other	 groups	 showing	 that	 Th1	 cells	 may	 convert	 to	 IL-4	producing	 cells	 in	 response	 to	 infection	 with	 Nippostrongylus	 brasiliensis131.	Conversely,	 in	 the	 absence	of	GATA3,	CD4+	T	 cells	 enter	 into	 the	Th1	 rather	 than	Th2	cell	 lineage47,132.	Continued	research	 is	needed	to	 further	elucidate	 the	role	of	ubiquitylation	in	these	Th1/Th2	cell	fate	decisions.		 	
Th17	cells	can	exhibit	plasticity	in	vivo.	In	a	NOD/SCID	autoimmune	model	of	diabetes,	transfer	of	Th17s	cells	leads	to	acquisition	of	T-bet	and	IFNγ	secretion	by	these	 cells	 in	 vivo133.	 Furthermore,	 Th17	 cells	 can	 transdifferentiate	 into	Tr1	 cells	via	a	TGF-β/Smad3	pathway,	both	at	steady	state	and	during	immune	responses	to	worms	or	bacterial	infections134.	Since	Smad3	degradation	in	transformed	cell	lines	is	 mediated	 by	 the	 RING	 E3	 ligase,	 ROC1135	 and	 may	 be	 reversed	 by	 the	 DUB,	OTUB1136,	ubiquitylation	may	be	involved	in	the	transdifferentiation	of	Th17	cells.	 	
Bcl6	 is	 crucial	 in	 driving	 Tfh	 lineage	 identity.	 Bcl6	 levels	 may	 also	 be	increased	 downstream	 of	 STAT1,	 STAT3	 and	 STAT4137,138.	 During	 Th1	differentiation,	there	is	a	Tfh-like	transition	stage	during	which	both	Bcl6	and	T-bet	are	 expressed.	 However	 as	 T-bet	 expression	 increases,	 Bcl6	 levels	 decrease,	
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resulting	 in	 a	 bias	 towards	 Th1	 cell	 identity137,138.	 Interestingly,	 although	 the	 E3	ligase,	SLIM,	degrades	STAT1	and	STAT4	in	Th1	cells37	and	STAT3	in	Th17	cells71,	a	role	for	SLIM	E3	ligase	in	regulating	Tfh	differentiation	has	not	yet	been	reported.	It	is	possible	 that	by	degrading	STAT1,	 STAT3	and	STAT4,	 SLIM	E3	 ligase	may	keep	levels	of	Bcl6	 low	and	negatively	regulate	Tfh	differentiation	at	 the	expense	of	 the	increased	Th1	differentiation.	Therefore	SLIM-/-	mice	 could	 show	aberrantly	high	Tfh	differentiation.	This	connection	remains	to	be	explored.	 	
Stability	 of	 Tregs	 continues	 to	 be	 a	 controversial	 topic.	 Some	 studies	 have	shown	 remarkable	 stability	of	 these	 cells	 in	both	 lymphoreplete	 and	 lymphopenic	hosts139,140.	Other	studies	have	shown	that	Tregs	can	lose	Foxp3	upon	transfer	into	lymphopenic	hosts	and	gain	the	capacity	to	express	effector	cytokines	such	as	IL-2,	IL-17A	 or	 IL-4,	 IFNγ	 and	 TNFα141,142.	 It	 is	 not	 clear	 what	 determines	 the	 kind	 of	effector	cytokines	secreted	by	a	Treg	cell	after	it	loses	Foxp3.	However,	concerning	stability,	a	consensus	may	be	 that	while	most	 thymic-derived	Tregs	may	be	stable	and	 committed	 to	 the	 Treg	 lineage,	 inflammatory	 conditions	 exist	 that	 can	 drive	some	 loss	 of	 Foxp3	 protein	 and	 thus	 Treg	 instability.	 Alternatively,	 there	may	 be	conditions	in	which	a	small	subset	of	Tregs	that	are	not	fully	committed	to	the	Treg	fate,	may	 lose	 their	 Foxp3	 expression143,144.	 In	 autoimmune	 arthritis,	 for	 example,	“exTregs”	which	acquire	the	capacity	to	secrete	IL-17A	can	play	a	pathogenic	role	in	the	disease145.	Bcl6-/- Tregs	are	also	more	likely	to	lose	Foxp3	and	to	express	GATA3,	and	 to	 secrete	 Th2	 cytokines	 and	 IL-17A146.	 Since	 Bcl6	 may	 be	 degraded	 by	ubiquitylation,	as	discussed	in	the	Tfh	section,	it	will	be	beneficial	in	future	studies	
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to	 determine	 how	 ubiquitylation	 and	 degradation	 of	 Bcl6	 regulates	 Treg	 stability	under	steady	state	and	under	inflammatory	conditions.		 	 	
With	 over	 600	 E3	 ligase	 enzymes	 encoded	 in	 the	 human	 genome,	 our	knowledge	of	the	substrates	and	functions	of	all	of	these	enzymes	is	 in	 its	 infancy.	To	 date,	 relatively	 little	 is	 known	 about	 the	 contribution	 of	 these	 ligases	 to	 CD4	effector	fate	and	function	(Fig.	1).	As	gene	targeting	becomes	more	efficient,	such	as	with	 the	 advances	 of	 CRISPR	 technology,	 our	 understanding	 of	 how	 these	 ligases	function	 in	 vivo	 will	 be	 more	 fully	 explored.	 Additionally,	 as	 whole	 exome	sequencing	 becomes	more	 commonplace,	mutations	 in	 E3	 ligases	 are	 likely	 to	 be	found	to	associate	with	immune-mediated	disease,	thus	providing	a	more	complete	understanding	of	how	these	 ligases	regulate	 immune	 function.	Also,	 the	continued	use	 of	 modern	 genetic	 technology	 such	 as	 reporter	 mice	 for	 many	 of	 the	 known	lineage-defining	 transcription	 factors	 and	 their	 key	 cytokines,	 future	 work	 may	continue	to	reveal	conditions	under	which	different	T	cell	subsets	may	be	unstable	and	 how	 this	 is	 regulated	 by	 ubiquitylation.	 Further	 work	 focusing	 on	understanding	how	ubiquitylation	regulates	the	human	proteome,	should	also	help	shed	 more	 light	 on	 the	 role	 of	 ubiquitylation	 in	 regulating	 CD4+	 T	 cell	 identity,	function	and	stability.		
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FIGURE	1		E3	ubiquitin	ligases	and	deubiquitinating	enzymes	regulate	the	proteins	that	shape	
CD4+	T	cell	identity	and	function.	T	helper	cells	differentiate	from	naïve	CD4	T	cells	after	T	cell	activation	by	an	antigen-presenting	cell	(APC),	such	as	a	dendritic	cell.		The	effector	cell	fates	have	various	roles	in	defense	against	non-self.	All	 of	 the	 key	 transcriptional	 factors	 that	 drive	 effector	 fates	 can	 be	 regulated	 via	 ubiquitylation	(mediated	by	the	indicated	E3	ubiquitin	ligases)	or	by	deubiquitinating	enzymes	(DUBS).	 	 	Modified	 from	Layman,	A.	 A.	K.	&	Oliver,	 P.	M.	Ubiquitin	 Ligases	 and	Deubiquitinating	Enzymes	 in	CD4+	 T	 Cell	 Effector	 Fate	 Choice	 and	 Function.	 J.	 Immunol.	 196,	 3975–3982	 (2016).	 	 Copyright	
2016.	The	American	Association	of	Immunologists,	Inc	
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Ndfip1	is	an	adaptor	in	the	protein	ubiquitylation	cascade	Ndfip1	(originally	named	N4WBP5)	was	identified	from	a	far-western	screen	as	 an	 embryonic	 protein	 that	 could	 bind	 to	 the	 E3	 ligase	 called	 Nedd4	 (Neural	precursor	cell	expressed	developmentally	down-regulated	4)	protein147.	Nedd4	was	known	to	belong	a	family	of	E3	ligases	that	had	a	conserved	modular	structure	and	were	able	to	bind	to	other	proteins	via	their	WW	motifs.	It	was	shown	that	the	WW	motifs	on	Nedd4	were	essential	 for	binding	to	proline-rich	PY	motifs	on	Ndfip1147.	Further	 discoveries	 since	 then	 have	 revealed	 that	 Ndfiip1	 has	 a	 transmembrane	domain,	 can	 be	 golgi-associated148,	 and	 has	 a	 very	 homologous	 family	 member	named	 Ndfip2	 (originally,	 N4WBP5A)149.	 Excitingly,	 it	 has	 now	 been	 shown	 that	Ndfip1	 is	capable	of	binding	 in	vitro to	not	 just	Nedd4	but	all	of	 the	nine	HECT	E3	ligases	that	comprise	the	Nedd4	family49.	These	are:	Nedd4,	Nedd4-2,	Itch,	WWP1,	WWP2,	 Smurf1,	 Smurf2,	NedL1	 and	NedL2.	This	 has	 spurred	many	 investigations	into	determining	which	E3	ubiquitin	ligases	work	with	Ndfip1	in	different	cell	types	as	well	as	the	functional	outcomes	of	substrate	ubiquitylation.	
Ndfip1	has	roles	outside	of	T	cells.	
	In	vivo	studies	of	Ndfip1-deficient	animals	indicate	that	Ndfip1	is	capable	of	working	with	several	HECT	E3	ligases	and	of	mediating	pleiotropic	functions	in	non-T	cells.	Ndfip1	activates	Nedd4-2	to	degrade	DMT1	(Divalent	Metal	Transporter	1)	and	decrease	iron	storage150	in	neurons.	However,	to	carry	out	this	same	function	in	hepatocytes,	 Ndfip1	 activates	 a	 different	 Nedd4	 E3	 ligase,	 namely,	 WWP2151.	 In	neurons,	Ndfip1	also	activates	an	unknown	E3	ligase	to	maintain	Phosphatase	and	
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Tensin	 homolog	 (PTEN)	 nuclear	 localization	 and	 to	 suppress	 proliferation152.	 In	macrophages,	 Ndfip1	works	with	 Smurf1	 to	 target	MAVS	 (mitochondrial	 antiviral	signaling	 protein)	 for	 degradation	 as	 a	 mechanism	 to	 dampen	 Interferon	 β	production39.	Many	of	these	studies	of	were	done	using	 in	vitro	over-expression	or	siRNA	knockdown	of	Ndfip1	in	cell	lines.		
Ndfip1	is	important	in	T	cells	Most	of	the	work	done	in	T	cells,	however,	has	been	done	 in	vivo	due	to	the	generation	of	two	early	mouse	models	of	Ndfip1-deficiency.	The	first	is	the	deletion	of	Ndfip1	in	mice	using	a	homozygous	gene	trap	insertion	that	disrupts	the	Ndfip1	gene25,	 	 and	 the	 second	 is	 the	 generation	 of	mice	 bearing	 a	 truncating	 splice	 site	mutation	 in	 the	 Ndfip1	 gene153.	 These	 two	 mice	 models	 have	 made	 major	contributions	to	our	understanding	of	Ndfip1	in	vivo	biology	and	paved	the	way	for	even	more	targeted	mouse	models	of	Ndfip1	deficiency.	Mice	that	lack	Ndfip1	in	all	cells	 due	 to	 the	 homozygous	 gene	 trap	 insertion	were	 the	 first	 to	 be	 generated25.	These	mice	showed	that	the	loss	of	Ndfip1	globally	led	to	spontaneous	inflammation	in	 several	 sites	 including	 ears,	 liver,	 and	 spleen;	 and	 death	 of	 most	 mice	 by	 14	weeks.	 The	 inflammation	was	 driven	 by	 an	 increase	 in	 activated	 CD4,	 CD8	 and	 B	cells	 found	 at	 the	 affected	 sites.	 The	 activated	 CD4	 T	 cells	 in	 these	 animals	made	copious	 amounts	 of	 IL-4	 and	 had	 markedly	 increased	 proliferation.	 Biochemical	work	established	that	this	dysregulation	was	in	part	due	to	a	loss	of	the	interaction	between	Ndfip1	and	Itch,	which	is	important	for	the	ubiquitylation,	and	degradation	of	 the	 transcription	 factor,	 JunB,	 in	 T	 cells	 to	 prevent	 IL-4	 transcription	 and	
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production.	 	 Ndfip1-/-	 Rag	 -/-	 double	 knockout	 mice	 which	 lack	 Ndfip1	 as	 well	 as	CD4+	and	CD8+	T	cells,	and	B	cells,	were	generated	and	showed	no	sign	of	disease	at	any	 stage	 in	 their	 life154.	 	 This	 indicated	 that	 Ndfip1	 was	 playing	 an	 important	regulatory	 role	 in	 the	adaptive	 immune	system	 to	 suppress	 inflammatory	disease.	Consequently,	 mice	 were	 generated	 that	 lack	 Ndfip1	 in	 all	 CD4	 and	 CD8	 T	 cells	(Ndfip1fl/fl	CD4	Cre	animals,	Ndfip1	cKO)155.	The	histological	and	cellular	pathology	in	these	animals	is	strikingly	similar	to	Ndfip1	global	knockout	animals,	suggesting	that	much	of	the	pathology	in	Ndfip1-deficient	animals	is	driven	by	T	cells155.		
	To	examine	a	role	for	Ndfip1	in	the	regulatory	arm	of	CD4	T	cell	subsets,	one	study	looked	at	Treg	cells	generated	in	Ndfip1	global	knockout	animals117.	As	early	as	4	weeks	of	age,	thymic	Treg	cells	were	increased.	However,	at	the	small	bowel,	a	site	 of	 induced	 Treg	 (iTreg)	 generation,	 there	 was	 a	 decrease	 in	 total	 Treg	 cells,	driven	by	a	decrease	in	these	Foxp3+	helioslo	iTreg	cells.	Further	work	showed	that	IL-4	produced	by	CD4	T	cells	was	responsible	for	aborting	iTreg	differentiation.	This	work	established	 that	 an	extrinsic	 effect	of	 the	high	 IL-4	 in	Ndfip1-/-	 animals	 is	 to	prevent	 iTreg	 generation	 and	 uncovered	 a	 role	 for	 Ndfip1	 in	 promoting	 iTreg	differentiation	 in	 order	 to	 maintain	 immune	 homeostasis	 in	 the	 small	 bowel.	However,	 this	 work	 did	 not	 address	 whether	 there	 are	 changes	 to	 total	 Treg	numbers	 at	 other	 tissue	 sites	 such	 as	 the	 lungs	 or	 spleen,	 and	whether	Ndfip1	 is	important	 for	 the	 function	 and/or	 maintenance	 of	 Treg	 cells	 that	 have	 already	differentiated	into	Foxp3+	Treg	cells.		
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Another	 study	used	 the	mice	bearing	 the	 truncating	 splice	 site	mutation	of	the	Ndfip1	gene	to	study	the	role	of	Ndfip1	in	T	cell	activation153.	The	study	revealed	that	the	T	cell	defects	 in	Ndfip1-deficient	mice	was	not	rescued	by	the	presence	of	normal,	 functional	Treg	cells	 in	mixed	chimera	models.	This	suggested	that	even	if	there	were	defects	 in	Treg	 cells,	 there	were	additional	 cell-autonomous	defects	 in	the	CD4	T	cell	effector	populations.	The	study	reiterated	that	Ndfip1-deficient	Th2	cells	 have	 an	 intrinsic	 defect	 in	 limiting	 IL-4	production	due	 to	 failure	 to	degrade	JunB.	Interestingly,	the	study	was	also	the	first	to	publish	a	cell-intrinsic	increase	in	IFNγ+	cells	due	to	a	loss	of	Ndfip1	and	yet	whether	this	finding	had	implications	for	the	 role	of	Ndfip1	 in	Th1	 cells	was	not	 addressed	or	 explored.	 	The	 study	 further	demonstrated	that	CD4	T	cells	lacking	Ndfip1	continue	to	stay	in	the	cell	cycle	and	proliferate	in	response	to	the	same	amount	of	antigen	seen	by	a	WT	CD4	T	cell.		This	finding	 complemented	 another	 study	 which	 showed	 that	 activation	 of	 Ndfip1-deficient	CD4	T	cells	and	their	increased	proliferation	was	in	part	due	to	a	failure	to	turn	 down	 IL-2	 signaling	 even	 when	 CD28	 co-stimulation	 had	 not	 occurred155.		Together,	 all	 of	 these	previous	 studies	 established	 that	Ndfip1	 functions	 in	CD4	T	cells	to	limit	T	cell	activation	and	proliferation.	However,	with	the	exception	of	Th2	cells	and	iTreg	cells,	 it	was	not	understood	whether	or	how	Ndfip1	was	regulating	other	subtypes	of	CD4	T	cells.		
To	 understand	 Ndfip1’s	 role	 in	 other	 CD4	 subtypes,	 one	 study	 examined	Th17	cells	found	in	Ndfip1-deficient	animals68.	They	found	that	the	frequencies	and	numbers	 of	 Th17	 cells	 are	 increased	 in	 mice	 that	 lack	 Ndfip1	 globally.	 Further	
24	
investigation	 revealed	 that	 the	 abundance	 of	 Th17	 cells	 could	 be	 dramatically	reduced	by	treating	with	blocking	antibodies	against	IL-6	or	by	knocking	out	the	IL-4	gene.	They	discovered	that	the	high	IL-4	production	by	T	cells	in	Ndfip1-deficient	animals	 leads	 to	 increased	 IL-5-secreting	Th2	cells.	The	high	 IL-5	 led	 to	 increased	recruitment	 of	 eosinophils154,	 which	 are	 known	 to	 both	 directly	 modulate	 GI	pathology	 and	 also	 release	 IL-6	 that	 can	 drive	 increased	 in	 situ	 differentiation	 of	Th17	 cells68.	 	 Thus,	mice	 deficient	 in	 both	 Ndfip1	 and	 IL-4	would	 be	 expected	 to	show	decreases	 in	Th17	generation	due	 to	 a	 loss	 of	 the	upstream	 IL-4-dependent	processes.	Correspondingly,	 the	 study	 showed	 that	Ndfip1	 IL-4	DKO	animals	have	decreased	lung	eosinophil	recruitment,	decreased	serum	IL-6	and	some	reduction	in	the	frequency	of	Th17	cells.	However	the	study	failed	to	address	whether	the	slight	apparent	reduction	 in	Th17	cells	 in	the	DKO	animals	was	different	 from	the	 levels	observed	in	an	Ndfip1-deficient	animal	if	quantified	for	several	animals,	or	whether	CD4	T	cells	that	have	already	differentiated	in	to	Th17	cells	require	Ndfip1	for	their	function.		
Lastly,	 one	 study	 examined	CD8	T	 cell	 identity	 and	 function	 in	mice	which	lack	Ndfip1	globally	or	in	the	T	cell	compartment	(Ndfip1	cKO	mice)	and	determined	that	CD8	T	cells	in	these	mice	have	an	activation	and	virtual	memory	phenotype	that	is	a	completely	CD8-extrinsic	and	results	 from	the	 IL-4	rich	environment	 in	which	these	 CD8	 T	 cells	 develop156.	 	 The	 phenotype	 was	 reversed	 in	 Ndfip1	 IL-4	 DKO	animals,	showing	that	it	was	IL-4	dependent.	
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These	 previous	 studies	make	 it	 evident	 that	 Ndfip1	 is	 important	 in	 CD4	 T	cells	 for	 dampening	 activation	 in	 two	ways.	 One,	 Ndfip1	 regulates	 the	 timed	 and	orderly	cell	exit	from	the	cell	cycle,	and	two,	enforces	dependency	on	CD28	in	order	to	 prevent	 autocrine	 IL-2	 production	 that	would	 bypass	 or	 decrease	 the	 need	 for	CD28	in	T	cell	activation.	Furthermore,	Ndfip1	represses	T	cell	proliferation	in	order	to	limit	the	numbers	of	different	T	cell	populations.	
Investigating	 a	 cell-autonomous	 role	 for	 Ndfip1	 in	 Th17	 and	 Treg	 cells	
requires	new	mouse	models		 However,	 despite	 all	 that	 is	 known	 about	 Ndfip1’s	 action	 in	 T	 cells,	 it	 is	unclear	 whether	 Ndfip1	 has	 roles	 in	 other	 CD4	 T	 cell	 subsets	 independent	 of	 its	influence	on	Th2	cells,	and	importantly,	whether	Ndfip1	is	 important	in	CD4	T	cell	subsets	 beyond	 the	 differentiation	 step.	 Ndfip1’s	 role	 in	 limiting	 IL-4	 production	from	 Th2	 cells	 demonstrably	 affects	 multiple	 other	 immune	 cell	 types	 and	 has	hampered	the	ability	to	investigate	a	Th2-independent	role	for	Ndfip1	in	other	CD4	T	cell	subsets.		Therefore,	for	my	thesis	work,	I	wanted	to	determine	if	there	was	a	role	 for	 Ndfip1	 in	 the	 function	 of	 Th17	 and	 Treg	 cells.	 I	 needed	 two	models	 that	would	permit	the	study	of	Th17	and	Treg	cells	in	the	absence	of	excessive	Th2	cells.	For	Th17	cells,	I	used	mice	that	lack	both	the	Ndfip1	gene	and	the	IL-4	gene	(Ndfip1	IL-4	 DKO)	 since	 IL-4KO	 animals	 have	 very	 little	 to	 no	 Th2	 cells68,157,158.	 To	 study	Treg	 cells,	 we	 used	 mice	 that	 are	 sufficient	 for	 Ndfip1	 in	 all	 cells	 in	 the	 body	(including	Th2	cells)	but	lack	Ndfip1	in	Foxp3+	Treg	cells.		With	these	tools	in	hand,	
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I	began	investigating	whether	Ndfip1	plays	a	cell-autonomous	role	in	regulating	the	numbers	and	function	of	Th17	and	Treg	cells.	
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CHAPTER	2:	Ndfip1	drives	RORγT	degradation	to	limit	Th17	cell	
pathogenicity	and	prevent	spontaneous	inflammatory	disease2		
Introduction	
Since	their	discovery	over	a	decade	ago,	Th17	cells,	or	CD4+	T	cells	producing	the	 signature	 cytokine	 IL-17A,	have	been	determined	 to	play	an	 important	 role	 in	defense	 against	 fungal	 and	 extracellular	 pathogens60–62.	 Th17	 cells	 express	 the	transcription	 factors	 RORγT66,	 RORα67	 and	 STAT3159,160	 and	 can	 secrete	 several	additional	 cytokines	 including	 IL-17F,	 IL-22,	 IFNγ	 and	 TNFα.	 Humans	 bearing	mutations	 that	 prevent	 Th17	 cell	 differentiation	 or	 IL-17	 receptor	 signaling,	 are	susceptible	 to	 fatal	 candidiasis65,161–163	 indicating	 the	 importance	 of	 Th17	 cells	 in	anti-fungal	immunity.	On	the	other	hand,	increased	numbers	of	Th17	cells	in	certain	inflammatory	 disorders	 have	 been	 correlated	with	 disease	 severity.	 This	 includes	conditions	 such	 as	 Crohn’s	 disease,	 multiple	 sclerosis,	 rheumatoid	 arthritis,	psoriasis	 and	psoriatic	 arthritis.	Blocking	antibodies	 that	 target	 IL-17A	or	 IL-23,	 a	cytokine	that	increases	Th17	cell	numbers,	have	been	used	in	clinical	trials	for	these	diseases,	 with	 mixed	 results164,165.	 In	 some	 cases,	 treatment	 has	 led	 to	 increased	susceptibility	 to	 infection166–168.	 Thus,	 identifying	 ways	 to	 adjust	 the	 potency	 of	Th17	cell	pathogenicity	may	be	of	therapeutic	benefit.		 	 	
In	 most	 cases,	 it	 is	 not	 known	 how	 the	 Th17	 cells	 that	 drive	autoinflammatory	 diseases	 develop;	 whether	 they	 develop	 from	 previously																																									 																					2This	chapter	has	previously	been	published	as:	Layman,	A.	A.	K.,	Sprout,	S.	L.,	Phillips,	D.	&	Oliver,	P.	M.	Ndfip1	restricts	Th17	cell	potency	by	limiting	lineage	stability	and	proinflammatory	cytokine	production.	Sci.	Rep.	7,	39649	(2017)	
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functional	Th17	cells	that	become	dysregulated	or	whether	they	can	be	identified	ab	
initio	based	on	unique	characteristics.	In	support	of	the	hypothesis	that	pathogenic	Th17	cells	may	be	programmed	to	be	pathogenic	at	their	induction,	it	is	thought	that	the	 inflammatory	 conditions	under	which	 a	Th17	 cells	 is	 generated	may	 affect	 its	pathogenicity.	 Related	 to	 this,	 some	 factors	 that	 are	 reported	 to	 influence	 the	pathogenic	 potency	 of	 Th17	 cells	 include	 their	 exposure	 to	 IL-23	 during	differentiation.	 Such	 exposure	 results	 in	 the	 formation	 of	 a	 complex	 that	 contains	the	 transcription	 factors	 Blimp1,	 RORγT,	 STAT3,	 p300,	 HIF1α,	 BATF	 and	 IRF4.	Together,	 these	 factors	 cooperate	 to	 drive	 the	 expression	 of	 genes	 such	 as	 Il17a,	
Il23r	 and	Csf265,169.	Furthermore,	pathogenic	Th17s	have	been	reported	 to	 show	a	gene	profile	that	includes	Tbx21,	Csf2	and	Ccl5	(Rantes),	among	others77.	Csf2-driven	GM-CSF	production	in	particular	is	thought	to	be	important	for	the	pathogenicity	of	Th17	 cells,	 especially	 in	 disease	 models	 such	 as	 Experimental	 Autoimmune	Encephalomyelitis	(EAE)79,80.	 IFNγ	expression	by	Th17	cells,	which	can	be	 induced	by	 IL-23	 signaling	 and/or	high	 levels	 of	Tbx21,	 is	 also	 associated	with	worse	EAE	and	 colitis,	 in	 models	 of	 multiple	 sclerosis	 and	 Inflammatory	 Bowel	 Disease	(IBD)170,171.	Defining	mechanisms	that	restrict	these	factors	and	thus	limit	Th17	cell	pathogenicity	 could	 aid	 the	 development	 of	 therapeutics	 that	 could	 reduce	 the	pathogenic	potency	of	Th17	cells.		
Ubiquitylation	 of	 transcription	 factors	 and	 lineage-defining	 proteins	 is	 one	under-appreciated	means	of	regulating	the	differentiation	and	function	of	T	helper	subsets,	 including	 Th17	 cells.172.	 Surprisingly	 little	 is	 known	 about	 how	
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ubiquitylation	 of	 proteins	 affects	 the	 generation	 of	 pathogenic	 versus	 non-pathogenic	 Th17	 cells.	 Ndfip1	 has	 been	 indirectly	 implicated	 in	 the	 regulation	 of	Th17	cells.	It	has	been	shown	that	excessive	IL-4	production	from	Ndfip1-deficient	Th2	cells	drives	tissue	damage	and	eosinophilia,	which	in	turn	leads	to	an	increase	in	secreted	factors	such	as	IL-6,	and	favors	in	vivo	Th17	generation68.	However,	it	is	unknown	whether	Ndfip1	has	direct	roles	within	Th17s.	Very	recently,	the	catalytic	E3	 ligase,	 Itch,	 was	 shown	 to	 ubiquitylate	 RORγT,	 driving	 its	 degradation	 and	helping	 to	 limit	 the	 generation	 of	 Th17	 cells	 in	 the	 colon173.	 However,	 it	 remains	unclear	how	the	increased	levels	of	RORγT	that	occur	in	the	absence	of	Itch	impact	Th17	cell	function.	 	 	 	 	 	 	 	 	 	
In	 this	 study,	 we	 show	 that	 Ndfip1	 or	 Itch	 E3	 ligase	 deficiency	 drives	 an	increase	in	Th17	cell	numbers	at	barrier	surfaces.	Increased	Th17	cell	abundance	in	Itch-	 or	Ndfip1-deficient	 animals	 does	not	 depend	on	 the	well-characterized	 roles	for	these	two	proteins	in	T	cell	activation	or	in	IL-4-mediated	inflammation.	Ndfip1	and	Itch	do	not	control	the	numbers	of	cells	differentiating	into	Th17	cells	in	vitro.	Rather,	they	limit	the	production	of	cytokines	by	the	cells	following	differentiation.	As	with	their	 Itch-deficient	counterparts,	Ndfip1-deficient	Th17	cells	are	unable	to	degrade	 RORγT	 upon	 T	 cell	 stimulation,	 and	 increased	 RORγT	 correlated	with	 an	elevated	 production	 of	 the	 proinflammatory	 cytokines	 IL-17A,	 IFNγ	 or	 GM-CSF	 in	
vivo,	 Th17	 cells	 lacking	 Ndfip1	 were	 more	 likely	 than	 their	 WT	 counterparts	 to	maintain	 lineage	 commitment,	 based	 on	 production	 of	 IL-17A,	 were	 much	 more	likely	 to	 co-produce	 other	 pathogenic	 cytokines,	 and	 caused	 more	 severe	 colitis.	
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Thus,	 Th17	 cells	 require	Ndfip1	 and	 Itch	 to	 limit	 RORγT	 levels	 and	 prevent	 Th17	cells	from	causing	severe	tissue	inflammation	and	inflammatory	bowel	disease.		
Results	
Loss	of	Ndfip1	results	in	a	T	cell-intrinsic	increase	in	Th17	cell	numbers		Naïve	CD4	T	cells	differentiate	into	Th17	cells	at	mucosal	surfaces	such	as	the	lung	and	colon	in	response	to	TCR	stimulation,	co-stimulation,	and	the	availability	of	lineage-instructing	 cytokines	 including	 TGFβ,	 IL-6,	 IL-1β	 and	 IL-23174–176.	Downstream	 of	 these	 signals,	 proteins	 such	 as	 RORγT,	 BATF	 and	 STAT3	 are	produced	to	drive	the	transcription	and	translation	of	proteins	that	are	needed	for	establishing	and	maintaining	Th17	identity65.	 	 	 	
In	 Ndfip1-deficient	 animals,	 tissue	 destruction	 mediated	 by	 potent	 IL-4	producing	Th2	cells	has	been	shown	to	cause	increased	IL-6	at	tissue	sites,	and	this	is	thought	to	drive	an	increase	in	mucosal	Th17	generation	in	vivo	154.	However,	it	is	also	possible	that	this	increase	in	Th17	cells	may	be	due	to	a	loss	of	Ndfip1	within	the	T	cell	lineage.	To	investigate	how	Ndfip1	functions	within	CD4	T	cells	to	limit	the	abundance	of	Th17	cells,	we	first	compared	the	Th17	cell	(CD4+	IL-17A+)	frequency	and	number	in	mice	which	constitutively	lack	Ndfip1	to	those	that	lack	Ndfip1	only	in	T	cells	 (Ndfip1fl/fl	CD4-Cre,	referred	to	as	cKO	mice).	Consistent	with	previously	published	 data,	 we	 found	 an	 increase	 in	 the	 frequency	 of	 Th17	 cells	 in	 the	 lungs	(Fig.	2.1,	a,	b)	of	mice	constitutively	lacking	Ndfip1	over	WT	controls.	Importantly,	with	 T	 cell-specific	 deletion	 of	 Ndfip1,	 we	 found	 similarly	 increased	 numbers	 of	
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Th17	cells.	An	increase	in	IFNγ+	CD4	T	cells	in	the	lungs	has	also	been	described153,	supporting	 the	 possibility	 that	 Ndfip1	 regulates	 IFNγ+	 and	 IL-17A+	 cells	 via	 a	similar	mechanism.	 Consistent	 with	 this,	 both	 Ndfip1-deficient	 animals,	 and	mice	with	the	T	cell-specific	deletion	in	Ndfip1,	also	showed	an	increase	in	IFNγ+	CD4	T	cells	in	the	lungs	compared	to	the	WT	controls	(Fig.	2.1c).	These	data	reveal	that	a	loss	of	Ndfip1	 in	T	cells	can	 lead	to	an	 increase	 in	numbers	of	both	Th17	and	Th1	cells.
	
FIGURE	2.1	Ndfip1	limits	the	abundance	of	Th17	cells.		Flow	cytometric	 analysis	of	CD3+	CD4+	T	 cells	 among	cells	 isolated	 from	 lungs	of	wild	 type	 (WT),	Ndfip1	knockout	(KO),	or	Ndfip1fl/fl	CD4-Cre	(cKO)	animals.	Percentages	of	 lung	CD4+	T	cells	 that	are	 IL-17A+	(a,b)	or	 IFNγ+	(a,	c).	n=8-11	animals	per	genotype,	analyzed	at	7-9	weeks	of	age	 in	7	independent	 experiments	 using	 one-way	 ANOVA	 and	 Holm-Sidak's	 multiple	 comparisons	 test.	*p<0.05,	**p<0.01,	***p<0.001,	****p<0.0001.	All	error	bars	represent	mean	±	SEM	Mice	 that	 lack	 Ndfip1	 constitutively,	 or	 in	 the	 T	 cell	 compartment,	 contain	 high	numbers	of	CD44+	CD4+T	cells25,153,155.	In	order	to	become	a	Th17	cell,	a	naïve	CD4	T	cell	must	first	become	an	activated,	CD44+	cell.	Thus,	we	next	tested	whether	the	increase	 in	Th17	cells	was	due	to	 increased	T	cell	activation.	We	gated	exclusively	on	CD44+	CD4	T	cells	 (Fig.	2.2a)	and	then	determined	 frequency	of	 IL-17A+	or	of	IFNγ+	cells.	For	Th17	cells,	even	after	 limiting	our	analysis	to	CD44+	cells,	Ndfip1-deficient	 T	 cells	 were	 significantly	 more	 likely	 to	 produce	 IL-17A	 (Fig.	 2.2b).	 In	contrast,	when	we	gated	in	this	manner,	WT	and	Ndfip1-deficient	T	cells	were	less	
IF
N
γ 14.8
3.97
14.2
4.88
4.88
1.13  %
C
D
4
+
 
T
 c
e
lls
IL-17A
0
10
20
30
40
***
***
0
2
4
6
8
10 **
**
a b cIL-17A IFNγ
 %
C
D
4
+
 
T
 c
e
lls
0.12 0.99 0.17
WT Ndfip1 KO Ndfip1 cKO
WT cKO KO WT cKO KO
32	
likely	to	be	IFNγ+	Th1	cells,	but	this	difference	was	not	significant	(Fig.	2.2c).	Taken	together	these	data	support	that	Ndfip1	regulates	both	Th1	and	Th17	cell	numbers	via	limiting	T	cell	activation.	However,	these	data	also	support	that	Ndfip1	imposes	additional	restrictions	that	selectively	limit	Th17	cell	abundance.		
	
FIGURE	2.2	Ndfip1	limits	the	abundance	of	activated	Th17	cells.		(a)	Flow	cytometric	analysis	of	CD3+	CD4+	T	cells	among	cells	isolated	from	lungs	of	wild	type	(WT),	Ndfip1	knockout	(KO),	or	Ndfip1fl/fl	CD4-Cre	(cKO)	animals.	Percentages	of	CD44+	CD4+	cells	 that	are	IL-17A+	(b)	or	IFNγ+	(c)	in	a	pooled	cohort.	n=8-11	animals	per	genotype,	analyzed	at	7-9	weeks	of	age	in	7	independent	experiments	using	one-way	ANOVA	and	Holm-Sidak's	multiple	comparisons	test.	*p<0.05,	**p<0.01,	***p<0.001,	****p<0.0001.	All	error	bars	represent	mean	±	SEM.	Ndfip1-deficient	CD4+	T	cells	secrete	excess	IL-425,117,177	and	this	can	impact	the	differentiation	of	alternate	cell	fates	or	affect	the	activation	state	of	T	cells.	For	Th17	 cells,	 IL-4	 has	 been	 shown	 to	 both	 promote	 or	 inhibit	 their	differentiation68,174,176,178.	 To	 determine	 whether	 IL-4	 was	 responsible	 for	 the	increased	Th17	cell	frequencies	in	Ndfip1-deficient	animals,	we	analyzed	Th17	cells	in	mice	 that	 lack	 both	 IL-4	 and	Ndfip1	 (Ndfip1	 IL-4	DKO	 animals).	 In	 the	 IL-4KO	controls,	 as	 in	WT	animals,	 there	were	 very	 few	 (<1%)	Th17	 cells	 in	 the	 lungs	 at	steady	 state.	 However,	 in	 Ndfip1	 IL-4	 DKO	 animals,	 we	 observed	 increased	frequencies	 of	 Th17	 cells	 (Fig.	 2.3a,b)	 as	 well	 as	 IFNγ+	 CD4	 cells	 (Fig.	 2.3c).	Consistent	with	our	prior	findings,	when	only	CD44+	CD4+	T	cells	were	considered,	DKO	 T	 cells	 were	 more	 likely	 to	 produce	 IL-17A	 (Fig.	 2.3d),	 but	 there	 was	 no	
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difference	in	the	percentage	of	cells	that	made	IFNγ+	(Fig.	2.3e).	This	indicated	that	Ndfip1	limits	Th17	cell	numbers	via	an	IL-4	independent	mechanism.	 	 	
	
FIGURE	2.3	Ndfip1	limits	the	abundance	of	Th17	cells,	independent	of	IL-4. 	
	Flow	cytometric	analysis	of	CD3+	CD4+	T	cells	 from	lungs	of	Ndfip1-/- IL-4-/- (DKO)	mice	or	 IL-4-/- (IL-4KO)	 controls,	 showing	 representative	 (a)	 or	 combined	 (b-e)	 data	 from	multiple	 experiments.	Percentages	 of	 lung	 IL-17A+	 (b)	 or	 IFNγ+	 (c)	 CD4+	 T	 cells.	 (d-e)	 Percentages	 of	 CD44+	 cells	 that	produce	 IL-17A+	 (d)	 or	 IFNγ+.	 (e).	 n=9-11	 animals	 per	 genotype	 analyzed	 at	 6-16	weeks	 old	 in	 4	independent	experiments	using	an	unpaired	T	test.	*p<0.05,	**p<0.01,	***p<0.001,	****p<0.0001.	All	error	bars	represent	mean	±	SEM.	Ndfip1	restriction	of	Th17	cell	numbers	could	be	intrinsic,	due	to	the	loss	of	Ndfip1	within	Th17	cells,	or	extrinsic,	due	 to	 factors	produced	by	Ndfip1-deficient	T	cells	that	drive	 in	vivo	Th17	generation.	To	distinguish	between	 these	 two	possibilities,	we	 generated	 mixed	 chimera	 animals	 in	 which	 Ndfip1-sufficient	 IL-4	 KO	 and	Ndfip1-deficient	DKO	Th17	cells	would	develop	in	the	same	cytokine	milieu.	Even	in	this	 mixed	 setting,	 we	 found	 similar	 results:	 Ndfip1-deficient	 T	 cells	 were	 more	likely	to	be	IL-17A+	(Fig.	2.4a)	and	IFNγ+	(Fig.	2.4b),	and	while	activation	could	not	account	 for	 the	 increased	 Th17	 cells	 (Fig.	 2.4c),	 it	 explained	 the	 increased	 IFNγ+	cells	(Fig.	2.4d).	Taken	together,	these	data	support	that	Ndfip1	limits	the	numbers	
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of	Th17	cells	in	a	T	cell	intrinsic	manner	via	a	mechanism	that	is	not	shared	between	Th1	and	Th17	cells,	and	is	independent	of	IL-4	mediated	inflammation.	
	
FIGURE	2.4	Ndfip1	regulates	Th17	cell	abundance	via	a	cell-intrinsic	mechanism.		 	Flow	 cytometric	 analysis	 of	 CD3+	 CD4+	 T	 cells	 from	 lungs	 of	 CD45.1	 IL-4-/- (IL-4KO)	 and	 CD45.2	Ndfip1-/- IL-4-/- (DKO)	mixed	chimeras.	(a-d)	Percentages	of	lung	IL-17A+	(a)	or	IFNγ+	(b)	producing	cells	 of	 CD45.2	 DKO	 or	 CD45.1	 IL-4KO	 origin.	 (c-d)	 Percentages	 of	 IL-17A+	 (c)	 or	 IFNγ+	 (d)	 cells	among	CD44+	T	cells	of	CD45.2	DKO	or	CD45.1	 IL-4KO	origin.	n=13	mixed	chimera	animals	at	7-8	weeks	 old	 in	 2	 independent	 experiments	 using	 a	 paired	 t	 test.*p<0.05,	 **p<0.01,	 ***p<0.001,	****p<0.0001.	All	error	bars	represent	mean	±	SEM.	
Ndfip1	does	not	limit	the	differentiation	of	Th17	cells	in	vitro 	The	 increased	 numbers	 of	 Th17	 cells	 in	 Ndfip1-deficient	 animals	 could	reflect	an	increase	in	the	ability	of	naïve	CD4	T	cells	to	differentiate	into	Th17	cells	or	 an	 expansion	 of	 existing	 Th17	 cells,	 or	 both.	 Thus,	 we	 examined	 Th17	differentiation	 in	 vitro.	 Again,	 to	 eliminate	 the	 confounding	 presence	 of	 IL-4,	 we	used	Ndfip1	 IL-4	DKO	or	 IL-4KO	CD4+	T	 cells.	When	we	differentiated	Th17	 cells	using	 TGF-β,	 IL-6,	 IL-1β	 and	 IL-23,	 Ndfip1	 IL-4	 DKO	 cells	 were	 just	 as	 likely	 as	controls	cells	to	become	IL17A+	cells	(Fig.	2.5a).	We	then	tested	different	mixtures	of	 cytokines	 and	 found	 the	 same	 result	 (Fig.	 2.5b).	 Next,	 to	 determine	 whether	Ndfip1-deficient	CD4	T	cells	were	more	likely	than	controls	to	become	IL-17A+	cells	when	stimulated	with	a	particular	strength	of	TCR	signal,	we	tested	altered	peptide	ligands	 with	 B3K	 TCR	 transgenic	 (B3K-Tg+)	 T	 cells179.	 In	 this	 model,	 B3K-Tg+	
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animals	contain	CD4	T	cells	with	a	fixed	T	cell	receptor	that	recognizes	the	foreign	peptide,	3K,	in	the	context	of	I-Ab	(MHC	II).	By	creating	amino	acid	substitutions	of	the	3K	peptide,	altered	peptides	have	been	generated	which	have	 low,	medium	or	high	T	cell	activation	potency180.	We	generated	Ndfip1+/+	(WT)	or	Ndfip1-/- B3K-Tg+	animals	on	a	RAG1-/-	background,	and	used	a	low	potency	(p-1K),	medium	potency	(p-1A)	 or	 high	 potency	 (p3K)	 peptides	 to	 stimulate	 the	 cells.	 We	 found	 that	increasing	 peptide	 potency	 drove	 higher	 in	 vitro Th17	 generation	 (Fig.	 2.6a,b).	However,	 Ndfip1-/- and	 WT	 CD4	 T	 cells	 were	 equally	 likely	 to	 become	 Th17s.	Therefore	Ndfip1	does	not	restrict	in	vitro Th17	differentiation.	
	
	
FIGURE	2.5	Ndfip1	does	not	limit	the	differentiation	of	Th17	cells	in	vitro.		Naïve	sorted	CD4+	T	cells	 from	IL-4	KO	or	Ndfip1	 IL-4	DKO	animals	were	cultured	under	various	 Th17-polarizing	 conditions	 for	 5	 days	 as	 noted.	 (a)	 Representative	 Th17	differentiation	 using	 IL-1β,	 IL-23,	 TGFβ,	 and	 IL-6.	 (b)	 Average	 percentages	 of	 Th17	 cells	generated	 with	 different	 combinations	 of	 TGFβ,	 IL-6,	 IL-1β	 and	 IL-23.	 n=5	 animals	 per	group	 in	 at	 least	 three	 independent	 experiments,	 and	 statistical	 significance	 was	 tested	using	a	using	2-way	ANOVA.	All	error	bars	represent	mean	±	SEM.		
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FIGURE	 2.6	 Ndfip1-deficient	 naïve	 CD4	T	 cells	 do	 not	 have	 altered	 sensitivity	 to	 TCR	 signal	
strength	during	Th17	differentiation.		T	 cells	 from	Ndfip1	KO	RAG1-/- B3K+	or	RAG1-/- B3K+	 control	 animals	were	 incubated	with	APCs	pulsed	with	 peptides	 of	 low	 (p-1K),	medium	 (p-1A)	 or	 high	 (p-3K)	 TCR-stimulating	 potency	 for	 5	days	 under	 Th17	 polarizing	 conditions.	 (a)	 Representative	 plots	 showing	 Th17	 generation.	 (b)	Combined	data	 for	multiple	experiments.	Data	 is	 from	2	 independent	experiments.	Analyzed	via	2-way	ANOVA.	All	error	bars	represent	mean	±	SEM.	
Ndfip1-deficient	Th17	cells	are	more	proliferative	and	accumulate	in	vivo		To	 understand	why	Ndfip1–deficient	 Th17	 cells	 numbers	were	 elevated	 in	
vivo,	 we	 returned	 to	 the	 mixed	 bone	 marrow	 chimera	 model	 to	 test	 Ndfip1-	sufficient	 (CD45.1+)	 and	 -deficient	 (CD45.2+)	Th17	 cells	 that	develop	 in	 the	 same	cytokine	 environment.	 After	 reconstitution,	 we	 treated	 mice	 with	 5-bromo-2'-deoxyuridine	 (BrdU)	 to	 assess	 cell	 cycle.	 Following	 treatment,	 cells	were	 isolated	from	the	lungs	of	mice	and	analyzed	by	flow	cytometry.	Consistent	with	published	data153,	we	 found	 that	CD4	T	 cells	 that	 lack	Ndfip1	were	more	 likely	 than	 control	cells	 to	undergo	proliferation	 in	 vivo	 (Fig.	2.7a,c).	BrdU+	Ndfip1-sufficient	 cells	 in	the	 lung	 were	 not	 more	 likely	 to	 be	 Th17	 cells	 (Fig.	 2.7a-b),	 but	 BrdU+	 Ndfip1-
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37	
deficient	 cells	were	more	 likely	 to	be	Th17	cells	 (Fig.	2.7c-d).	These	data	 support	that	cells	 lacking	Ndfip1	are	highly	proliferative	and	that	Ndfip1-deficient	cells	are	more	 likely	 to	 produce	 IL-17A	 compared	 to	 Ndfip1-sufficient	 cells.	 Furthermore,	Ndfip1-deficient	T	cells	are	more	likely	to	make	IL-17A	than	IFNγ.		 	
	
FIGURE	2.7	Ndfip1-deficient	Th17	cells	have	intrinsic	in	vivo	fitness.		CD45.2	 Ndfip1	 IL-4	 DKO	 and	 CD45.1	 IL-4KO	 bone	marrow	was	 injected	 into	 RAG1-/- animals	 and	BrdU	was	administered	3	days	prior	to	harvest.	BrdU+	CD4+	cells	in	the	lungs	were	examined	by	flow	cytometry.	(a)	A	representative	plot	showing	the	percentages	of	CD45.1	IL-4KO	BrdU+	T	cells	in	the	lung	as	well	as	their	production	of	IL-17A	or	IFNγ.	(b)	The	percentages	of	IL-17A	or	IFNγ	producing	cells	 from	multiple	mice.	(c-d)	Same	as	 in	a	and	b	but	showing	percentages	for	CD45.2	DKO	BrdU+	cells	in	the	lung.	n=12	mixed	chimera	animals	in	2	independent	experiments.	Statistical	significance	was	 calculated	 by	 paired	 two-tailed	 T	 tests.	 *p<0.05,	 **p<0.01,****p<0.0001.	 Error	 bars	 represent	mean	±	SEM.	Note:	data	in	Fig.	2.7b	does	not	reach	significance.	I	mistakenly	placed	an	error	bar	
in	the	printed	journal	article	version	of	this	data!	We	next	used	a	mixed	T	cell-transfer	model	to	test	the	capacity	of	Ndfip1-sufficient	and	 -deficient	 Th17	 cells	 to	 accumulate	 in	 a	 setting	 in	 which	 T	 cells	 of	 both	genotypes	 were	 similarly	 activated.	 To	 assess	 this,	 congenically	 marked	 CD45.1	Ndfip1-sufficient	and	CD45.2	Ndfip1-deficient	T	cells	(both	sets	of	cells	also	lack	IL-4	 to	 eliminate	 any	 confounding	 effects	 of	 IL-4-driven	 inflammation)	 were	
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transferred	into	RAG1-/- recipient	mice.	Since	IL-17A	and	IFNγ	are	the	predominant	cytokines	 expressed	 by	 T	 cells	 in	 this	 system,	 we	 could	 examine	 how	 the	 loss	 of	Ndfip1	 impacts	 the	 numbers	 of	 CD4	 T	 cells	 that	 express	 these	 cytokines.	Importantly,	 this	 was	 a	 system	 in	 which	 even	 control	 cells	 would	 generate	 a	measurable	 population	 of	 Th17	 cells	 so	 that	 we	 could	 better	 compare	 Ndfip1-sufficient	 and	 Ndfip1-deficient	 Th17s	 in	 the	 same	 environment.	 Naïve	 sorted	Ndfip1-sufficient	 (CD45.1)	and	 -deficient	 (CD45.2)	CD4+	cells	were	mixed	at	a	1:1	ratio	 and	 injected	 into	 RAG1-/- animals	 and	 7	 weeks	 after	 transfer,	 animals	 were	analyzed.	 Ndfip1-deficient	 T	 cells	 (CD45.2+)	 outcompeted	 their	 Ndfip1-sufficient	counterparts	 (CD45.1+)	 in	 the	 lungs	 (Fig.	 2.8a,b).	 Furthermore,	 if	 we	 gated	specifically	 on	 Th17	 cells,	 we	 found	 they	 were	 much	 more	 likely	 to	 be	 Ndfip1-deficient	(Fig.	2.8c,d)	and	this	was	true	even	after	normalization	for	the	differences	in	CD4	cell	frequency	(Fig.	2.8e).	IFNγ+	cells	were	less	likely	to	be	Ndfip1-deficient	if	frequencies	were	normalized	in	this	manner	(Fig.	2.8f).	Thus,	Ndfip1-deficient	Th17	cells	are	able	to	outnumber	control	cells	when	generated	in	the	same	setting	in	vivo.	We	also	performed	similar	transfers	but	instead	placed	Ndfip1-deficient	and	control	T	 cells	 (both	 were	 IL-4-deficient	 to	 eliminate	 any	 effect	 of	 IL-4-mediated	inflammation	 on	 Th17	 cell	 generation	 in	 vivo)	 into	 separate	 RAG1-/- recipients.	Animals	 that	 received	 Ndfip1-deficient	 cells	 lost	 much	 more	 of	 their	 initial	 body	weight	 than	 those	 that	 received	 control	 cells	 (Fig.	 2.9a).	 Furthermore,	 recipient	animals	that	received	T	cells	lacking	Ndfip1	showed	a	higher	spleen	weight	to	body	weight	 ratio,	 (Fig.	 2.9b),	 increased	 lung	 cellularity,	 and	 had	 significantly	 higher	percentages	 and	 numbers	 of	 Th17	 cells	 in	 their	 lungs	 (Fig.	 2.9c).	 These	 data	 are	
39	
consistent	 with	 the	 hypothesis	 that	 Ndfip1	 deficient	 Th17	 cells	 accumulate	 and	drive	more	pathology	in	vivo.		
	
FIGURE	2.8	Ndfip1-deficient	naïve	CD4	T	cells	outcompete	WT	and	generate	more	Th17	cells	
after	an	adoptive	transfer.		1:1	mixtures	of	naïve	sorted,	CD4+	T	cells	from	Ndfip1	IL-4	DKO	and	IL-4KO	were	injected	into	RAG1-/- animals.	After	7-8	weeks,	cells	were	isolated	from	the	lungs,	stimulated	with	PMA/Ionomycin,	and	analyzed	using	flow	cytometry.	(a)	Percentages	of	CD45.2	DKO	versus	CD45.1	IL-4KO	CD4+	T	cells	in	the	injection	mixture	and	in	the	lungs	at	analysis.	(b)	Ratio	of	frequencies	of	CD45.2+	versus	CD45.1+	CD4+	T	cells	in	the	lungs	at	harvest,	compared	to	the	ratio	in	the	input	injection	mixture.	(c-d)	Total	Th17	cells	 in	 the	 lungs	and	the	 frequencies	of	CD45.1	or	CD45.2	among	Th17	cells.	 (e)	Normalized	ratio	of	percentages	of	congenic	Th17	cells	relative	to	CD4+	cells	bearing	each	congenic	marker.	(f)	The	 same	 analysis	 as	 in	 panel	 e	 but	 focused	 on	 Th1	 cells.	 n=11	 animals	 in	 2	 independent	experiments.	Significance	was	calculated	by	paired	T	test.	*p<0.05,	**p<0.01,****p<0.0001.	Error	bars	represent	mean	±	SEM.	
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FIGURE	2.9	Ndfip1-deficient	CD4	T	cells	generate	abundant	Th17	cells	in	vivo	and	drive	colitis.		Sorted	CD4+	CD45RBhi	naïve	T	cells	were	injected	into	RAG-/- recipients.	(a)	Weight	change	relative	to	starting	body	weight.	(b)	Spleen	weight	normalized	for	body	weight	at	harvest.	(c)	Total	number	of	Th17	cells	found	in	the	lungs	of	recipients	of	IL-4KO	or	DKO	T	cells.	n=10	IL-4KO	animals	and	n=9	DKO	animals	 in	 2	 experiments,	 analysis	 by	 unpaired	T	 test.	 *p<0.05,	 **p<0.01,****p<0.0001.	 Error	bars	represent	mean	±	SEM.	
Ndfip1	limits	secretion	of	IL-17A	upon	restimulation	of	Th17	cells		Given	 that	 Th17	 cells	 lacking	 Ndfip1	were	 able	 to	 accumulate	 in	 vivo,	 and	their	 heightened	 frequency	 correlated	with	 increased	 pathology,	we	 hypothesized	that	 Ndfip1-deficient	 Th17	 cells	 could	 be	 potent	 producers	 of	 proinflammatory	cytokines.	Limiting	cytokine	secretion	 from	effector	Th17	cells	and	controlling	 the	formation	 of	 memory	 Th17	 cells	 helps	 to	 ensure	 long-term	 defense	 against	extracellular	 pathogens181,182.	 To	 begin	 to	 determine	 whether	 Ndifp1	 regulates	proinflammatory	 cytokine	 production	 in	 Th17	 cells,	 we	 first	 tested	 when	 Ndfip1	was	expressed	in	Th17	cells	after	TCR	stimulation.	We	generated	Th17	cells	in	vitro,	expanded	 them	 in	 IL-2,	 and	 then	 restimulated	 them	on	plate-bound	 anti-CD3	 and	anti-CD28	 for	 various	 time	points,	 and	 analyzed	Ndfip1	 expression	by	qPCR.	Cells	lacking	 IL-4	 were	 used	 since	 Ndfip1-deficient	 T	 cells	 secrete	 high	 levels	 of	 IL-4	which	inhibit	in	vitro Th17	differentiation68.	We	found	that	Ndfip1	levels	increased	over	the	first	6	hours,	and	then	returned	close	to	base	line	levels	by	24	hours	(Fig.	
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2.10a).	These	data	suggested	that	Ndfip1	might	be	particularly	functional	between	4	and	24	hours	after	restimulation.	To	prepare	for	testing	Th17	producing	cytokines,	we	 first	 wanted	 to	 ensure	 that	 Ndfip1-deficient	 and	 control	 cells	 had	 similar	numbers	of	Th17	cells	 following	 IL-2	expansion.	Thus,	we	 tested	 the	 cells	directly	following	differentiation	and	after	expansion	for	percentages	of	cells	expressing	IL-17A	 and	 IFNγ.	 We	 found,	 as	 in	 prior	 experiments,	 that	 cells	 lacking	 Ndfip1	 and	control	CD4	T	cells	were	equally	likely	to	differentiate	into	Th17	cells	that	expressed	IL-17A	 but	 not	 IFNγ	 (Fig.	 2.10b-c).	 As	 has	 been	 reported183,	 we	 noticed	 a	 slight	decrease	 in	 the	 percentage	 of	 IL-17A+	 cells	 in	 culture	 after	 three	 days	 of	 IL-2	expansion	(Fig.	2.10d-e).	Nevertheless,	 the	decrease	 in	 frequency	of	 IL-17A+	cells	was	quite	similar	in	both	Ndfip1-deficient	and	Ndfip1-sufficient	IL-4	KO	cells	T	cells	and	thus	an	equal	number	of	these	cells	were	placed	on	an	anti-CD3	and	anti-CD28	-coated	plate	for	restimulation.	We	then	examined	the	secretion	of	IL-17A	and	other	proinflammatory	 cytokines	 that	 can	 be	 made	 by	 Th17	 cells.	 By	 6hrs	 post	stimulation,	Th17-polarized	cells	lacking	Ndfip1	had	already	begun	to	secrete	more	IL-17A	 into	 culture,	 compared	 to	 their	 Ndfip1-sufficient	 counterparts	 (Fig.	 2.10f)	and	by	24	hours	 the	 IL-17A	 in	 the	Ndfip1-deficient	Th17	culture	 supernatant	was	significantly	 higher	 than	 in	 cultures	 of	 control	 cells.	 Importantly,	 this	 time	 point	correlated	with	 the	peak	of	Ndfip1	expression	 in	control	cells.	Furthermore,	when	the	supernatant	was	assayed	to	detect	other	Th17-related	cytokines,	we	found	that	the	 Ndfip1	 IL-4	 DKO	 Th17s	 secreted	 more	 IFNγ	 (Fig.	 2.10g)	 and	 GM-CSF	 (Fig.	
2.10h)	 than	 their	Ndfip1-expressing	control	 counterpart	cells.	These	data	 indicate	that	 Ndfip1-deficient	 Th17	 cells	 are	 polyfunctional	 and	 secrete	 more	
42	
proinflammatory	cytokines.	Another	 interpretation	of	the	data,	could	be	that	there	were	 more	 IFNγ+	 Th1	 cells	 in	 the	 Ndfip1-deficient	 cultures	 prior	 to	 stimulation,	however	 the	plots	 in	 Fig.	 2.5a	do	not	 support	 this	 conclusion	 and	when	 the	 same	experiment	was	performed	using	Th1	polarizing	conditions,	we	found	that	Ndfip1-deficient	Th1	cells	secrete	less	IFNγ	than	controls	upon	restimulation	(Fig.	2.10i-j).	Thus,	 we	 conclude	 that	 Ndfip1	 limits	 the	 secretion	 of	 proinflammatory	 cytokines	from	Th17	cells	upon	re-encounter	with	TCR	stimulus.		 	
	
FIGURE	 2.10	 Ndfip1	 limits	 proinflammatory	 cytokine	 production	 from	 Th17	 cells	 upon	
restimulation.		(a)	 Ndfip1	mRNA	 expression,	 relative	 to	 beta	 actin,	 in	 restimulated	 Th17	 cells	 over	multiple	 time	points	indicated.	(b)	Representative	plot	showing	IL-17A+	and	IFNγ+	cells	after	the	initial	5	days	of	Th17	 polarization.	 (c)	 Summary	 data	 for	 (b)	 over	 multiple	 experiments.	 (d)	 Representative	 plot	showing	 IL-17A+	 or	 IFNγ+	 Th17	 cells	 after	 IL-2	 expansion	 of	 cells	 haven	 in	 panels	 b	 and	 c.	 (e)	
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Summary	 of	 data	 over	 multiple	 experiments.	 Cytokines	 were	 analyzed	 by	 ELISA,	 following	restimulation	 of	 the	 Th17	 cells	 (f-h)	 or	 of	 Th1	 cells	 (i-j).	 (f)	 IL-17A	 (g)	 IFNγ	 and	 (h)	 GM-CSF.	 (i)	Representative	 plot	 showing	 Tbet+	 IFNγ+	 Th1	 cells	 after	 Th1	 polarization	 and	 subsequent	 IL-2	expansion	of	 IL-4-/- or	Ndfip1	IL-4	DKO	CD4+	T	cells.	 (j)	Summary	of	 IFNγ	ELISAs	 from	plated	Th1	cells.	In	a-h,	n=8	per	genotype	analyzed	in	4	independent	experiments.	In	i-j,	data	is	pooled	for	n=2	Ndfip1	IL-4	DKO	and	n=3	IL-4-/- animals.	Significance	was	calculated	by	unpaired	T	tests	for	panels	c	and	e	and	by	2-way	ANOVA	for	panels	f-j.	*p<0.05	,***p<0.001.	All	error	bars	represent	mean	±	SEM.	
Ndfip1	mediates	ubiquitylation	and	degradation	of	RORγT	RORγT	 is	 the	 lineage-defining	 transcription	 factor	 for	 Th17	 cells66	 and	 has	been	shown	to	drive	the	production	of	cytokines	such	as	IL-17A66	and	GM-CSF79,80.	Since	 Ndfip1-deficient	 Th17	 cells	 produce	 higher	 amounts	 of	 IL-17A	 and	 GM-CSF	upon	 restimulation,	 we	 hypothesized	 that	 Ndfip1-deficient	 cells	 might	 fail	 to	degrade	RORγT.	Supporting	 this,	 it	was	recently	shown	that	 Itch	ubiquitylates	and	degrades	RORγT173.	Given	that	Ndfip1	can	help	to	activate	Itch	in	T	cells25,	we	tested	whether	in	the	absence	of	Ndfip1,	RORγT	fails	to	be	degraded.	We	generated	Th17	cells	 from	Ndfip1	 IL-4	DKO,	and	 IL-4	KO	control	cells.	We	 then	restimulated	 these	cells	for	0.5	hours	or	4	hours	(Fig.	2.11a)	and	analyzed	lysates	for	levels	of	RORγT.	We	found	that	Ndfip1-sufficient	Th17	cells	decreased	their	levels	of	RORγT	between	0.5	 hours	 and	 4	 hours.	 In	 contrast,	 Th17	 cells	 lacking	 Ndfip1	 maintained	 RORγT	protein	levels	after	stimulation.	To	investigate	whether	the	decrease	seen	in	Ndfip1-sufficient	Th17	cells	was	due	to	RORγT	protein	degradation,	we	stimulated	the	Th17	cells	in	the	presence	of	cycloheximide	(Fig.	2.11b).	Indeed,	IL-4KO	Th17	cells	had	a	significant	loss	of	RORγT	protein	levels	after	4	hours	of	stimulation	in	the	presence	of	 cycloheximide,	 in	contrast,	Ndfip1	 IL-4	DKO	Th17	cells	maintained	 their	RORγT	levels	(Fig.	2.11c).	Taken	together,	these	data	support	that	Ndfip1	is	important	for	normal	RORγT	protein	degradation	after	TCR	stimulation.		
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FIGURE	2.11	Ndfip1	promotes	RORγT	degradation.		Naïve	CD4+	T	cells	were	differentiated	into	Th17	cells	and	then	restimulated	with	αCD3/CD28	(TCR)	for	 0.5hrs	 or	 for	 4hrs	 in	 the	 absence	 (a)	 or	 presence	 (b)	 of	 cycloheximide	 (CHX).	 Lysates	 were	analyzed	 for	 RORγT	 and	 GAPDH	 levels	 using	 western	 blot.	 (c)	 Quantification	 over	 multiple	experiments	of	RORγT	levels	relative	to	GAPDH	loading	control.	n=4	per	genotype	in	3	independent	experiments.	All	error	bars	represent	mean	±	SEM.	
Itch	E3	ligase	is	required	for	restricting	Th17	cell	abundance	in	vivo		Ndfip1	 is	 a	well-known	 activator	 of	 the	 E3	 ligase,	 Itch,	 and	 related	Nedd-4	family	E3	ubiquitin	ligases.	Loss	of	Itch	results	in	a	spontaneous,	auto-inflammatory,	Th2-predominant	disease,	 similar	 to	 that	seen	 in	Ndfip1-deficient	animals26,	albeit	with	a	delayed	onset.	Recently	it	was	shown	that	mice	lacking	Itch	have	colitogenic	Th17	 cells	 which	 secrete	 can	 accelerate	 the	 development	 of	 colon	 cancer173.	 To	investigate	 whether	 Itch,	 like	 Ndfip1,	 is	 required	 for	 the	 regulation	 of	 Th17	 cell	numbers	 and	 cytokine	 production,	 we	 generated	 Itch	 IL-4	 DKO	 animals	 and	examined	 Th17	 cells	 in	 their	 lungs.	 We	 found	 that,	 similar	 to	 mice	 lacking	 both	Ndfip1	and	 IL-4,	 the	absence	of	 Itch	and	 IL-4	 led	 to	an	 increase	 in	Th17	cells	 and	IFNγ+	cells	(Fig.	2.12a-c).	Furthermore,	Itch	IL-4	DKO	CD4+T	cells	were	more	likely	
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to	be	activated	(Fig.	2.12d)	and	while	this	increase	in	activated	cells	could	explain	the	 increase	 in	 IFNγ+	CD4+	T	 cells	 (Fig.	2.12f),	 it	 failed	 to	 explain	 the	 increase	 in	Th17	cells	in	these	animals	(Fig.	2.12e).	Additionally,	as	was	seen	with	the	CD4+	T	cells	 lacking	 Ndfip1,	 there	 was	 no	 increased	 propensity	 towards	 in	 vitro Th17	differentiation	 in	 Itch-deficient	 CD4	 T	 cells	 (Fig.	 2.13a,b).	 However	 upon	 re-stimulation,	Itch-deficient	Th17	cells	were	more	likely	to	secrete	significantly	higher	amounts	of	IL-17A,	IFNγ,	and	GM-CSF	(Fig.	2.13c-e).	These	data	support	that	Ndfip1	and	Itch	limit	Th17	cell	numbers	and	proinflammatory	cytokine	secretion	and	this	is	independent	of	the	established	roles	for	Ndfip1	and	Itch	in	limiting	IL-4	production	from	T	cells	and	in	limiting	T	cell	activation.	
	
FIGURE	2.12	Itch	E3	ligase	is	required	to	restrict	numbers	of	Th17	cells	in	vivo.	Flow	cytometric	analysis	of	lung	cells	from	Itch	IL-4	DKO	mice	or	IL-4KO	controls.	(a)	Percentage	of	IL-17A+	or	IFNγ+	CD4+	cells.	 (b-c)	Percentage	of	 IL-17A+	(b)	or	 IFNγ+	(c)	among	CD3+	CD4+	lung	cells.	 (d-f)	 Percentages	 of	 previously	 activated	 CD44+	 lung	 cells	 among	 CD4+	 T	 cells	 (d)	 and	percentages	of	IL-17A+	(e)	or	IFNγ+	(f)	previously	activated	cells	haven	in	panel	d.	n>6	animals	per	group	in	at	least	2	independent	experiments.	Significance	was	calculated	by	unpaired	t	tests.	*p<0.05,	**p<0.01,***p<0.001,	****p<0.0001.	All	error	bars	represent	mean	±	SEM.	
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FIGURE	2.13	Itch	E3	ligase	restricts	proinflammatory	cytokine	production	from	Th17	cells.		Naïve	 sorted	CD4+	T	cells	were	differentiated	 into	Th17	cells	 for	5	days	and	expanded	 in	 IL-2.	 (a)	Representative	plot	showing	IL-17A+	or	IFNγ+	Th17	cells	after	differentiation.	(b)	Summary	of	Th17	data	over	multiple	experiments.	(c-e)	Cytokines	were	analyzed	using	ELISA	following	restimulation	of	equal	numbers	of	IL-2	expanded	Th17	cells.	(c)	IL-17A	(d)	IFNγ	and	(e)	GM-CSF.	In	all	summarized	plots,	 each	 dot	 represents	 an	 individual	 mouse	 analyzed	 in	 at	 least	 2	 independent	 experiments.	Significance	was	calculated	by	2-way	ANOVA.	*p<0.05,	**p<0.01,***p<0.001,	****p<0.0001.	All	error	bars	represent	mean	±	SEM.	
Ndfip1-deficient	 Th17	 cells	 recruit	 more	 neutrophils	 and	 drive	 severe	
mucosal	barrier	destruction	Secretion	 of	 proinflammatory	 cytokines	 from	 Th17	 cells	 is	 one	 way	 Th17	cells	exert	pathogenic	 functions	 in	vivo.	These	cytokines	act	on	non-hematopoietic	cells	 such	 as	 stromal	 cells,	 leading	 to	 their	 secretion	 of	 proteins,	 including	chemokines,	which	recruit	other	immune	cells	to	sites	of	inflammation.	Additionally,	Th17	 cell	 cytokines	 can	 directly	 recruit	 neutrophils.	 Uncontrolled	 recruitment	 of	immune	 cells	 to	 the	 site	 of	 inflammation	 increases	 the	 likelihood	 of	immunopathology.	Mice	that	constitutively	lack	Ndfip1	develop	inflammation	in	the	small	bowel	and	colon	by	6	weeks	of	age,	characterized	by	increased	frequencies	of	eosinophils,	 likely	as	a	 consequence	of	Th2-inflammation154,	 and	neutrophils.	This	
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inflammation	was	not	seen	when	these	mice	are	bred	onto	a	RAG-/- background	and	therefore	 lack	 B	 and	 T	 cells154.	 We	 examined	 the	 colons	 in	 unmanipulated	 mice	lacking	Ndfip1	only	in	their	T	cells	(cKO)	or	control	animals	at	10	weeks	of	age.	We	observed	spontaneous	disruption	of	the	mucosal	layer	of	the	colon	epithelium	in	the	cKO	 animals	 (Fig.	 2.14a).	 Furthermore,	 colons	 from	 cKO	 mice	 showed	 a	 trend	towards,	 but	 no	 significant,	 decrease	 in	 colon	 length	 (Fig.	 2.14b)	 but	 higher	frequencies	of	neutrophils	(Fig.	2.14c).	However,	since	the	cKO	mice	are	potent	IL-4	producers,	and	IL-4	mediated	 inflammation	can	also	 lead	to	colon	 inflammation,	 it	was	 not	 clear	 whether	 the	 increased	 neutrophils	 in	 the	 colons	 of	 these	unmanipulated	mice	was	driven	by	an	increase	in	Th17	cells	in	these	mice.		 	
	
FIGURE	2.14	Loss	of	Ndfip1	in	T	cells	drives	a	spontaneous	colitis	in	mice.		(a)	Colon	histology	of	 ten	week	old	Ndfip1	 fl/fl	CD4	Cre+	(cKO)	or	WT	(Ndfip1	 fl/fl	Cre-	or	Ndfip1	fl/+	 Cre-)	 animals	 showing	 evidence	 of	 spontaneous	 colon	 inflammation	 in	 cKO	 animals.	 Bars	represent	100um	and	inset	shows	enlarged	version	of	the	boxed	section	of	the	image.	(b)	Ndfip1	fl/fl	CD4	Cre+	 (cKO)	and	WT	animals	do	not	 show	differences	 in	colon	 length.	 (c)	Flow	cytometry	data	indicating	a	trend	towards	increased	CD11b+	CD11c-	Ly6G+	neutrophils	in	the	colons	of	Ndfip1	fl/fl	CD4	Cre+	(cKO)	versus	WT	animals.	Data	 is	shown	for	an	n=	3	Ndfip1	 fl/fl	CD4	Cre	+	and	n=3	WT	(Ndfip1	fl/fl	Cre-	or	Ndfip1	fl/+	Cre-)	animals	at	ten	weeks	old.	All	error	bars	represent	mean	±	SEM.	
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Thus,	 we	 sought	 to	 test	 whether	 the	 increased	 production	 of	proinflammatory	 cytokines	 by	 Th17	 cells	 lacking	 Ndfip1	 would	 drive	 increased	pathology	in	an	environment	free	of	IL-4,	in	order	to	focus	only	on	the	role	of	Ndfip1	in	Th17	cells	and	to	exclude	IL-4-mediated	effects.	To	do	this,	we	generated	Ndfip1-/- IL-4-/- IL-17A-GFP	mice,	and	IL-4-/- IL-17A-GFP	controls,	which	lack	both	Ndfip1	and	IL-4	 and	 harbor	 a	 fluorescent	 GFP-reporter	 that	 identifies,	 and	 thus	 allows	purification	 of,	 Th17	 cells.	 We	 then	 differentiated	 CD4+	 T	 cells	 under	 Th17	polarizing	 conditions,	 as	 detailed	 above,	 sorted	 IL-17A-GFP+	 (Th17)	 cells,	 and	injected	 them	 into	 RAG1-/- recipients	 or	 analyzed	 them	 by	 qPCR	 for	 mRNA	expression.	 We	 found	 that	 Ndfip1-deficient	 Th17	 cells	 have	 higher	 expression	 of	
ccl5	and	csf2	(which	encodes	GM-CSF)	(Fig.	2.15a,	left	and	middle	panels),	factors	associated	 with	 Th17	 cell	 pathogenicity77.	We	 also	 analyzed	 rorc	 (which	 encodes	RORγT),	 which	 was	 not	 different	 between	 Ndfip1-sufficient	 and	 –deficient	 Th17	cells	(Fig.	2.15a,	right	panel),	supporting	that	increased	RORγT	in	Ndfip1-deficient	cells	 is	 not	 due	 to	 increased	 transcription.	 Since	 previous	 data,	 indicating	 that	Ndfip1-deficient	 Th17	 cells	 produce	 more	 IL-17A,	 GM-CSF	 and	 IFNγ	 upon	restimulation	was	generated	using	Th17	cells	that	had	been	expanded	in	IL-2	for	3	days,	 we	 wanted	 to	 verify	 that	 expansion	 in	 IL-2	 does	 not	 significantly	 alter	 the	characteristics	of	the	Ndfip1-deficient	Th17	cells.	Therefore	we	obtained	additional	mRNA	 expression	 data	 from	 Th17	 cells	 generated	 as	 before	 but	 additionally	expanded	 in	 IL-2	 for	 3	 days.	 After	 IL-2	 expansion,	 Ndfip1-deficient	 Th17	 cells	similarly	showed	higher	expression	of	Csf2	and	Ccl5	 (Fig.	2.15b)	and	furthermore,	showed	higher	expression	of	the	Th17-related	cytokines	Ifng	and	Tnfa	but	not	Il21	
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(Fig.	 2.15c)	 compared	 to	Ndfip1-sufficient	 Th17	 cells.	 The	 gene	 expression	 levels	for	 transcription	 factors	 such	 as	 Rorc,	 Tbx21	 (which	 encodes	 T-bet)	 and	 Blimp1,	which	 have	 all	 been	 associated	 with	 Th17	 cell	 pathogenicity,	 were	 not	 different	between	Ndfip1-sufficient	and	–deficient	Th17	cells	(Fig.	2.15d).	Therefore	Ndfip1-deficient	 Th17	 cells	 have	 a	 gene	 expression	 profile	 associated	with	 pathogenicity	and	this	is	not	altered	by	exposure	to	IL-2.	 	
We	 then	 assessed	 the	 function	 of	 these	 cells	 in	 vivo.	 By	 approximately	 6	weeks	after	transfer	of	purified	Th17	cells,	mice	that	received	Ndfip1-deficient	Th17	cells	 had	 lost	 significantly	more	 body	weight	 than	 their	Ndfip1-sufficient	 controls	(Fig.	 2.16a).	 Additionally,	 colon	 histology	 revealed	 that	 recipients	 of	 Ndfip1-deficient	Th17	cells	had	higher	incidence	of	transmural	inflammation	and	erosion	of	normal	 mucosal	 structure	 (Fig.	 2.16b).	 Strikingly,	 in	 all	 recipient	 mice,	 less	 than	20%	 of	 all	 CD4	 T	 cells	 recovered	 from	 the	 colons,	whether	 expressing	 or	 lacking	Ndfip1,	were	still	IL-17A+,	indicating	the	remarkable	instability	of	the	Th17	cells	in	this	 model	 (Fig.	 2.16,	 c	 and	 d).	 However,	 mice	 which	 received	 Ndfip1-deficient	Th17	 cells	 had	 a	 higher	 frequency	 of	 IL-17A+	 cells	 in	 the	 colon,	 suggesting	 that	Ndfip1	 limits	 Th17	 stability	 (Fig.	 2.16c-d).	 Considering	 our	 prior	 results,	we	 also	tested	other	cytokines	produced	by	Th17	cells	 including:	TNFα,	 IFNγ,	GM-CSF	and	IL-10.	We	 found	 that	 Ndfip1-deficient	 CD4	 cells	 in	 the	 colon	were	 not	 only	more	likely	to	be	making	exclusively	IL-17A,	but	we	also	found	more	Ndfip1-deficient	IL-17A+	cells	that	were	simultaneously	making	TNFα,	TNFα	with	IFNγ,	or	GM-CSF	with	IFNγ	 (Fig.	 2.16e).	 Given	 the	 well-described	 role	 of	 TNFα	 and	 IL-17A	 in	 driving	
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neutrophil	recruitment	to	sites	of	inflammation184–189,	we	examined	the	numbers	of	neutrophils	 in	 the	 colons	 of	 the	mice	 that	 received	Ndfip1-deficient	 or	 –sufficient	Th17	cells.	We	found	that	recipients	of	Ndfip1-deficient	Th17	cells	had	significantly	higher	numbers	of	neutrophils	(Fig.	2.16f).	This	was	not	true	for	other	innate	cells	examined	 such	 as	 eosinophils,	 dendritic	 cells,	 or	 monocytes	 (Fig.	 2.16f).	 Thus,	Ndfip1	 limits	 production	 of	 proinflammatory	 cytokines	 such	 as	 IL-17A,	 IFNγ,	 and	TNFα;	Th17	stability;	and	Th17-mediated	pathology.		
	
FIGURE	 2.15	 Th17	 cells	 lacking	 Ndfip1	 have	 a	 gene	 expression	 profile	 associated	 with	
pathogenicity.		CD4+	naïve	cells	from	IL-4	KO	or	DKO	T	cells	from	IL-17A	GFP	reporter	mice	were	differentiated	into	Th17	cells	for	5	days	and	used	for	analysis	(a)	or	expanded	in	IL-2	for	three	days	before	being	used	for	qPCR	analysis	(b-d).	(a)	GFP-IL-17A+	Th17	cells	from	these	cultures	were	sorted	and	analyzed	for	gene	 expression	 via	 qPCR.	 mRNA	 expression	 for	 ccl5	 (left	 panel),	 csf2	 (middle	 panel)	 rorc	 (right	panel)	 was	 analyzed	 and	 is	 shown	 relative	 to	 beta-actin.	 (b-d)	 IL-2	 expanded	 Th17	 cells	 were	
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subjected	to	qPCR	analysis.	n=4	mice	per	genotype	in	2	independent	differentiation	experiments.	All	error	bars	represent	mean	±	SEM.		
	
FIGURE	2.16	Th17	cells	lacking	Ndfip1	are	more	likely	to	produce	proinflammatory	cytokines	
and	drive	tissue	destruction.		IL-4	KO	or	DKO	Th17	 cells	 from	 IL-17A	GFP	 reporter	mice	were	 sorted	 for	Ndfip1-deficient	 and	 -sufficient	 GFP-IL-17A+	 Th17	 cells	 that	 were	 then	 injected	 into	 RAG1-/- recipients.	 Mice	 were	analyzed	 for	 weight	 loss	 (expressed	 as	 percentage	 of	 starting	 weight)	 (a)	 and	 colon	 integrity	 (b)	using	Hemaoxylin	and	Eosin	(H&E)	staining.	Inset	represents	a	separate	higher	magnification	image	of	the	colon.	All	size	bars	represent	100um.	(c-d)	Percentages	and	absolute	numbers	of	Th17	cells	in	the	colons	as	determined	by	flow	cytometry.	(e)	Boolean	analysis	of	flow	cytometry	data	from	DKO	versus	 IL-4KO	colon	CD3+	CD4+	cells	 that	secrete	 IL-17	or	 IL-17	 together	with	other	cytokines.	 (f)	Frequencies	 of	 CD11b+	 Ly6G+	 neutrophils,	 CD11c+	 MHCII+	 dendritic	 cells,	 CD11b+	 Siglec	 F	eosinophils,	and	CD11b+	Ly6G-	Ly6C+	monocytes	in	the	colon	as	determined	by	flow	cytometry.	Data	is	 pooled	 for	 n=	 8	 recipients	 of	 each	 genotype	 in	 two	 independent	 experiments.	 *p<0.05,	**p<0.01,****p<0.0001.	 p	 values	 were	 calculated	 by	 unpaired	 two-tailed	 T	 tests.	 All	 error	 bars	represent	mean	±	SEM.	
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Discussion	
Ndfip1	 and	 Itch	 are	 known	 to	 limit	 the	 activation	 of	 T	 cells,	 as	 well	 as	 to	control	 the	 differentiation	 of	 specific	 lineages	 of	 T	 cells,	 namely	 Th2	 cells	 and	peripherally-generated	Foxp3+	regulatory	T	cells	(iTreg	cells)25,26,117.	Less	is	known	about	whether	 and	 how	 these	 proteins	 impact	 the	 fate	 or	 function	 of	 T	 cells	 that	have	already	committed	to	a	cytokine-producing	effector	cell	lineage.	Here,	we	show	that	 Ndfip1	 and	 Itch	 play	 an	 important	 role	 in	 Th17	 cells	 after	 differentiation.	Specifically,	our	data	reveal	a	new	role	for	these	proteins	in	limiting	the	abundance	and	pathogenicity	of	Th17	cells	and	show	that	Ndfip1	and	Itch	regulate	the	effector	responses	of	Th17	cells	following	lineage	specification.	 	 	
This	 study	 focused	 predominantly	 on	 Ndfip1,	 an	 activator	 of	 Itch	 catalytic	activity25,50,177,190.	The	loss	of	Ndfip1	globally,	or	following	conditional	deletion	in	T	cells,	 causes	 spontaneous	 autoinflammatory	 disease	 that	 is	 associated	 with	 high	numbers	of	 activated	CD4	T	cells,	 increased	numbers	of	Th1,	Th2,	 and	Th17	cells,	and	premature	death25,68,117,153.	 Prior	 studies	have	detailed	how	Ndfip1	 limits	Th2	cell	 numbers	 and	 how	 the	 production	 of	 IL-4	 can	 drive	much	 of	 the	 pathological	sequela68,117.	 In	 this	 study,	we	made	use	of	Ndfip1	 IL-4	DKO	animals	 to	 show	 that	while	IL-4	over-production	by	Ndfip1-deficient	T	cells	may	influence	the	generation	of	 Th17	 cells	 in	 vivo	 according	 to	 previous	 reports68,	 Ndfip1	 has	 a	 previously	unrecognized	 cell-intrinsic	 role	 in	 the	 regulation	 of	 already-differentiated	 Th17	cells.	Furthermore,	 this	study	also	reveals,	 for	 the	 first	 time,	 that	Ndfip1	 limits	 the	numbers	of	Th1	and	Th17	cells	by	two	distinct	mechanisms.	We	show	that	Ndfip1	
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restricts	T	cell	activation	to	limit	the	numbers	of	Th1	cells.	In	contrast,	Ndfip1	limits	Th17	cell	abundance	by	limiting	T	cell	activation	as	well	as	by	dampening	Th17	cell	proliferation	and	working	together	with	Itch	to	degrade	RORγT.		 	
ROR	 family	members	 include	RORα,	RORβ	and	RORγ.	RORγT	(Retinoic	Acid	Receptor	 Related	Orphan	Receptor	 gamma	T	 isoform)	 is	 an	 isoform	 of	 RORγ	 that	was	initially	found	to	be	expressed	in	the	thymus191	but	has	now	been	shown	to	be	expressed	in	mature	αβT	cells,	γδT	cells	as	well	as	CD4-	lamina	propria	cells66.	Both	RORα	and	RORγT	are	important	for	Th17	development;	mice	that	lack	both	of	these	factors	 are	 entirely	 devoid	 of	 Th17	 cells67.	 As	 a	 nuclear	 receptor,	 RORγT	 has	 five	important	regions:	a	variable	A-B	domain	or	N-terminal	regulatory	domain;	a	very	conserved	 C	 domain	 or	 DNA-binding	 domain;	 a	 D	 domain	 or	 hinge	 region,	 an	 E	domain	or	Ligand-binding	domain;	and	an	F	domain	or	C-terminal	domain192.	Both	RORα	 and	 RORγT	 respond	 to	 endogenous	 ligands	 such	 as	 cholesterols	 and	oxysterols,	 which	 bind	 to	 the	 E	 or	 ligand-binding	 domain	 and	 affect	 the	transcriptional	activities	of	these	nuclear	receptors.	
	In	 Th17	 cells	 lacking	 Ndfip1,	 RORγT	 levels	 accumulate	 and	 the	 Th17	 cells	become	 polyfunctional,	 producing	 several	 proinflammatory	 cytokines	 and	chemokines	simultaneously.	Some	of	these	factors	are	known	to	be	transcriptional	targets	of	RORγT,	namely	GM-CSF,	CCL5	(a.k.a.	RANTES)	and	 IL-17A,	while	others,	IFNγ	 and	 TNFα,	 are	 not66,79,193.	 Thus,	 it	 remains	 unclear	 whether	 the	 increase	 in	RORγT	 is	 sufficient	 to	 explain	 the	 full	 pathogenic	 potential	 of	 Th17	 cells	 that	 lack	Ndfip1,	or	whether	there	remain	other	substrates	of	Ndfip1/Itch	yet	to	be	identified.	
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We	propose	that	Ndfip1	helps	to	degrade	RORγT	and	thus	limits	the	production	of	CCL5,	GM-CSF	and	IL-17A	by	Th17	cells.	 	 	
IFNγ	production	by	Th17	cells	is	mechanistically	distinct	from	its	production	by	 Th1	 cells.	 In	 Th17	 cells,	 IFNγ	 synthesis	 does	 not	 depend	 on	 Tbet,	 STAT1	 or	STAT4194,	 and	 instead	 is	 linked	 to	 IL-23R	 signaling	 and	 the	 transcription	 factor	Blimp1194.	Ndfip1-deficient	Th17	cells	do	not	show	increased	levels	of	IL-23R	mRNA	compared	 to	 WT	 cells,	 however	 we	 have	 not	 explored	 IL23R	 protein	 levels	 or	protein	levels	of	Blimp1.	Blimp1	can	also	increase	the	production	of	IFNγ,	GM-CSF,	and	IL-17A	from	Th17	cells65,169.	Interestingly,	Blimp1,	like	RORγT,	contains	an	L-P-X-Y	motif	that	would	allow	binding	to	the	WW	domains	on	Itch.	Thus,	future	studies	should	determine	whether,	like	RORγT,	Blimp1	is	a	substrate	of	Itch/Ndfip1.		 	 	
Ndfip1-deficient	Th17	cells	concurrently	produce	TNFα,	IFNγ,	and	IL-17A	in	
vivo.	TNFα,	also	called	cachexin,	is	an	important	mediator	of	systemic	inflammation.	Mechanistically,	TNFα	may	suppress	appetite,	or	may	act	synergistically	with	IFNγ	to	target	the	degradation	of	myosin	heavy	chains	leading	to	muscle	wasting195.	Thus	concurrent	 production	 of	 TNFα	 and	 IFNγ	 by	 Ndfip1-deficient	 Th17	 cells,	 coupled	with	the	observed	destruction	of	the	colon	mucosa,	may	explain	the	severe	weight	loss	seen	in	the	colitis	model.	Like	IFNγ,	TNFα	production	is	unlikely	to	be	driven	by	RORγT	since	TNFα	expression	 in	Th17	cells	 increases	upon	 loss	of	RORγT193.	How	Ndfip1	regulates	TNFα	production	is	unknown	and	remains	to	be	explored.	 	
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Recently	published	work	found	that	Itch	ubiquitylates	RORγT,	targeting	it	for	degradation	 and	 helping	 to	 limit	 the	 abundance	 of	 Th17	 cells	 in	 the	 colon173.	We	found	that	Ndfip1	also	controls	RORγT	levels.	Furthermore,	our	data	revealed	that	Ndfip1	and	Itch	do	not	merely	limit	Th17	abundance	at	mucosal	sites,	but	also	limit	the	 pathogenic	 potential	 of	 these	 cells	 by	 restricting	 the	 amount	 of	 RORγT	 and,	consequently,	the	production	of	proinflammatory	cytokines	that	Th17	cells	secrete.	We	 find	 that	 in	 the	 absence	 of	 Ndfip1	 or	 Itch,	 Th17	 cells	 are	 polyfunctional	 and	secrete	 increased	amounts	of	 IL-17A,	 IFNγ,	GM-CSF	and	TNFα.	Of	 these	 cytokines,	increased	 amounts	 of	 IL-17A	 and	 TNFα	 are	 known	 to	 promote	 colorectal	 cancer	while	 the	 role	 of	 GM-CSF	 in	 colorectal	 cancer	 remains	 unclear196,197.	 Our	 data	suggests	that	the	observed	remarkable	susceptibility	of	Itch-deficient	mice	to	colitis	and	colorectal	 cancer173	 is	not	only	because	of	 the	quantity	of	Th17	cells	 found	 in	the	colon,	but	also	because	of	 the	pathogenic	polyfunctional	quality	of	 these	Th17	cells.	 	
We	 found	 that	 the	 loss	 of	 Ndfip1	 or	 Itch	 does	 not	 lead	 to	 increased	differentiation	of	Th17	cells.	Thus,	Ndfip1	and	Itch	are	primarily	regulating	RORγT	levels	 after	 the	 cells	 have	 increased	 RORγT	 and	 committed	 to	 the	 Th17	 lineage.	Interestingly,	while	 both	Ndfip1	 and	 Itch	 promote	 RORγT	 degradation,	 Th17	 cells	lacking	Itch	produce	higher	levels	of	IL-17A,	IFNγ	and	GM-CSF	than	Ndfip1-deficient	cells.	 This	 suggests	 that	 while	 Itch	may	 require	 Ndfip1	 for	 its	 activation	 in	 Th17	cells,	 it	may	 also	 rely	 on	 other	mechanisms	 of	 activation.	We	 recently	 found	 that	Ndfip2	 has	 similar	 functions	 to	 Ndfip1	 and	 can	 also	 activate	 Itch	 and	 related	 E3	
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ubiquitin	 ligases	 in	CD4	T	cells177.	 It	 remains	 to	be	seen	whether	Ndfip2	may	also	work	with	Itch	to	limit	Th17	cell	proinflammatory	cytokine	production.		 	
This	work	may	have	relevance	in	the	development	or	treatment	of	diseases	such	 as	 asthma.	 A	 sub-set	 of	 patients	with	 asthma	 do	 not	 respond	 to	 steroids	 or	other	 standard	 treatments	 and	 these	 patients	 are	 much	 more	 likely	 to	 have	neutrophilic	 accumulation	 in	 the	 airways198,199.	 Emerging	 data	 suggests	 that	neutralization	of	either	Th2	cytokines	alone	or	of	Th17	cytokines	alone	 in	asthma	may	 worsen	 disease,	 resulting	 in	 increased	 inflammation	 in	 the	 airways200.	However,	 neutralization	 of	 both	 Th2	 and	 Th17	 cytokines	 ameliorate	 neutrophilia,	eosinophilia,	and	overall	airway	 inflammation200.	Our	data	reveals	Ndfip1	as	a	key	regulator	 of	 both	 Th2-	 and	 Th17-cell	 functions,	 albeit	 via	 separate	 mechanisms.	Therapeutics	 designed	 to	 mimic	 Ndfip1,	 and	 activate	 Itch,	 would	 be	 predicted	 to	have	 high	 efficacy	 in	 treating	 asthma	 while	 having	 a	 minimal	 effect	 on	 anti-viral	immune	responses,	for	example.	Such	therapies	will	be	the	focus	of	future	studies.		
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Chapter	3:	Ndfip1	restricts	mTORC1	signalling	and	glycolysis	in	
regulatory	T	cells	to	prevent	autoinflammatory	disease.3		
Abstract		
Foxp3+	 T	 regulatory	 (Treg)	 cells	 suppress	 immune	 cell	 activation	 and	establish	normal	immune	homeostasis.	How	Treg	cells	maintain	their	identity	is	not	completely	understood.	Here	we	show	 that	Ndfip1,	 a	 co-activator	of	Nedd4-family	E3	ubiquitin	ligases,	is	required	for	Treg	cell	stability	and	function.	Ndfip1	deletion	in	 Treg	 cells	 results	 in	 autoinflammatory	 disease.	 Ndfip1-deficient	 Treg	 cells	 are	highly	proliferative	 and	 are	more	 likely	 to	 lose	 Foxp3	 expression	 to	 become	 IL-4-producing	 Th2	 effector	 cells.	 Proteomic	 analyses	 indicate	 altered	 metabolic	signature	 of	 Ndfip1-deficient	 Treg	 cells	 and	 metabolic	 profiling	 reveals	 elevated	glycolysis	and	 increased	mTORC1	signalling.	Ndfip1	restricts	Treg	cell	metabolism	and	 IL-4	 production	 via	 distinct	mechanisms,	 as	 IL-4	 deficiency	 does	 not	 prevent	hyper-proliferation	 or	 elevated	 mTORC1	 signalling	 in	 Ndfip1-deficient	 Treg	 cells.	Thus,	 Ndfip1	 preserves	 Treg	 lineage	 stability	 and	 immune	 homeostasis	 by	preventing	the	expansion	of	highly	proliferative	and	metabolically	active	Treg	cells,	and	by	preventing	pathologic	secretion	of	IL-4	from	Treg	cells.	
	
																																									 																					3	This	work	is	currently	accepted	and	in	press	at	Nature	Communications	with	the	following	authors	and	title:	Layman, Awo Akosua Kesewa; Deng, Guoping; O’Leary, Claire E.; Tadros, Samuel; Thomas 
Rajan; Dybas, Joe; Moser, Emily; Wells, Andrew; Doliba, Nicolai and Oliver, PM. Ndfip1 restricts 
mTORC1 signalling and glycolysis in regulatory T cells to prevent autoinflammatory disease.	
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Introduction	
Foxp3+	 Regulatory	 T	 (Treg)	 cells	 are	 required	 to	 prevent	 spontaneous	immune	 cell	 activation	 and	 limit	 effector	 cell	 function,	 thereby	 preventing	autoimmune	and	inflammatory	disorders105,201.	While	generally	stable,	Treg	lineage	cells	 can	 show	 a	 high	 degree	 of	 instability	 in	 inflammatory	 settings.	Treg	cell	instability	is	characterized	by	one	or	more	key	features:	loss	of	suppressive	function,	loss	 of	 Foxp3	 protein,	 or	 gain	 of	 pro-inflammatory	 cytokine	 production202.	Identifying	pathways	that	promote	Treg	cell	suppressive	function,	prevent	Treg	cell	production	of	 pro-inflammatory	 cytokine,	 and/or	maintain	Treg	 cell	 numbers	will	aid	in	the	development	of	new	Treg	cell-based	therapeutic	applications.	 	 	
Cellular	energetics	and	metabolic	 regulation	play	a	 central	 role	 in	Treg	 cell	function	 and	 lineage	 stability203.	 Unlike	 effector	 T	 cells,	 which	 rely	 heavily	 on	glycolysis,	 Treg	 cells	 rely	 on	 fatty	 acid	 oxidation	 for	 their	 energy	 needs204.	mTOR	(mechanistic	target	of	rapamycin)	is	a	serine-threonine	kinase,	which	forms	part	of	the	mTORC1	and	mTORC2	protein	complexes,	and	is	a	critical	regulator	of	cellular	metabolic	processes.	Both	complexes	have	 the	potential	 to	 limit	glycolysis	 in	Treg	cells	 and	 thus	 help	 to	 maintain	 lineage	 stability	 and	 suppressive	 functions205,206.	While	metabolic	state	is	clearly	important	for	Treg	maintenance	and	function,	many	factors	that	impact	Treg	cell	metabolism	remain	unknown.	 	 	
Ubiquitylation	 is	 a	 fundamental	 post-translational	 modification	 affecting	many	 aspects	 of	 T	 cell	 differentiation	 and	 function33,172.	 Nedd4	 family	 interacting	protein	1	 (Ndfip1)	 is	a	 trans-membrane	protein,	which	binds	and	activates	Nedd4	
59	
family	E3	ubiquitin	 ligases148.	These	highly	conserved	catalytic	E3	 ligases	perform	two	functions	in	protein	ubiquitylation:	binding	to	the	specific	ubiquitylation	target	and	 catalyzing	 the	 final	 transfer	 of	 ubiquitin.	 Ndfip1	 activation	 of	 the	 Nedd4	 E3	ligase	Itch	results	in	ubiquitylation	and	degradation	of	the	transcription	factor	JunB,	thereby	limiting	IL-4	cytokine	production	from	T	helper	type	2	(Th2)	cells	and	Th2-mediated	inflammatory	disease25,26.		 	 	 	
Ndfip1-deficient	mice	have	decreased	Treg	cell	numbers	in	the	small	bowel,	a	site	 of	 peripheral	 Treg	 generation,	 likely	 due	 to	 increased	 IL-4	 signaling	which	 is	inhibitory	to	Treg	differentiation117.	In	the	thymus,	however,	there	is	an	increase	in	Ndfip1-deficient	 Treg	 cells117.	Whether	 Ndfip1	 also	modulates	 Treg	 function	 after	cells	have	committed	to	the	Treg	cell	lineage,	has	not	been	explored.	Given	that	Treg	specific	 deletion	 of	 Itch	 results	 in	 a	 Th2-biased	 autoinflammatory	 disease104,	 it	seems	plausible	that	Ndfip1	might	be	required	to	support	Itch	function	in	Treg	cells.			 Here	 we	 show	 that	 Ndfip1	 expression	 in	 Treg	 cells	 prevents	 spontaneous	inflammation	 at	 several	 sites	 such	 as	 lungs	 and	 skin.	 Ndfip1	 limits	 both	 the	accumulation	and	proliferation	of	CD44+	effector	Treg	cells,	and	prevents	Treg	cell	production	 of	 IL-4.	 Consistent	 with	 increased	 proliferation	 and	 exposure	 to	 IL-4,	Treg	 cells	 lacking	Ndfip1	 show	 increased	CNS2	methylation	and	are	prone	 to	 lose	Foxp3	 in	 vivo.	 Increased	 proliferation	 is	 associated	 with	 increased	 mTORC1	signaling	 and	 high	 glycolytic	 activity,	 programs	 that	 can	 fuel	 effector	 function	 in	Treg	 cells	 and	 contribute	 to	 lineage	 instability.	 Thus,	 Ndfip1	 maintains	 lineage	identity	in	Treg	cells	and	prevents	these	cells	from	aberrant	acquisition	of	effector	T	
60	
cell	 programs.	 Ndfip1	 is	 therefore	 a	 critical	 molecular	 sentinel	 that	 prevents	autoinflammatory	disease.		
Results	
Treg-specific	loss	of	Ndfip1	results	in	inflammation		Mice	 that	 constitutively	 lack	 Ndfip1	 in	 all	 cells	 develop	 a	 severe	autoinflammatory	 disease	 by	 6	 weeks	 for	 age,	 resulting	 eventually	 in	 death25,154.	While	thymic	Treg	frequencies	in	Ndfip1-deficient	mice	is	not	altered	directly	by	the	loss	 of	 Ndfip1,	 but	 is	 increased	 due	 to	 inflammation117,	 Treg	 cell	 numbers	 are	reduced	at	sites	of	peripheral	Treg	induction117.	Therefore	to	test	the	role	of	Ndfip1	within	 committed	 Treg	 cells,	 we	 generated	mice	 in	which	 Ndfip1	 is	 conditionally	deleted	 in	Treg	 cells	 using	 the	Foxp3-Cre-YFP	 reporter	mice207.	We	observed	 that	Ndfip1	 mRNA	 is	 induced	 upon	 stimulation	 of	 control	 Ndfip1+/+Foxp3-Cre	 sorted	YFP+	 Treg	 cells,	 and	 that	Ndfip1	message	 is	 effectively	 ablated	 in	 Treg	 cells	 from	Ndfip1fl/fl	Foxp3-Cre	male	mice,	which	lack	Ndfip1	in	all	Treg	cells	(Fig.	3.1a).		 	
By	9-16	weeks	of	age,	Ndfip1fl/fl	Foxp3-Cre	male	mice	developed	pronounced	splenomegaly,	 lymphadenopathy,	 and	 progressive	 dermatitis.	 Histologically,	 the	skin,	 esophagus,	 and	 lung	 showed	marked	 immune	 infiltration	 inflammation	 (Fig	
3.1b).	Analysis	of	spleen	weight	to	body	weight	ratios	revealed	that	male	Ndfip1fl/fl	Foxp3-Cre	mice	showed	evidence	of	 lymphoid	expansion	(Fig.	3.1c).	To	determine	which	 immune	 responses	 were	 contributing	 to	 the	 observed	 inflammation,	 we	examined	 serum	 immunoglobulin	 (Ig)	 levels.	We	 found	 elevated	 levels	 of	 IgE	 and	IgG1,	 indicative	 of	 type-two	 inflammation,	 as	well	 as	 elevated	 IgM	 (Fig.	 3.1d).	 To	
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determine	the	contribution	of	CD4	T	cells	to	this	pathology,	we	examined	spleen	and	lung	of	the	mice	and	found	increased	activated	phenotype	(CD44+)	CD4	T	cells	(Fig.	
3.1e).	 CD4	 T	 cells	 present	 in	 the	 lung	 of	male	 Ndfip1fl/fl	 Foxp3-Cre	 animals	 were	more	 likely	 to	 express	 the	 effector	 cytokines	 IFNγ,	 IL-4	 and	 IL-17A	 upon	 ex	 vivo	stimulation	(Fig.	3.1f).	These	data	suggested	that	Ndfip1	expression	in	Treg	cells	is	required	for	suppression	of	tissue	inflammation	and	pathology.		
	
FIGURE	3.1	Mice	lacking	Ndfip1	in	their	Treg	cells	develop	inflammatory	disease.		(a)	Ndfip1	 expression	 assessed	 by	 qPCR	 before	 (-)	 or	 after	 (+)	 αCD3/CD28	 stimulation	 of	 sorted	YFP+	 Treg	 cells	 from	 WT	 and	 Ndfip1fl/fl	 Foxp3-Cre	 mice.	 A	 representative	 example	 of	 Ndfip1	expression	relative	to	Actb	after	αCD3/CD28	stimulation	 is	shown.	(b)	Representative	H&E	stained	histological	sections	of	skin,	esophagus	and	lung	from	genotypes	as	indicated	are	shown.	Scale	bars	represent	100uM.	Far	right	 image	 in	panel	 is	a	representative	 image	of	spleen	and	 lymph	nodes	 to	
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illustrate	size.	(c)	Inflammation	index,	calculated	as	a	spleen	weight/body	weight	for	male	Ndfip1+/+	
Foxp3-Cre	 (WT)	 and	 Ndfip1fl/fl	 Foxp3-Cre	 (cKO)	 mice	 at	 9-16	 weeks	 of	 age.	 (d)	 Levels	 of	 serum	antibody	isotypes	as	quantified	by	ELISA.	(e,f)	T	cells	from	lung	homogenates	were	analyzed	by	flow	cytometry	for	(e)	the	percentages	of	CD44+	cells	among	CD4+	cells,	and	(f)	percentages	of	CD4+	cells	making	 the	 indicated	 cytokines	 after	ex	 vivo	 (P/I)	 stimulation.	 P	 values	determined	by	 student’s	T	test,	 with	 correction	 for	 unequal	 variances	 as	 appropriate.	 *p<0.05	 **	 p<0.01	 ***	 p<0.001	****p<0.0001.	For	panels	(a)	and	(c-f),	bars	indicate	mean	±	SEM.	Data	in	panel	(a)	is	representative	of	 4	 male	 animals	 of	 each	 genotype,	 9-16	 weeks	 old,	 and	 for	 panels	 (c-f)	 each	 dot	 represents	 an	individual	male	mouse	 between	 9-16	weeks	 old.	 All	 experiments	were	 performed	 on	 at	 least	 two	independent	occasions.		
Ndfip1fl/fl	Foxp3-Cre	mice	have	more	CD44+	eTreg	cells		The	observed	pathology	could	result	from	a	loss	Treg	cell	numbers	(as	occurs	with	mice	 lacking	 Foxp3208)	 or	 Treg	 cell	 function	 (as	 is	 seen	 in	 Treg-specific	 CTLA4	deficiency209).	We	therefore	examined	Treg	percentages	and	numbers	in	the	spleens	and	lung	of	Ndfip1fl/flFoxp3-Cre	and	controls.	Surprisingly,	Treg	cell	numbers	were	increased	in	Ndfip1fl/flFoxp3-Cre	animals	(Fig.	3.2a-c).	Further,	analysis	of	the	Treg	cell	 effector	 proteins:	 Inducible	 T-Cell	 Co-Stimulator	 (ICOS),	 Programmed	 cell	Death-1	(PD-1),	and	Glucocorticoid-Induced	TNFR-Related	protein	(GITR),	revealed	increased	expression	on	Treg	cells	from	Ndfip1fl/flFoxp3-Cre	male	mice	compared	to	Cre+	controls	(Fig.	3.2d).	We	did	not	see	consistent	changes	in	CD25	levels.	Taken	together,	these	data	suggest	that	the	immunopathology	observed	in	Ndfip1fl/flFoxp3-Cre	male	mice	 is	 not	 due	 to	 decreased	 Treg	 numbers	 or	 loss	 of	 effector	 proteins	known	to	support	Treg	function.		 	 	
	 Treg	 cells	 can	 be	 quiescent	 or	 activated;	 these	 two	 subsets	 can	 be	distinguished	 by	 expression	 of	 CD44	 and	 CD62L210.	 Analysis	 of	 the	 lung	 of	 male	Ndfip1fl/fl	 Foxp3-Cre	 mice	 revealed	 an	 increase	 in	 frequency	 (Fig.	 3.2e,f)	 and	numbers	 (Fig.	 3.2g)	 of	 Foxp3+	 cells	 with	 an	 activated	 or	 “effector”	 (eTreg)	phenotype	 (CD62LloCD44+).	 In	 contrast,	 Ndfip1fl/fl	 Foxp3-Cre	 and	 control	 mice	
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contained	 equivalent	 numbers	 of	 cells	 with	 a	 quiescent	 or	 “central”	 (cTreg)	phenotype	 (CD62LhiCD44-)	 (Fig.	 3.2g).	 WT	 eTreg	 cells	 show	 high	 expression	 of	ICOS,	 PD-1,	 and	 GITR	 while	 CD25	 is	 higher	 on	 WT	 cTreg	 cells210.	 Therefore,	 the	observed	 increase	 in	surface	expression	of	 ICOS,	PD-1	and	GITR	observed	on	 total	Treg	cells	from	Ndfip1fl/flFoxp3-Cre	animals	could	be	due	to	an	increased	proportion	of	 eTreg	 cells.	 To	 assess	 this,	 we	 examined	 the	 surface	 expression	 of	 ICOS,	 GITR,	CD25	 and	 PD-1	 on	 the	 eTreg	 and	 cTreg	 populations.	 cTreg	 cells,	 as	 previously	described,	had	 low	levels	of	 ICOS,	GITR,	and	PD-1,	and	 loss	of	Ndfip1	did	not	alter	this	(Fig.	3.2h).	However,	cTreg	cells	from	Ndfip1fl/flFoxp3-Cre	mice	had	decreased	levels	of	CD25.	Strikingly,	in	addition	to	their	increased	frequency,	eTreg	cells	from	Ndfip1fl/flFoxp3-Cre	 mice	 showed	 higher	 levels	 of	 ICOS,	 GITR,	 CD25	 and	 PD-1	compared	to	WT	counterparts	(Fig.	3.2h).	 	
	 cTreg	 cells	 are	 thymically	 derived	 and	 undergo	 peripheral	 conversion	 to	eTreg	 cells	 under	 the	 instruction	 of	 TCR	 stimulation	 and	 ICOS	 stimulation210.	Therefore,	observing	increased	frequency	and	number	of	eTreg	cells	could	indicate	either	increased	conversion	of	cTreg	cells	or	expansion	of	eTreg	cells.	An	increased	cTreg	 conversion	 rate	would	 be	 expected	 to	 decrease	 the	 numbers	 of	 cTreg	 cells,	unless	 compensated	 for	 by	 thymic	 output.	 As	 there	 was	 no	 decrease	 in	 the	peripheral	 numbers	 of	 cTreg	 cells	 in	 Ndfip1fl/fl	 Foxp3-Cre+	 male	 mice,	 we	 next	examined	thymic	output	utilizing	mixed	bone	marrow	chimera	animals	in	which	WT	(Ndfip1+/+	 Foxp3-Cre+)	 and	 Ndfip1fl/fl	 Foxp3-Cre+	 Treg	 cells	 develop	 in	 the	 same	environment	to	control	for	effects	of	inflammation.	In	control	and	mixed	chimeras,	total	Treg	thymic	output	was	unchanged	(Fig.	3.3a).	Furthermore,	within	the	mixed	
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chimeras	 there	 was	 no	 significant	 difference	 in	 the	 percent	 of	 thymic	 Treg	 cells	derived	 from	 Ndfip1	 sufficient	 or	 deficient	 cells	 relative	 to	 the	 observed	reconstitution	ratio	of	all	thymic	CD4+	T	cells	(Fig.	3.3b).	Therefore	the	increase	in	eTreg	but	not	cTreg,	cell	number	in	the	periphery	is	not	driven	by	an	increased	rate	of	cTreg	conversion	to	eTreg	cells.			
	 Decreased	 suppressive	 function	 of	 Treg	 cells	 is	 known	 to	 lead	 to	inflammation.	Therefore,	we	examined	Treg	cell	 function.	 In	vitro,	Ndfip1-deficient	and	WT	Treg	 cells	 suppressed	proliferation	of	WT	Tconv	 cells	 to	 the	 same	degree	(Fig.	 3.3c,d).	We	 then	 examined	Treg	 cell	 function	 in	 vivo	 using	 a	model	 of	 T	 cell	transfer	 induced	 colitis.	 Similar	 to	 our	 results	 from	 the	 in	 vitro assays,	 Ndfip1-deficient	 and	 WT	 Treg	 cells	 were	 equally	 able	 to	 prevent	 weight	 loss	 due	 to	inflammation	caused	by	co-transferred	Tconv	cells	(Fig.	3.3e).	These	data	support	that	the	pathology	observed	in	Ndfip1fl/flFoxp3-Cre	mice	is	not	due	to	a	loss	of	Treg	number	or	an	overall	loss	of	Treg	cell	suppressive	function.		
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FIGURE	3.2	Regulatory	T	cells	lacking	Ndfip1	are	more	likely	to	be	CD44+	and	express	other	
markers	of	activated	Treg	cells.		Regulatory	T	cells	from	spleens	and	lung	(a-c)	or	lung	(d-h)	of	9-16	week	old	male	WT	and	Ndfip1fl/fl	Foxp3-Cre	 mice	 were	 analyzed	 by	 flow	 cytometry	 for	 numbers	 and	 surface	 markers.	 (a)	Representative	 flow	plots	 of	 Treg	 cells	 (previously	 gates	 as	 live	 CD3+CD4+	 cells)	 from	 spleen	 and	lung	homogenates	that	were	used	to	determine	percentages	and	total	numbers.	(b)	Treg	percentages	and	 (c)	 numbers	 compiled	 over	multiple	 experiments.	 (d)	Representative	 histograms	of	 lung	Treg	cells	 (gated	 as	 in	 panel	 a)	 analyzed	 for	 surface	 expression	 of	 ICOS,	 GITR,	 CD25	 and	 PD-1.	 (e)	Representative	flow	plots	showing	the	gating	of	Treg	cells	that	are	effector	(eTreg,	CD44hi	CD62Llo)	or	central	(cTreg	,	CD62Lhi	CD44lo).	This	gating	was	used	to	determine	the	(f)	percentages	and	(g)	total	numbers	of	these	cells.	(h)	Quantification	of	mean	fluorescence	intensities	(MFI)	of	ICOS,	GITR,	CD25	and	PD-1	on	 cTreg	 cells	 and	eTreg	 cells.	 P	 values	were	determined	by	 student’s	T	 test,	with	correction	for	unequal	variances	as	appropriate.	*	p<0.05	**	p<0.01	***	p<0.001	****p<0.0001.	Each	
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dot	indicates	data	acquired	from	a	single	male	mouse.	Graphs	with	compiled	data	show	mean	±	SEM.	All	experiments	were	performed	on	at	least	two	independent	occasions.		
	
FIGURE	 3.3	 Ndfip1-deficient	 regulatory	 T	 cells	 have	 no	 thymic	 competitive	 advantage	 and	
exhibit	normal	in	vitro and	in	vivo	suppression	of	wild	type	Tconv	cells.		(a-b)	WT	and	mixed	chimeras	were	analyzed	for	thymic	Foxp3+	cells	and	congenic	markers	by	flow	cytometry.	 (a)	 Percentages	 of	 TCRβ+	 CD4+	 CD8-	 Foxp3+	 Treg	 cells	 from	 YFP	 Cre+	 WT	 or	 WT/	Ndfip1fl/fl	Foxp3-Cre	mixed	chimeras.	 (b)	Percentages	of	congenic	contributions	 to	 the	 total	pool	of	TCRβ+CD4+	CD8-	Foxp3+	Treg	cells	within	the	thymus	of	each	mixed	chimera	animal,	normalized	for	reconstitution	 bias	 by	 dividing	 by	 congenic	 contribution	 to	 total	 CD4	 SP	 cell	 pool.	 (c-e)Ndfip1-deficient	regulatory	T	cells	exhibit	normal	in	vitro and	in	vivo	suppression	of	wild	type	Tconv	cells.	(c-
d)	 in	 vitro suppression	 of	 congenically	 marked	 (CD45.1),	 CFSE-labeled,	 WT	 CD4+	 Tconv	 cells	 by	congenic	WT	Treg	cells	or	Ndfip1fl/fl	Foxp3-Cre	Treg	cells	(c)	CFSE	dilution	of	Tconv	cells	after	4	days	in	culture	(d)	Quantification	of	the	percentage	of	Tconv	cells	that	diluted	CFSE	in	culture	(e)	Weight	
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changes	 during	 an	 in	 vivo	 suppression	 assay	 using	 CD45.1	 CD4+	 Tconv	 cells	 and	 CD45.2	 WT	 or	Ndfip1fl/fl	 Foxp3-Cre	Treg	cells.	Error	bars	 indicate	mean	±	SEM.	Each	dot	 represents	an	 individual	mouse.	Male	donors	were	used	for	mixed	bone	marrow	chimeras	(a-b).	(c-e)	represents	data	from	at	least	3	male	animals	of	each	genotype.	(e)	represents	one	experiment.	P	values	were	determined	by	a	paired	T	test	(a-b)	and	student’s	T	test	(c-e)	*	p<0.05	**	p<0.01,	ns=	not	significant.	
Ndfip1	limits	eTreg	proliferation	and	levels	of	ICOS	and	GITR	The	expansion	of	CD44+	eTreg	cells	 in	male	Ndfip1fl/flFoxp3-Cre	animals,	 in	the	absence	of	robust	changes	 in	cTreg	cells,	suggested	that	Ndfip1	restricts	eTreg	cell	numbers.	Additionally,	our	data	supported	that	Ndfip1	limits	expression	of	ICOS,	GITR,	 CD25	 and	 PD-1	 on	 eTreg	 cells.	 However,	 both	 expansion	 and	 phenotype	 of	eTreg	 cells	 could	 be	 altered	 in	 inflammatory	 environments,	 independent	 of	 an	intrinsic	 role	 for	 Ndfip1.	 To	 distinguish	 between	 these	 possibilities,	we	 examined	Ndfip1fl/flFoxp3-Cre+/-	female	animals.	These	mice	have	mixtures	of	WT	(YFP-Cre-)	and	 Ndfip1-deficient	 (YFP-Cre+)	 Foxp3+	 Treg	 cells,	 due	 to	 X	 chromosome	inactivation,	that	can	be	distinguished	by	expression	of	YFP.	 	
Surprisingly,	despite	the	presence	of	WT	Treg	cells,	female	Ndfip1fl/fl	Foxp3-Cre+/-	mice	had	similar	inflammatory	burden,	as	defined	by	ratio	of	spleen	weight	to	body	weight	(Fig.	3.4a)	and	contained	equally	high	percentages	of	IFNγ,	IL-4	and	IL-17A-	expressing	CD4	T	cells,	as	the	males	(Fig.	3.4b).	Compared	to	male	animals,	which	 are	 uniformly	 sick	 beyond	 16	 weeks	 of	 age,	 female	 animals	 had	 lower	incidence	 of	 skin	 dermatitis.	 Ndfip1fl/flFoxp3-Cre+/-	 mice	 contained	 increased	numbers	 of	 total	 lung	 Treg	 cells	 (Cre+	 plus	 Cre-),	 compared	 to	 Ndfip1+/+Foxp3-Cre+/-	counterparts	(Fig.	3.5a,b).	Similar	to	their	male	counterparts,	female	animals	had	 total	 lung	 Treg	 cells	 that	 were	 skewed	 towards	 the	 eTreg	 phenotype	 (Fig.	
3.5c,d).	 In	 Ndfip1+/+	 Foxp3-Cre+/-	 female	 mice,	 Foxp3-Cre+	 (YFP+)	 cells	 were	
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outnumbered	 by	 Foxp3-Cre-	 (YFP-)	 cells	 almost	 1:3	 (Fig.	 3.5e).	 Surprisingly,	 in	Ndfip1fl/flFoxp3-Cre+/-	 females,	 this	 ratio	 was	 skewed	 towards	 YFP+	 cells,	supporting	 an	 in	 vivo	 competitive	 advantage	 of	 Ndfip1-deficient	 Treg	 cells	 (Fig.	
3.5f).		 	 	
To	identify	intrinsic	effects	of	Ndfip1	deficiency	on	Treg	cells,	in	each	female	animal,	for	each	parameter	examined,	we	first	determined	the	ratio	of	the	value	for	YFP+	 to	 YFP-	 Treg	 cells.	 The	 aim	 of	 this	 analysis	 strategy	 was	 to	 first	 identify	whether	the	presence	of	Cre	had	an	effect	on	the	ratio	of	YFP+	to	YFP-	cells	in	a	WT	(Ndfip1+/+)	animal.	This	ratio	in	a	WT	animal	would	serve	as	the	baseline	to	use	to	compare	to	Ndfip1fl/flFoxp3-Cre+/-	females	to	see	whether	the	loss	of	Ndfip1	had	an	additional	effect.	If	the	expression	of	Cre	had	no	effect	on	the	parameter	examined,	the	ratio	of	YFP+	to	YFP-	cells	would	be	equal	to	1	in	a	WT	animal.	If	Ndfip1	did	not	affect	the	expression	of	the	parameter	examined,	the	YFP+:YFP-	ratio	in	the	WT	and	in	 the	 Ndfip1fl/flFoxp3-Cre+/-	 animals	 would	 be	 identical.	 Analysis	 of	 our	 data	revealed	that	the	expression	of	Cre	decreased	levels	of	CD44,	Ki67,	GITR,	and	PD-1	in	 a	 WT	 animal	 (i.e.	 YFP+:YFP-	 ratios	 were	 all	 less	 than	 1	 in	 WT	 animals).	Furthermore,	Ndfip1-deficient	Treg	cells	were	significantly	more	likely	to	display	an	eTreg	phenotype	(CD44+CD62Llo)	due	to	the	loss	of	Ndfip1	(Fig.	3.5g)	as	indicated	by	 the	 increased	 ratio	 in	 the	 Ndfip1fl/flFoxp3-Cre+/-	 female	 animal.	 Similarly,	 the	expression	 of	 the	 proliferative	marker,	 Ki67	 (Fig.	 3.5h)	was	 increased	 in	 Ndfip1-deficient	 eTreg	 cells	 and	 eTreg	 cells	 lacking	 Ndfip1	 also	 had	 significantly	 higher	levels	of	ICOS	(Fig.	3.5i)	and	GITR	(Fig.	3.5j).	Thus,	Ndfip1	restricts	eTreg	numbers	by	limiting	their	proliferation	and	their	expression	of	ICOS	and	GITR.	However,	the	
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ratios	representing	levels	of	CD25	and	PD-1	were	similar	between	Ndfip1fl/flFoxp3-Cre+/-	 animals	 and	 controls	 (Fig.	3.5k,l),	 suggesting	 that	 these	markers	were	not	directly	affected	by	the	loss	of	Ndfip1	in	Treg	cells.	 	
The	 expression	 of	 activation	 markers	 on	 Treg	 cells	 is	 known	 to	 increase	under	 inflammatory	 settings210.	 To	determine	how	 inflammatory	 conditions	 could	influence	 control	 Treg	 cells,	 we	 looked	 at	 the	 expression	 of	 surface	 markers	 by	CD44+	YFP-	Treg	cells	from	the	Ndfip1+/+Foxp3-Cre+/-	females	or	from	the	inflamed	environment	in	Ndfip1fl/flFoxp3-Cre+/-	female	mice.	CD44+	YFP-	Foxp3+	cells	from	Ndfip1fl/flFoxp3-Cre+/-	mice	showed	increased	expression	of	ICOS,	GITR,	CD25	and	PD-1	 (Fig.	 3.6a-d).	 Taken	 together	with	 the	 data	 in	 Figures	 3.2,	 3.4	 and	 3.5,	 this	supports	that	the	changes	in	CD25	and	PD-1	expression	in	male	Ndfip1fl/flFoxp3-Cre	mice	are	secondary	to	inflammation	but	Ndfip1	is	a	regulator	of	ICOS	and	GITR	on	Treg	cells	(Fig.	3.6e).		 	
To	 further	 address	 whether	 the	 changes	 observed	 in	 the	 Ndfip1-deficient	Treg	cells	were	driven	by	inflammation,	we	looked	in	young	mice	before	the	onset	on	 overt	 inflammation.	We	 analyzed	 lung	 cells	 from	 13-day-old	 female	 neonates.	There	 were	 no	 differences	 between	 the	 Ndfip1fl/flFoxp3-Cre+/-	 and	 Ndfip1+/+	Foxp3-Cre+/-	animals	in	spleen	weight	(Fig.	3.7a),	 inflammation	index	(Fig.	3.7b),	total	Foxp3+	Treg	cell	number	or	total	cytokine-producing	CD4	T	cells	(Fig.	3.7c-d).	However,	 lungs	 from	 Ndfip1fl/flFoxp3-Cre+/-	 female	 mice	 contained	 greater	frequencies	 of	 YFP+	Treg	 cells	 (Fig.	 3.7e-f)	 and	 greater	 frequencies	 of	 eTreg	 cells	
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(Fig.	3.7g).	Further,	these	eTreg	cells	had	higher	expression	of	ICOS	and	GITR	(Fig.	
3.7h,i).		
	
FIGURE	3.4	Ndfip1fl/fl	Foxp3-Cre	+/-	female	animals	develop	disease.		(a)	 Inflammation	 index	 calculated	 by	 spleen	 weight/body	 weight	 for	 male	 Ndfip1fl/flFoxp3-Cre+	animals,	 female	 Ndfip1fl/fl	 Foxp3-Cre	 +/-	 animals,	 compared	 to	 male	 Ndfip1+/+	 Foxp3-Cre	 +	 WT	controls	and	female	Ndfip1+/+	Foxp3-Cre	+/-	WT	controls	all	between	8-16	weeks	old.	Male	data	from	Figure	 1	 is	 added	 here	 for	 comparison.	 (b)	 Lung	 homogenates	 as	 analyzed	 by	 flow	 cytometry	 for	IFNγ,	IL-4	and	IL-17A	cytokine	production	from	WT	Ndfip1+/+	Foxp3-Cre	+	male,	Ndfip1fl/fl	Foxp3-Cre	male,	 and	 Ndfip1fl/fl	 Foxp3-Cre	 +/-	 female	 animals.	 Error	 bars	 indicate	 mean	 ±	 SEM.	 P	 value	calculated	by	one	way	ANOVA.	*	p<0.05	**	p<0.01	***	p<0.001	****p<0.0001,	ns	=	not	significant.		
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FIGURE	 3.5	 Loss	 of	 Ndfip1	 leads	 to	 an	 increase	 in	 eTreg	 cell	 frequency	 and	 elevated	
expression	of	some	of	the	markers	that	distinguish	these	cells.		(a-l)	Lung	homogenates,	from	8-16	week	old	hemizygous	female	Ndfip1fl/fl	Foxp3-Cre	+/-	mice	and	Ndfip1+/+	Foxp3-Cre	+/-	controls,	were	analyzed	ex	vivo	by	flow	cytometry.	(a)	Representative	flow	plots	showing	the	gating	of	Treg	cells	(previously	gated	as	live	CD3+CD4+	cells).	This	gating	was	used	to	 determine	 the	 overall	 frequencies	 of	 Treg	 cells	 (b)	 in	 mice	 from	 the	 indicated	 genotypes.	 (c)	Representative	 flow	plots	 showing	 the	 gating	 of	 Treg	 cells	 from	panel	 (a)	 that	 are	 eTreg	 or	 cTreg	cells.	This	gating	was	used	to	determine	the	(d)	 frequencies	of	eTreg	cells.	 (e)	Representative	 flow	plot	of	Treg	cells	as	gated	in	panel	(a)	and	analyzed	for	frequencies	of	YFP+	and	YFP-	cells.	(f)	Ratio	of	YFP+	 to	YFP-	Treg	 cells.	 (g-h)	Percentages	of	 (g)	 eTreg	 cells	or	 (h)	Ki-67+	eTreg	 cells,	 shown	as	a	ratio	of	YFP+:YFP-	cells	within	each	mouse	to	normalize	for	a	Cre	effect.	(i-l)	MFI	of	(i)	ICOS,	(j)	GITR,	(k)	 CD25,	 and	 (l)	 PD-1	 expression	 on	 eTreg	 cells,	 again	 shown	 as	 a	 ratio	 of	 YFP+:YFP-.	 P	 values	determined	 by	 student’s	 T	 test,	 with	 correction	 for	 unequal	 variances	 as	 appropriate.	 *	 p<0.05	 **	p<0.01	 ***	 p<0.001	 ****p<0.0001,	 ns=	not	 significant.	 Each	dot	 shows	data	 acquired	 from	a	 single	female	 mouse.	 Graphs	 show	 mean	 ±	 SEM.	 All	 experiments	 were	 performed	 on	 at	 least	 two	independent	occasions.	
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FIGURE	 3.6	 YFP-	 cells	 from	 female	 animals	 reveal	 inflammation-dependent	 changes	 in	WT	
Treg	cells.		(a-d)	 Analysis	 of	 ICOS,	 GITR,	 CD25	 and	 PD-1	MFI	 are	 shown	 for	 the	Ndfip1-sufficient	 (YFP-)	 Treg	cells	 found	 in	unstimulated	 lung	homogenates	 from	Ndfip1+/+	Foxp3-Cre	+	WT	 female	or	Ndfip1fl/fl	Foxp3-Cre	+/-	 female	animals.	(e)	Summary	of	Treg	cell	proteins	whose	expression	is	 increased	by	inflammation	 versus	 those	which	 are	 increased	 directly	 due	 to	 loss	 of	 Ndfip1.	 Error	 bars	 indicate	mean	±	SEM.	Each	dot	represents	an	individual	mouse.	All	experiments	were	performed	on	at	least	two	 independent	occasions	using	at	 least	3	 female	animals	of	each	genotype.	P	value	calculated	by	unpaired	T	test	.	*	p<0.05	**	p<0.01	***	p<0.001	****p<0.0001.	
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FIGURE	3.7	Ndfip1-deficient	Treg	cells	display	altered	phenotypes	before	overt	inflammation.		(a)	 Spleen	weights	 and	 (b)	 Inflammation	 index	 calculated	 by	 spleen	weight/body	weight	 for	 age-matched	13	day	old	female	Ndfip1fl/fl	Foxp3-Cre	+/-	animals	compared	to	Ndfip1+/+	Foxp3-Cre	+	WT	controls.	 (c-e)	 Lung	 homogenates	were	 analyzed	 by	 flow	 cytometry	 for	 total	 Foxp3+	 (c)	 and	 total	cytokine-producing	CD4+	T	cells	(d)	and	total	YFP+	Foxp3+	cells.	(e-h)	Percentages	of	Foxp3+	cells		(e)	or	CD44+	eTreg	cells	(f-h)	are	shown	as	a	ratio	of	YFP+:YFP-	cells	to	illustrate	changes	due	to	the	deletion	of	Ndfip1	and	to	normalize	for	effects	of	Cre.	(g-h)	Analysis	of	ICOS	(g)	and	GITR	(h)	MFI	on	unstimulated	lung	homogenates.	Error	bars	indicate	mean	±	SEM.	Each	dot	represents	an	individual	mouse.	All	experiments	were	performed	on	at	least	two	independent	occasions.	P	value	calculated	by	unpaired	T	test	(a-c,	e-h)	or	one-way	ANOVA	(d).	*	p<0.05	**	p<0.01	***	p<0.001	****p<0.0001,	ns=	not	significant	
Ndfip1	limits	IL-4	production	by	regulatory	T	cells		Our	data	 indicate	that	Ndfip1	 limits	eTreg	cell	expression	of	 ICOS	and	GITR	and	 restricts	 eTreg	 cell	 proliferation.	 However,	 it	 remained	 unclear	 why	
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Ndfip1fl/flFoxp3-Cre+/-	 females	 developed	 inflammation,	when	 approximately	 half	of	the	Treg	cells	in	these	mice	are	Ndfip1-sufficient.	This	suggested	a	pathologic	gain	of	 function	 in	 Ndfip1-deficient	 Treg	 cells.	 We	 thus	 investigated	 whether	 Ndfip1-deficient	Treg	 cells	 could	 contribute	 to	 the	pool	of	 cytokine-producing	 cells	 in	 the	lung	 of	 Ndfip1fl/flFoxp3-Cre	 male	 mice	 shown	 in	 Fig.	 3.1.	 Effector	 cytokine	production	 by	 WT	 Treg	 cells	 is	 relatively	 rare	 but	 has	 been	 described	 under	inflammatory211	 or	 lymphopenic	 settings142,212.	 Strikingly,	while	WT	Treg	 cells	did	not	 produce	 any	 IL-4	 upon	 ex	 vivo	 stimulation,	 Ndfip1-deficient	 Treg	 cells	 could	produce	 IL-4,	and	 this	was	detectable	at	both	 the	protein	 (Fig.	3.8a,b)	and	mRNA	level	(Fig.	3.8c).	Ndfip1-deficient	Treg	cells	were	also	more	likely	to	produce	IL-10,	IFNγ	 and	 IL-17A	 relative	 to	 WT	 controls.	 To	 determine	 whether	 this	 cytokine	production	 was	 due	 to	 the	 loss	 of	 Ndfip1,	 or	 was	 a	 result	 of	 the	 inflammatory	environment,	 we	 generated	 YFP-Cre+	 mixed	 bone	 marrow	 chimeras.	 Consistent	with	our	data	 from	the	 female	mice,	 these	mixed	chimeras	developed	dermatitis	8	weeks	after	reconstitution.	On	analysis,	CD45.1+	WT	Foxp3+	cells	did	not	produce	any	 IL-4	while	 CD45.2+	Ndfip1-deficient	 Foxp3+	 cells	 in	 the	 same	host	 expressed	significant	amounts	of	 IL-4	(Fig.	3.8d,e),	supporting	an	 intrinsic	role	 for	Ndfip1	 in	limiting	IL-4	production	from	Treg	cells.	Surprisingly,	when	we	analyzed	the	Foxp3-	Tconv	cells,	we	found	a	significant	population	of	CD45.2+	cells	that	also	expressed	IL-4	 (Fig.	 3.8f,g),	 raising	 the	 possibility	 that	 the	 IL-4-producing	 population	originated	from	Ndfip1fl/fl	Foxp3-Cre	Treg	cells	that	had	lost	Foxp3.		
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FIGURE	3.8	Ndfip1	prevents	Treg	cells	from	making	IL-4.		(a-b)	 Lung	 homogenates	 from	 WT	 and	 Ndfip1fl/fl	 Foxp3-Cre	 male	 mice,	 9-16	 weeks	 old,	 were	stimulated	ex	vivo	with	P/I	and	analyzed	for	IL-4	production	by	flow	cytometry.	(a)	Representative	flow	 plots	 of	 Treg	 cells	 (Foxp3+CD3+CD4+)	 producing	 IL-4.	 (b)	 Compiled	 percentages	 of	 IL-4	producing	Treg	cells.	 (c)	qPCR	analysis	of	 IL-4	 from	sorted	YFP+	Treg	cells	 from	WT	and	Ndfip1fl/fl	Foxp3-Cre	male	mice.	Cells	were	unstimulated	(-)	or	stimulated	(+)	with	αCD3/CD28.	IL-4	mRNA	is	shown	relative	to	Actb.	(d-g)	Lung	homogenates	from	mixed	chimeras	were	stimulated	ex	vivo	with	P/I	and	analyzed	for	IL-4	production	by	flow	cytometry.	(d)	Representative	flow	plots	showing	IL-4	production	 from	Treg	 cells	 from	WT	 (gated	 on	 CD45.1)	 or	Ndfip1fl/fl	 Foxp3-Cre	 (gated	 on	 CD45.2)	cells	 from	the	same	recipient.	 (e)	Graphs	showing	 the	percentages	of	 IL-4+	Treg	cells	 from	CD45.1	and	 CD45.2	 cells	 in	 each	 chimera,	 cells	 from	 the	 same	 recipient	 are	 connected	 by	 a	 line.	 (f)	Representative	 flow	 plots	 showing	 IL-4	 production	 from	 Tconv	 cells	 from	 the	 same	 chimeras	 (g)	Graphs	showing	the	percentages	of	IL-4+	Tconv	cells	as	per	panel	(e).	All	experiments	were	performed	on	 at	 least	 two	 independent	 occasions.	 Graphs	 show	mean	 ±	 SEM.	 Mixed	 bone	marrow	 chimeras	were	 generated	 and	 analyzed	 in	 two	 separate	 experiments	 using	 male	 donors.	 P	 values	 were	determined	by	student’s	T	test	for	(a-d)	or	a	paired	T	test	for	(e,g).	*	p<0.05	**	p<0.01	
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Ndfip1-deficient	Treg	cells	lose	Foxp3	expression	Given	 the	 IL-4	 production	 by	 Ndfip1-deficient	 Treg	 cells,	 and	 their	 increased	proliferative	 capacity,	 we	 posited	 that	 these	 cells	 would	 be	 likely	 to	 become	methylated	 at	 their	 Foxp3	 locus	 and	 become	 unstable.	 IL-4	 receptor	 signaling	 in	Treg	cells,	via	STAT6,	results	in	the	methylation	of	the	Conserved	Non-coding	DNA	Sequence	 2	 (CNS2)	 region	 of	 the	 Foxp3	 locus	 and	 repression	 of	 foxp3	 gene	expression213.	Therefore,	we	compared	the	 levels	of	methylation	at	12	CpG	islands	in	 the	 Foxp3	 CNS2	 region	 in	 Ndfip1-sufficient	 and	 Ndfip1-deficient	 Treg	 cells,	 as	well	 as	 WT	 Tconv	 cells.	 As	 expected,	 the	 CNS2	 CpG	 motifs	 were	 predominantly	methylated	 in	 Tconv	 cells	 (Fig.	 3.9a)213.	 Both	WT	 and	Ndfip1-deficient	 Treg	 cells	had	 unmethylated	 CpG	 motifs	 in	 their	 Foxp3	 promoter	 regions	 (Fig.	 3.9b),	consistent	 with	 their	 ability	 to	 normally	 transcribe	 Foxp3	 mRNA	 (Fig.	 3.9c).	However,	in	Ndfip1fl/flFoxp3-Cre	Treg	cells,	there	was	an	increase	in	methylation	at	the	 12	 examined	 CNS2	 CpG	 sites,	 compared	 to	 WT	 Treg	 cells,	 which	 remained	unmethylated	at	these	sites	(Fig.	3.9d,e).			
	 These	data	 suggested	 that	Ndfip1	deficiency,	via	 concomitant	expression	of	IL-4,	 negatively	 impacts	 lineage	 stability	 of	 Treg	 cells.	 To	 test	 whether	 Ndfip1	sufficient	 and	 deficient	 Treg	 cells	 have	 differential	 responses	 to	 destabilizing	cytokines,	 we	 cultured	 Ndfip1-sufficient	 and	 -deficient	 Foxp3+	 cells	 in	 stabilizing	(IL-2)	 or	 destabilizing	 (IL-4	 plus	 anti-IL-2)	 conditions,	 and	 analyzed	 Foxp3	expression	as	a	surrogate	for	lineage	stability.	We	found	that	Ndfip1-deficient	Treg	cells	 were	 equally	 stabilized	 by	 IL-2	 and	 destabilized	 by	 IL-4	 compared	 to	 their	
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Ndfip1-sufficient	 counterparts	 (Figure	 3.10a-c).	 Thus,	 Ndfip1-deficient	 Treg	 cells	are	not	uniquely	sensitive	 to	 the	destabilizing	effects	of	 IL-4;	Ndfip1-deficient	 IL-4	producing	 Treg	 cells	 may	 just	 be	more	 likely	 to	 encounter	 destabilizing	 cytokine	milieus	in	vivo.	 	
	 To	 test	 Treg	 lineage	 stability	 in	 vivo,	 we	 sorted	 WT	 or	 Ndfip1-deficient	CD45.2+	 YFP+	 Treg	 cells	 and	 co-transferred	 them	with	 sorted	 naïve	 CD45.1+	WT	Tconv	cells	 into	RAG1-/- hosts	 (Fig	3.11a).	As	previously	observed,	mice	 receiving	either	Ndfip1-deficient	or	sufficient	Treg	cells	did	not	develop	colitis	(Fig.	3.11b).	At	harvest,	 we	 determined	 the	 frequencies	 of	 CD45.2+	 cells	 that	 were	 still	 Foxp3+	(current	Treg	cells)	or	that	had	lost	Foxp3	(former	Treg	cells).	In	mice	that	received	WT	Treg	cells,	on	average,	30%	had	lost	Foxp3,	similar	to	previous	reports	by	other	groups142,206.	Strikingly,	 in	mice	that	had	received	Ndfip1-deficient	Treg	cells,	60%	on	average	had	lost	expression	of	Foxp3	(Fig.	3.11c,d).	These	Foxp3-	CD45.2+	cells	could	represent	Ndfip1-deficient	Treg	cells	that	had	lost	Foxp3	expression	in	vivo,	or	a	 very	proliferative	Tconv	 cell	 contamination	 from	 cell	 sorting.	 If	 the	 Foxp3-	 cells	represented	 former	 Treg	 cells,	 they	 would	 lack	 Ndfip1,	 due	 to	 excision	 following	expression	 of	 Foxp3-Cre.	 Contaminating	 Tconv	 cells,	 on	 the	 other	 hand,	 would	continue	 to	 express	 Ndfip1.	 We	 sorted	 current	 Treg	 cells,	 former	 Treg	 cells,	 and	Tconv	cells	and	stimulated	 to	 induce	Ndfip1	mRNA	expression.	We	 found	 that	 the	WT	 Tconv	 cells	 expressed	 Ndfip1	 mRNA,	 while	 neither	 the	 Ndfip1fl/flFoxp3-Cre+	current	Treg	cells	nor	former	Treg	cells	expressed	detectable	levels	of	Ndfip1	mRNA	(Fig.	 3.11e).	 Thus,	 Treg	 cells	 lacking	 Ndfip1	 were	 more	 likely	 to	 lose	 Foxp3	expression	than	their	WT	counterparts.		 	
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	 Current	 (Fig.	 3.11f)	 and	 former	 (Fig.	 3.11g)	 Treg	 cells	 lacking	 Ndfip1	produced	IL-4,	while	current	and	former	WT	Treg	cells	did	not.	Importantly,	none	of	the	WT	Tconv	cells	produced	very	much	IL-4	(Fig.	3.11h).	This	was	not	true	for	all	cytokines	 since	 WT	 and	 Ndfip1-deficient	 cells	 were	 equally	 likely	 to	 make	 IFNγ	regardless	of	whether	 they	were	Treg	cells	 (Fig.	3.12a,b)	or	co-transferred	Tconv	cells	 (Fig.	 3.12c).	 Additionally,	 compared	 to	WT	 Treg	 cells,	 Ndfip1-deficient	 Treg	cells	expanded	to	greater	numbers	in	vivo	(Fig.	3.12d,e)	suggesting	an	advantage	in	proliferation	and/or	survival	of	both	current	and	former	Ndfip1-deficient	Treg	cells.		
In	 summary,	 in	 a	 setting	 where	 Treg	 cells	 are	 pushed	 to	 undergo	lymphopenia-induced	proliferation,	Ndfip1-deficient	Treg	cells	have	an	advantage	in	growth	 and	 expansion,	 which	 leads	 to	 a	 large	 increase	 total	 numbers	 of	 Ndfip1-deficient	 current	and	and	 former	Treg	cells.	 Since	 the	majority	of	Ndfip1-deficient	former	Treg	 cells	 (~50%)	make	 IL-4,	 this	may	 explain	 the	dramatic	 loss	 of	 Foxp3	observed	in	vivo.	
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FIGURE	3.9	Ndfip1-deficient	Treg	cells	have	evidence	of	Foxp3	locus	instability.		YFP+	eTreg	 cells	were	 sorted	 from	9-12	week	old	WT	or	Ndfip1fl/fl	 Foxp3-Cre	male	mice,	and	 assessed	 for	 CNS2	 methylation	 using	 bisulfite	 sequencing.	 (a)	 Analysis	 of	 the	methylation	status	of	the	CNS2	region	in	Foxp3-	(Cre	negative)	cells	isolated	from	WT	male	animals.	 (b)	 Representative	 alleles	 showing	 methylation	 status	 of	 the	 Foxp3	 promoter	region	from	eTreg	cells	isolated	from	9-12	week	old	male	WT	or	Ndfip1fl/fl	Foxp3-Cre	mice.	(c)	 Expression	 of	 Foxp3,	 as	 measured	 by	 qPCR	 analysis	 in	 unstimulated	 or	 αCD3/CD28-bead-stimulated	 Treg	 cells.	 Foxp3	 mRNA	 expressed	 as	 2^dCT,	 relative	 to	 actb.	 (d)	Representative	 data	 of	 methylation	 at	 the	 Foxp3	 CNS2	 locus	 in	 Treg	 cells	 from	 the	 two	genotypes.	(e)	Quantification	of	methylation	at	12	CpG	islands	in	the	Foxp3	CNS2	locus.	Data	shown	 are	 compiled	 from	 3	 mice	 of	 each	 genotype.	 Data	 are	 the	 percent	 of	 alleles	methylated	at	each	position.	Each	dot	represents	cells	 from	an	 individual	mouse.	P	values	were	calculated	by	one-way	ANOVA.	*	p<0.05	**	p<0.01	***	p<0.001	****p<0.0001.	Graphs	show	mean	±	SEM.		
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FIGURE	3.10	Ndfip1-deficient	Treg	cells	are	not	more	likely	to	be	destabilized	by	IL-4.		Representative	plots	(a)	showing	that	the	in	vitro percentages	(b)	and	MFI	(c)	of	sorted	YFP+	Foxp3	cells	 are	 increased	 in	 response	 to	 IL-2	 and	 decreased	 in	 response	 to	 IL-4	 and	 anti-IL-2.	 P	 values	calculated	by	one	way	ANOVA	*	p<0.05	**	p<0.01	***	p<0.001	****p<0.0001.		
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FIGURE	3.11	Ndfip1-deficient	Treg	cells	are	more	likely	than	controls	to	lose	Foxp3	in	vivo.	(a)	YFP+	Treg	cells	from	CD45.2+	WT	or	Ndfip1fl/fl	Foxp3-Cre	mice	were	mixed	1:5	with	CD45.1+	WT	naïve	Tconv	cells	and	transferred	to	RAG1-/- recipients.	Cells	from	lung	homogenates	were	analyzed	for	Foxp3	 and	 IL-4	 expression	 using	 flow	 cytometry	 13	 weeks	 after	 transfer.	 (b)	 Graph	 shows	percentage	 change	 in	 weight	 over	 the	 course	 of	 the	 experiment.	 (c)	 A	 representative	 flow	 plot	showing	CD45.2+	WT	and	Ndfip1fl/fl	Foxp3-Cre	cells	that	were	analyzed	for	expression	of	Foxp3.	(d)	Compiled	data	 from	multiple	mice	analyzed	as	 in	panel	 (c).	 (e)	Lung	homogenates	were	sorted	 for	Treg	 cells	 that	 remained	 Foxp3+	 (current	 Treg	 cells),	 those	 that	 had	 become	 Foxp3-	 following	transfer	(former	Treg	cells),	and	for	CD45.1	Tconv	cells,	restimulated,	and	analyzed	for	Ndfip1	mRNA	by	qPCR.	(f)	Percentages	of	 IL-4	producing	cells	 that	remained	Foxp3+	(current	Treg	cells)	and	(g)	that	 had	 become	 Foxp3-	 following	 transfer	 (former	 Treg	 cells).	 (h)	Percentages	 of	 IL-4	 producing	CD45.1	Tconv	cells.	All	experiments	were	performed	on	at	 least	two	separate	occasions.	P	value	was	calculated	 by	 one-way	 ANOVA	 (a,d)	 or	 by	 unpaired	 T	 tests	 (f-h).	 *p<0.05	 **p<0.01	 ***p<0.001	****p<0.0001			
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FIGURE	3.12	Current	and	 former	Ndfip1-deficient	Tregs	are	not	more	 likely	 to	express	 IFNγ 	
but	are	more	likely	to	expand	in	vivo.		(a-e)	I	CD45.1	CD4+	Tconv	cells	and	CD45.2	WT	or	Ndfip1fl/fl	Foxp3-Cre	YFP+	Treg	cells	cells	were	co-injected	 via	 IP	 at	 a	 5	 Tconv:	 1	 Treg	 ratio	 into	 RAG1-/- animals,	 as	 described	 in	 Figure	 3.11.	 IFNγ	production	by	current	(a)	and	former	(b)	Treg	cells	and	from	the	co-transferred	Tconv	cells	(c).	(d-e)	Absolute	 numbers	 of	 CD45.2+	 current	 and	 former	 Treg	 cells	 (d)	 or	 of	 total	 CD45.2+	 cells	 (e)	 in	recipients	 of	WT	or	Ndfip1fl/fl	 Foxp3-Cre	Treg	 cells.	All	mice	were	 analyzed	13	weeks	 after	 the	 co-	transfer.	 Error	 bars	 indicate	 mean	 ±	 SEM.	 Each	 dot	 represents	 an	 individual	 recipient	 mouse.	 All	experiments	were	performed	on	at	least	two	independent	occasions	using	at	least	2	animals	of	each	genotype.	P	value	was	calculated	by	unpaired	T	tests	(a-c,	and	e)	or	by	one-way	ANOVA	(d).	*p<0.05	**p<0.01	***p<0.001	****p<0.0001	,	Ns=	not	significant	
IL-4	 is	 dispensable	 for	 Ndfip1-deficient	 eTreg	 activation,	 expansion	 and	
surface	marker	expression		To	assess	whether	IL-4	 is	required	for	the	phenotypic	changes	 in	Treg	cells	lacking	 Ndfip1,	 we	 examined	 Treg	 cells	 in	 mice	 that	 lack	 both	 Ndfip1	 and	 IL-4	(Ndfip1	 IL-4	DKO	mice)68.	These	animals	 lack	overt	 signs	of	 inflammation	 such	as	dermatitis68,214	 compared	 to	 age-matched	 Ndfip1fl/flFoxp3-Cre	 animals.	 However,	they	do	have	aberrant	Th17	differentiation	and	 increased	activated	CD4	T	cells	as	previously	discussed	in	Chapter	2.	We	observed	increased	frequencies	of	Treg	cells	(Fig.	3.13a,b)	 compared	 to	 IL-4	deficient	 controls.	The	Ndfip1-deficient	Treg	cells	
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that	lacked	IL-4	were	more	proliferative	than	controls,	as	determined	by	Ki67	(Fig.	
3.13c).	 Similar	 to	 the	Ndfip1fl/flFoxp3-Cre	mice,	Treg	 cells	 in	 the	Ndfip1	 IL-4	DKO	mice	were	predominantly	eTreg	cells	(Fig.	3.13d,e).	Additionally,	the	Ndfip1-	IL-4-	deficient	 eTreg	 cells	 expressed	 higher	 levels	 of	 Ki67	 (Fig.	 3.13f)	 and	 ICOS	 (Fig.	
3.13g).	Thus,	while	IL-4	from	current	and	former	Treg	cells	likely	contributes	to	the	inflammation	observed	 in	Ndfip1fl/flFoxp3-Cre	mice,	 increased	Treg	cell	 activation,	proliferation,	 and	 ICOS	 expression	 are	 not	 due	 to	 IL-4	 signaling.	 Thus,	 IL-4	 is	insufficient	to	explain	the	increased	fitness	of	Ndfip1-deficient	Treg	cells.	
	
FIGURE	3.13	IL-4	does	not	drive	the	in	vivo	fitness	of	Ndfip1-deficient	Treg	cells.		(a-g)	Regulatory	T	cells	 from	the	 lung	of	 IL-4KO	and	Ndfip1	 IL-4	DKO	mice	were	analyzed	by	 flow	cytometry	ex	vivo.	(a)	Representative	flow	plots	of	Foxp3+	Treg	cells	from	lung.	(b-c)	Percentage	of	(b)	total	lung	Treg	cells	or	(c)	total	lung	Ki67+	Treg	cells.	(d)	Representative	flow	plots	of	eTreg	and	cTreg	cells,	 identified	by	CD44	and	CD62L	staining	of	 lung	homogenate.	Previously	gated	on	Foxp3.	(e)	 Summary	 of	 percentages	 of	 eTreg	 cells	 from	 (d).	 (f-g)	 CD44+	 lung	 Foxp3+	 eTreg	 cells	 were	analyzed	for	expression	of	the	proliferation	marker,	Ki67	(f)	or	ICOS	(g).	Error	bars	indicate	mean	±	SEM.	 N=2-4	 (age-matched	 male	 or	 female)	 animals	 per	 genotype	 in	 one	 experiment.	 P	 values	determined	by	student’s	T	test	*	p<0.05	**	p<0.01		
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Ndfip1-deficient	eTreg	cells	have	altered	metabolic	activity	To	 identify	molecular	 pathways	 underlying	 the	 increased	 proliferation	 and	altered	 eTreg	 cell	 phenotype	 of	 Ndfip1	 deficient	 Treg	 cells,	 we	 used	 label-free	quantitative	proteomics	to	compare	WT	and	Ndfip1-deficient	cTreg	and	eTreg	cells.	We	sorted	YFP+	eTreg	and	cTreg	cells	from	young	WT	or	Ndfip1fl/flFoxp3-Cre	male	mice,	 subjected	 these	 cells	 to	 LC	 MS/MS	 analysis,	 and	 quantified	 proteins	 using	intensity	based	absolute	quantification	(iBAQ)215–217	(Fig.	3.14a).	We	achieved	good	reproducibility	of	identified	proteins	across	three	experiments,	pooling	two	to	three	mice	of	each	genotype	per	experiment	(Fig.	3.14b).	Comparing	proteins	 identified	in	 control	 eTreg	 and	 cTreg	 proteomes,	 our	 data	 fit	 well	 with	 what	 has	 been	published	previously	on	proteins	unique	to	each	sub-type.	Namely,	among	proteins	that	were	significantly	more	abundant	in	cTreg	than	eTreg	proteomes	or	that	were	found	 exclusively	 in	 cTreg	 proteomes,	 defined	 here	 as	 having	 a	 cTreg	 “bias”,	 we	identified	CD62L	and	Bcl2210	(Fig.	3.14c).	Proteins	that	were	increased	in,	or	biased	toward,	 the	 eTreg	 proteome,	 included	 CD44	 and	 several	 proteins	 associated	with	eTreg	cells	such	as	Integrin	alpha	E/itgae	(CD103)218	(Fig.	3.14c).		 	 	
To	 characterize	 differential	 protein	 expression	 in	 Ndfip1	 sufficient	 and	deficient	Treg	cells,	we	compared	the	ratio	of	protein	abundance	in	eTreg:cTreg	for	each	of	the	three	experiments.	This	revealed	widespread	changes	in	the	proteomes	of	 Ndfip1-deficient	 Treg	 cells.	 Given	 that	 Ndfip1	 deficiency	 drove	 changes	predominantly	in	eTreg	cells,	we	focused	our	comparisons	on	the	levels	of	proteins	identified	in	WT	and	Ndfip1-deficient	eTreg	cells	(Fig.	3.14d).	Our	flow	cytometric	
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finding	of	increased	GITR	expression	was	supported	by	these	Treg	proteomes	(Fig.	
3.14d).	 Surprisingly,	 proteins	 associated	 with	 increased	 mTORC1	 activity	 were	increased	 in	 Ndfip1-deficient	 eTreg	 cells.	 This	 included	 Lamtor1	 (Fig.	 3.14d),	 as	well	 as	 the	 V-ATPase	 subunit	 d1	 and	 Lamtor3,	 which	 are	 components	 of	 the	 v-ATPase-ragulator	 complex	 that	 drives	 mTORC1	 activation	 in	 cells219–221.	 We	 then	performed	 network	 visualization	 of	 gene-ontology-enrichment	 analysis	 for	differentially	 regulated	 proteins	 in	 Ndfip1	 sufficient	 and	 deficient	 eTreg	 cells	 and	identified	 clusters	of	nodes	 relating	 to	metabolic	processes	 that	were	 significantly	enriched	 (Fig.	 3.14e).	 Thus,	 loss	 of	 Ndfip1	 led	 to	 an	 altered	 proteomic	 profile	indicative	of	altered	metabolic	activity.	
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FIGURE	3.14	A	comparison	of	proteomes	from	WT	and	Ndfip1fl/fl	Foxp3-Cre	eTreg	cells	suggest	
altered	metabolic	activity.		(a)	Representative	flow	cytometry	dot	plots	and	gel	pixelation	to	illustrate	procedure	used	to	analyze	cTreg	 and	 eTreg	 cell	 proteomes	 using	 mass	 spectrometry.	 (b)	 Area-proportional	 Venn	 diagrams	illustrating	 the	 reproducibility	 of	 proteins	 identified	 in	 cTreg	 (left)	 or	 eTreg	 (right)	 cells	 from	 3	independent	experiments.	WT	cells	were	compared	for	this	analysis	and	data	was	compiled	using	the	intensity	based	absolute	quantification	 (iBAQ)	method.	 (c)	A	volcano	plot	 illustrating	differentially	expressed	proteins	 between	 eTreg	 versus	 cTreg	 cells	 in	WT	mice.	 (d)	A	 volcano	plot	 representing	differentially	expressed	proteins	between	eTreg	cells	 from	Ndfip1fl/fl	 Foxp3-Cre	or	WT	animals.	 (e)	Network	 diagram	 of	 enriched	 GO	 terms	 with	 nodes	 representing	 GO	 annotations	 and	 edges	connecting	 similar	 terms	 based	 on	 the	 GO	 hierarchy.	 The	 size	 of	 the	 nodes	 corresponds	 to	 the	number	of	genes	associated	with	the	respective	GO	term	and	the	color	of	the	nodes	corresponds	to	the	 level	 of	 significance	 of	 the	 enrichment	 of	 the	 respective	 term	 in	 the	 dataset	 (darker	 color	corresponds	 to	 a	 higher	 level	 of	 significance).	 Clusters	 of	 GO	 terms	 were	 manually	 analyzed	 and	annotated	 to	 identify	 broad	 functional	 similarity.	 Data	 is	 shown	 for	 YFP+	 eTreg	 cells	were	 sorted	from	9-12	week	old	WT	or	Ndfip1fl/fl	Foxp3-Cre	male	mice.	
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Ndfip1-deficient	Treg	cells	have	increased	glycolysis	Based	 on	 this	 proteomics	 profiling,	 we	 sought	 to	 analyze	 the	 metabolic	capacity	 of	 Ndfip1-deficient	 Treg	 cells.	 To	 obtain	 sufficient	 cell	 numbers	 for	metabolic	 testing,	 we	 used	 in	 vitro IL-2	 expanded	 Treg	 cells.	 We	 evaluated	 the	bioenergetics	of	these	expanded	WT	and	Ndfip1fl/flFoxp3-Cre	Treg	cells	at	“rest”	and	also	upon	 re-stimulation.	We	measured	 the	 extracellular	 acidification	 rate	 (ECAR)	under	 glycolytic	 stress	 conditions	 (Fig.	 3.15a-d)	 and	 oxygen	 consumption	 rate	(OCR)	 under	mitochondrial	 stress	 conditions	 (Fig.	 3.15e-h).	 Prior	 to	 stimulation,	WT	Treg	cells	had	low	basal	rates	of	glycolysis,	but	rates	increased	when	cells	were	stimulated	(Fig.	3.15a,b).	In	Ndfip1-deficient	Treg	cells,	the	“resting”	glycolytic	rate	was	only	modestly	 increased	over	WT	cells	 (Fig.	3.15a,c).	However,	 re-stimulated	Ndfip1-deficient	 Treg	 cells	 had	 a	 considerably	 increased	 glycolytic	 rate	 and	glycolytic	 capacity	 compared	 to	 restimulated	 WT	 Treg	 cells	 (Fig.	 3.15b-d).	 To	assess	 mitochondrial	 function,	 we	 measured	 cell	 respiratory	 control,	 which	 is	 a	general	 test	 of	mitochondrial	 function	 in	 cells.	 Loss	 of	 Ndfip1	 did	 not	 change	 the	maximum	 respiratory	 capacity	 of	 Treg	 cells	 and	 caused	 a	 slight	 decrease	 in	 the	spare	 respiratory	 capacity	of	Treg	 cells	 (Fig.	3.15e-h).	Taken	 together,	 these	data	indicate	that	the	loss	of	Ndfip1	drives	a	metabolic	switch	in	activated	regulatory	T	cells,	 promoting	 a	 more	 effector	 cell-like	 reliance	 on	 glycolysis	 to	 supply	 cellular	energetic	demands.	
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FIGURE	3.15	Ndfip1-deficient	Treg	cells	have	a	significantly	increased	rate	of	glycolysis.		(a-h)	 YFP+	 Treg	 cells	 were	 sorted	 from	 Ndfip1+/+	 Foxp3-Cre	 WT	 or	 Ndfip1fl/fl	 Foxp3-Cre	 mice,	expanded	 in	 culture,	 and	 then	 were	 left	 unstimulated	 or	 were	 re-stimulated	 before	 metabolic	function	was	assessed.	(a-b)	Extracellular	acidification	rate	(ECAR)	was	measured	during	a	glycolysis	stress	test	in	(a)	unstimulated	or	(b)	stimulated	Treg	cells	treated	with	drugs	as	indicated.	(c)	Rate	of	glycolysis	 is	 the	 difference	 in	 ECAR	 between	 post-glucose	 addition	 and	 baseline.	 (d)	 Glycolytic	capacity	 is	 the	 difference	 between	 post-Oligomycin	 ECAR	 and	 baseline	 ECAR.	 (e-f)	 Oxygen	consumption	 rate	 (OCR)	 changes	 during	 a	 mitochondrial	 function	 assessmenT	 test	 in	 (e)	unstimulated	or	(f)	stimulated	WT	or	Ndfip1fl/fl	Foxp3-Cre	Treg	cells	treated	with	drugs	as	indicated.	(g)	Maximum	respiratory	capacity	 is	 the	difference	 in	OCR	after	addition	of	rotenone/Antimycin	A,	versus	 after	 addition	 of	 FCCP.	 (h)	 Spare	 respiratory	 capacity	 is	 the	 difference	 in	 increased	 OCR	following	addition	of	FCCP	(fluoro-carbonyl	cyanide	phenylhydrazone)	compared	to	baseline.	Graphs	show	mean	±	SEM.	(a-d)	represents	n=4	mice	(male	or	female,	7-12	week	old)	per	genotype	in	two	independent	experiments.	Final	Foxp3%	after	in	vitro expansion	was	74.45%	±	8.03	for	Ndfip1	fl/fl	Foxp3-Cre+	versus	74.8	±	9.80	for	Ndfip1+/+	Foxp3-Cre	+.	e-h	represents	n=6-8	mice	(male	or	female,	7-12	 week	 old)	 in	 three	 experiments.	 Final	 Foxp3%	 was	 88.1	 ±	 2.08	 for	 Ndfip1	 fl/fl	 Foxp3-Cre+	versus	86.43	±	1.94	for	Ndfip1+/+	Foxp3-Cre	+.	P	values	were	calculated	by	one-way	ANOVA.	*	p<0.05	**	p<0.01	***	p<0.001	****p<0.0001.	
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Ndfip1-deficient	Treg	cells	have	elevated	mTORC1	activity	Effector	T	cells	utilize	glycolysis	while	regulatory	T	cells	are	more	dependent	on	oxidative	phosphorylation	as	 their	main	source	of	energy222–226.	High	glycolytic	activity	 in	 Treg	 cells,	 as	 can	 occur	 when	mTORC1	 activity	 is	 increased,	 has	 been	associated	Treg	 cell	 dysfunction204,205,227.	 To	 investigate	whether	mTORC1	 activity	was	increased	in	Ndfip1-deficient	Treg	cells,	we	cultured	WT	and	Ndfip1fl/fl	Foxp3-Cre	 Treg	 cells	 in	 vitro.	 We	 found	 that	 Ndfip1fl/flFoxp3-Cre	 Treg	 cells	 quickly	outnumbered	 their	WT	counterparts	 (Fig.	3.16a),	were	 increased	 in	cell	 size	 (Fig.	
3.16b),	and	proliferated	more	(Fig.	3.16c).	This,	 together	with	observed	increases	in	 ICOS	 and	 GITR	 expression	 (Fig.	 3.16d-e),	 suggested	 that	 this	 in	 vitro culture	system	recapitulates	the	phenotype	of	Ndfip1-deficient	Treg	cells	in	vivo.	Given	that	ICOS	 can	 be	 driven	 by	 mTORC1227	 activity,	 we	 examined	 other	 proteins	 in	 the	mTORC1	pathway,	including	the	amino	acid	transporter,	CD98	and	phosphorylated	S6	 (pS6).	CD98	and	pS6	 (Fig.	3.16f-g)	were	both	 increased	 in	Ndfip1fl/flFoxp3-Cre	Treg	 cells.	 Co-culture	 confirmed	 that	 these	 changes	 are	not	directly	 linked	 to	 IL-4	signaling	(Fig.	3.16h).		 	 	
Increased	responsiveness	to	IL-2	could	explain	the	fitness	of	Ndfip1-deficient	Treg	cells	in	this	IL-2	expansion	system.	To	test	this,	we	sorted	Ndfip1-sufficient	and	deficient	Treg	cells	and	rested	them	overnight	without	cytokine	or	TCR	stimulation.	Upon	brief	IL-2	stimulation,	we	detected	STAT5	phosphorylation	by	flow	cytometry.	pSTAT5	 levels	 (MFI)	 were	 similar	 between	 WT	 and	 Ndfip1-deficient	 Treg	 cells	before	and	after	 IL-2	stimulation	(Fig.	3.17a,b).	This	 is	consistent	with	our	recent	
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report	showing	that	both	Ndfip1	and	its	homologue,	Ndfip2,	are	required	in	Tconv	cells	 to	 drive	 the	 degradation	 of	 Jak1,	 and	 decrease	 STAT5	 phosphorylation	 in	response	to	cytokine	such	as	IL-2177.	Therefore,	the	increased	metabolic	activity	of	Ndfip1fl/flFoxp3-Cre+	 Treg	 cells	 is	 cell-intrinsic	 but	 not	 just	 because	 of	 enhanced	responsiveness	to	IL-2.	
	
FIGURE	 3.16	 Loss	 of	 Ndfip1	 in	 Treg	 cells	 leads	 to	 elevated	 mTORC1	 signaling	 and	 this	
correlates	with	their	increased	metabolic	fitness	and	proliferative	capacity.		(a-h)	Treg	cells	were	sorted	 from	congenically	distinct	CD45.1	WT	or	CD45.2	Ndfip1fl/fl	 Foxp3-Cre	mice.	 Treg	 cells	 were	 expanded	 in	 vitro (a-g)	 individually	 or	 (h)	 in	 mixed	 co-cultures.	 (a)	 Cell	numbers	 in	 the	 cultures	were	 analyzed	daily	 for	7	days.	 (b-f)	After	7	days,	 cells	were	 analyzed	by	flow	cytometry	for	cell	size	(forward	scatter-FSC),	(b)	Ki67	expression,	(c)	or	their	surface	levels	of:	(d)	ICOS,	(e)	CD98	and	(f)	GITR.	(g)	Cells	were	also	re-stimulated	at	the	end	of	the	culture	period	and	analyzed	for	expression	of	pS6.	(h)	Co-cultured	WT	and	Ndfip1fl/fl	Foxp3-Cre	Treg	cells	were	similarly	examined	 for	 expression	 of	 Ki67,	 ICOS,	 GITR,	 CD98,	 and	 pS6.	 Each	 dot	 represents	 an	 individual	mouse.	All	 experiments	were	performed	on	at	 least	 two	 independent	occasions	using	age-matched	male	or	female,	7-12	week	old	mice	of	each	genotype.	P	values	were	calculated	by	multiple	T	tests.	*	p<0.05	**	p<0.01	***	p<0.001	****p<0.0001.	Error	bars	indicate	mean	±	SEM.	
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FIGURE	3.17	Ndfip1-deficient	Treg	 cells	do	not	have	exaggerated	STAT5	phosphorylation	 in	
response	to	IL-2.		Sorted	YFP+	 total	 Treg	 cells	were	 rested	 overnight	without	TCR	or	 cytokines.	 The	MFI	 for	 STAT5	phosphorylation	as	measured	by	flow	cytometry,	is	shown	for	the	Treg	cells	with	or	without	addition	of	119	IU/ml	(~50ng/ml)	of	rhIL-2	for	30minutes	at	37	degrees.		(a)	Representative	flow	cytometry	data	for	pSTAT5	staining	(b)	Summary	data	for	Treg	cells	from	several	animals.	Each	dot	represents	data	acquired	from	a	single	mouse	(male	or	female,	between	9-16	weeks	old).	Graphs	show	mean	±	SEM	and	represent	data	from	at	least	two	independent	experiments.		P	values	were	calculated	by		an	ANOVA,	ns=	not	significant.	
mTORC1	signaling	drives	increased	GITR	levels	on	Ndfip1-deficient	Treg	cells	Finally,	 we	 investigated	 the	 effect	 of	 blocking	 mTORC1	 on	 some	 of	 the	observed	 phenotypes	 in	 the	 Ndfip1-deficient	 Treg	 cells.	We	 found	 that	 treatment	with	 the	mTORC1	 inhibitor,	 rapamycin,	 did	 not	 change	 the	 percentage	 of	 Foxp3+	cells	in	culture	(Fig.	3.18a),	However,	in	preliminary	results,	inhibition	of	mTORC1	reduced	Ndfip1-deficient	Treg	cell	proliferation	 to	 the	 levels	 seen	 in	a	 treated	WT	Treg	cell	(Fig.	3.18b).	Furthermore,	inhibition	of	mTORC1	decreased	GITR	levels	on	Ndfip1-deficient	Treg	cells	 to	 levels	 found	 in	untreated	WT	Treg	cells	 (Fig.	3.18c)	indicating	 that	 the	 increased	GITR	 expression	 is	mTORC1-driven	 and	 is	 unique	 to	Treg	cells	that	lack	Ndfip1.	Over	the	4-day	in	vitro culture,	ICOS	levels	on	the	Ndfip1-deficient	 Treg	 cells	 were	 not	 significantly	 higher	 than	 the	 WT	 Treg	 levels	 (Fig.	
3.18d).	 This	may	 be	 due	 to	 differences	 in	 level	 of	 ICOS	 induction	 in	 response	 to	
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plate-bound	 antibody	 stimulation	 (4day	 culture)	 versus	 the	 anti-CD3/CD28	 bead	stimulation	(used	in	the	7day	in	vitro expansion)	or	in	response	to	different	amount	of	 IL-2:	 200U/ml	 (4day	 culture)	 versus	 2000U/ml	 (used	 in	 the	 7day	 in	 vitro expansion).	However,	 treatment	with	 rapamycin	decreased	 the	 ICOS	 levels	 on	 the	Ndfip1-deficient	 Treg	 cells	 similar	 to	 the	 reduction	 seen	 in	 WT	 Treg	 cells	 (Fig.	
3.18d).	 Furthermore,	 when	 glycolysis	 was	 inhibited	 via	 treatment	 with	dichloroacetate,	 both	GITR	 and	 ICOS	 levels	 in	Ndfip1-deficient	 Treg	 cells	 dropped	below	 the	 levels	 found	 in	 treated	WT	Treg	 cells	 (Fig.	 3.18e,f).	 These	 preliminary	data	suggest	that	GITR	levels	(unlike	ICOS	levels)	on	Ndfip1-deficient	Treg	cells	are	mTORC1-dependent.		
In	 additional	 preliminary	 data,	 we	 also	 found	 that	 IL-4	 secretion	 in	 this	culture	system	over	 the	 four-day	period	 is	minimal	 (preliminary	data	not	 shown).	We	detected	 low	 levels	of	 IL-4	 in	 the	supernatant	 from	Ndfip1-deficient	Treg	cells	treated	 with	 DMSO.	 Addition	 of	 rapamycin	 did	 not	 decrease	 IL-4	 secretion	 from	these	 cells.	 Furthermore,	 WT	 Treg	 cells	 did	 not	 produce	 IL-4	 whether	 DMSO	 or	rapamycin	 was	 added	 (preliminary	 data	 not	 shown).	 Taken	 together,	 our	 data	suggests	 that	 increased	 GITR	 expression	 on	 the	 Ndfip1-deficient	 Treg	 cells	 is	downstream	 of	 the	 increased	 mTORC1	 signaling	 and	 thus	 can	 be	 decreased	 by	mTORC1	 inhibition.	 Furthermore,	mTORC1	 signaling	may	 be	 dissociated	 from	 the	IL-4	production	in	Ndfip1-deficient	Treg	cells.		
93	
	
FIGURE	3.18	mTORC1	drives	increased	levels	of	GITR	on	Ndfip1-deficient	Treg	cells.		Treg	cells	were	sorted	from	WT	or	Ndfip1fl/fl	Foxp3-Cre	mice.	Treg	cells	were	plated	with	plate-bound	TCR	 stimulation	 in	 the	 presence	 or	 absence	 of	 50nM	 rapamycin	 (mTORC1	 inhibitor)	 or	 10mM	Sodium	dicholoracetate,	DCA,	(glycolysis	inhibitor)	in	complete	RPMI	media.	After	4	days,	cells	were	analyzed	by	flow	cytometry	for	(a)	Foxp3	expression	(b)	Ki67	expression,	or	surface	 levels	of	(c,e)	GITR	or	(d,f)	ICOS	in	response	to	rapamycin	treatment	(c-d)	pr	dichloroacetate	treatment	(e-f).	Each	dot	 represents	 an	 individual	mouse.	All	 experiments	were	performed	on	 at	 least	 two	 independent	occasions	using	age-matched	male	or	 female,	9-16	week	old	mice	of	 each	genotype.	P	values	were	calculated	 by	 one-way	 ANOVA.	 *	 p<0.05	 **	 p<0.01	 ***	 p<0.001	 ****p<0.0001.	 Error	 bars	 indicate	mean	±	SEM	
Discussion	
Therapies	 using	 adoptively	 transferred	 Treg	 cells	 or	 that	 target	 Treg	 cell	function	 are	now	being	developed,	making	 it	 essential	 to	understand	mechanisms	that	 maintain	 Treg	 cell	 identity	 and	 how	 these	 pathways	 integrate	 with	 TCR	activation	and	cellular	metabolic	processes.	Our	data	identify	Ndfip1,	an	activator	of	E3	ubiquitin	ligases,	as	a	new	molecular	target	impacting	Treg	stability	and	function.	
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We	 demonstrated	 that	 Ndfip1-deficient	 Treg	 cells	 are	 highly	 proliferative,	 and	concomitantly	 gain	 the	 capacity	 to	 produce	 the	 proinflammatory	 cytokine	 IL-4.	Importantly,	Ndfip1	 deficiency	 can	 lead	 to	 the	 expansion	 of	 Treg	 cells	 and	 loss	 of	Foxp3	in	vivo.		 	 	 	 	 	 	 	 	
Both	 mTORC1	 and	 mTORC2	 play	 important	 roles	 in	 preventing	 Treg	 cells	from	adopting	a	glycolytic	metabolic	profile.	mTORC1-mediated	glycolytic	activity	in	Treg	 cells	 is	 modulated	 by	 the	 serine	 threonine	 phosphatase	 PP2A	 and	 by	 the	autophagy	 proteins,	 Atg5	 and	 Atg7205,206.	 The	 lipid	 phosphatase,	 PTEN,	 inhibits	mTORC2-mediated	metabolic	pathways	in	Treg	cells	to	prevent	Treg	cell	instability	and	 maintain	 suppression	 of	 Th1	 and	 Tfh	 effector	 T	 cell	 functions228,229.	 Ndfip1-deficient	 Treg	 cells	 have	 increased	 protein	 levels	 of	 ICOS,	 CD98	 and	 pS6,	 all	indicators	of	high	mTORC1	signaling.	mTORC1	deletion	in	Treg	cells	leads	to	defects	in	 efficiently	 synthesizing	 lipids	 from	 glucose,	 and	 to	 defects	 in	 homeostatic	proliferation	in	vivo227.	Therefore	it	is	not	surprising	that	Ndfip1-deficient	Treg	cells,	with	 high	 mTORC1	 signature,	 show	 greater	 homeostatic	 expansion	 in	 vivo,	 show	greater	metabolic	 fitness	 in	 vitro and	 in	 vivo,	 and	 are	more	 efficient	 at	 glycolysis.	This	altered	glycolytic	metabolism	fuels	dysfunction	in	vivo	by	driving	the	expansion	of	e	Treg	cells	that	are	prone	to	produce	IL-4	and	lose	Foxp3.	 	
We	 propose	 that	 Treg	 cells	 lacking	 Ndfip1	 progress	 through	 a	 series	 of	changes	 that	 is	 precipitated	 by	 increased	 proliferation	 of	 activated	 (CD44+)	 Treg	cells	 and	 accompanied	 by	 the	 acquisition	 of	 IL-4	 production.	 These	 changes	 are	likely	 initiated	 in	 eTreg	 cells	 since	 Ndfip1	 is	 inducibly	 expressed	 upon	 T	 cell	
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activation.	 The	 elevated	 glycolytic	 metabolism	 in	 these	 cells	 drives	 further	expansion	of	IL-4-producing	current	and	former	Treg	cells.	Autocrine	IL-4	signaling	can	 then	 lead	 to	 loss	 of	 Foxp3.	 Supporting	 this,	 CD44+	Ndfip1-deficient	Treg	 cells	have	 increased	 methylation	 at	 the	 CNS2	 region	 of	 the	 Foxp3	 locus,	 indicating	susceptibility	 towards	 instability.	Ndfip1-deficient	Th2	 cells	 are	 capable	of	 driving	tissue	 damage	 and	 inflammation	 as	 already	 described	 by	 our	 lab	 and	others25,117,153,177.	 	 	
Loss	of	IL-4	did	not	affect	the	activation,	proliferation	and	in	vivo	expansion	of	 Ndfip1-deficient	 Treg	 cells	 leading	 us	 to	 conclude	 that	 the	metabolic	 fitness	 in	Ndfip1-deficient	 Treg	 cells	 precedes	 or	 is	 independent	 of	 the	 gain	 in	 Treg	 cell-intrinsic	 IL-4	 production.	 Furthermore,	 IL-4-overexpressing	 transgenic	 mice	 have	been	 described	 and	 have	 increased	 recruitment	 of	 different	 immune	 cell	 subsets	into	 the	 skin	 but	 do	 not	 develop	 spontaneous	 dermatitis230	 as	 observed	 in	Ndfip1fl/flFoxp3-Cre	mice.	Lastly,	 loss	of	 the	mTORC1	subunit,	 raptor,	 in	Treg	cells	does	 not	 lead	 to	 a	 cell-intrinsic	 increase	 in	 Treg	 cell	 IL-4	 or	 other	 effector	cytokines227	suggesting	that	cytokine	regulation	and	metabolic	regulation	by	raptor	in	 Treg	 cells	 may	 be	 two	 independent	 events227.	 An	 attractive	 hypothesis	 that	warrants	 further	 future	 investigation	 is	whether	 two	 parallel	 (but	 perhaps	 cross-talking)	 cellular	 pathways	 are	 regulated	 by	Ndfip1:	 one	which	 dampens	mTORC1	activity	and	glycolysis	in	order	to	limit	Treg	cell	activation	and	proliferation,	and	a	second	that	 limits	Treg	cell	 IL-4	production.	These	pathways,	 though	independent,	may	 cooperate	 to	 account	 for	 the	 severity	 of	 the	 inflammation	 observed	 in	Ndfip1fl/flFoxp3-Cre	mice.		Thus,	by	promoting	stable	Foxp3	expression	and	limiting	
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cytokine	 production	 in	 Treg	 cells,	 Ndfip1	 ensures	 two	 important	 aspects	 of	 Treg	stability.		
Ndfip1	 is	 a	 known	 activator	 of	 Itch49,50,177.	 Mice	 bearing	 a	 Treg-specific	deletion	of	Itch	show	some	overlapping	features	with	the	Ndfip1fl/flFoxp3-Cre	mice	described	here104:	Itch-deficient	Treg	cells	have	an	effector	Treg	cell	phenotype,	an	increase	 in	 proliferation,	 and	 intact	 suppression	 in	 traditional	 in	 vivo	 and	 in	 vitro suppression	 assays.	 Itch-deficient	 Treg	 cells	 are	 unstable	 as	 defined	 by	 their	increased	production	of	IL-4	but	these	Treg	cells	do	not	have	defects	in	their	ability	to	 maintain	 Foxp3	 expression	 in	 a	 lymphoreplete	 animal104.	 Future	 work	 will	 be	needed	 to	determine	whether	mTORC1	signaling	 is	 elevated	 in	 Itch-deficient	Treg	cells	and	whether	 this	contributes	 to	 their	dysfunction.	Future	studies	on	 Itch	and	Ndfip1	 will	 be	 of	 particular	 interest	 as	 therapies	 that	 activate	 or	 inhibit	 these	pathways	are	being	developed.	If	such	therapeutic	strategies	can	be	used	to	regulate	Treg	cell	functions,	their	use	in	the	clinic	could	have	broad	potential.	
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CHAPTER	4:	Discussion	and	future	directions	
Discussion:	
At	 first	 glance,	 the	 observation	 that	 both	 Th17	 cells	 and	 Treg	 cells	 are	increased	in	Ndfip1	global	knockout	animals	is	confusing,	given	the	well	described	antagonicity	 between	 Th17	 cells	 and	 Treg	 cells.	 That	 is,	 if	 Th17	 cells	 are	proinflammatory	drivers	of	disease	and	Treg	cells	are	anti-inflammatory	cells,	then	why	isn’t	an	increase	in	Th17	cells	accompanied	by	a	decrease	in	Treg	cells?	Or	why	doesn’t	 the	 increase	 in	 Treg	 cell	 number	 lead	 to	 a	 decrease	 in	 the	 Th17	 cell	population?	Our	 investigations	 have	 revealed	 cell-autonomous	 roles	 for	Ndfip1	 in	Th17	and	Treg	cell	abundance	and	function.	Our	data	indicate	that	Ndfip1	limits	the	numbers	and	functions	of	Th17	cells	but	also	limits	the	numbers	of	Treg	cells	while	promoting	 Treg	 lineage	 stability.	 	 The	 net	 effect	 of	 Ndfip1	 is	 thus	 to	 balance	 the	abundance	 of	 proinflammatory	Th17	 cells	with	 the	numbers	 of	 anti-inflammatory	Treg	cells	and	maintain	normal	immune	homeostasis.	
Ndfip1	 limits	 the	 abundance	 of	 RORγT	 protein,	 which	 is	 essential	 for	 the	identity	of	Th17	cells.	By	so	doing,	Ndfip1	also	limits	the	pathogenicity	of	Th17	cells	since	RORγT	also	drives	the	production	of	proinflammatory	Th17	cytokines	such	as	IL-17A	and	GM-CSF.	 In	Treg	cells,	Ndfip1	promotes	 lineage	stability	by	preventing	excessive	expansion	while	limiting	the	production	of	the	destabilizing	cytokine,	IL-4.	In	spite	of	Ndfip1’s	reciprocal	effects	on	the	identity	of	Th17	and	Treg	cells,	loss	of	Ndfip1	has	 similarly	 negative	 consequences	 in	 both	 cells	with	 regards	 to	 immune	homeostasis;	both	Th17	and	Treg	cells	that	lack	Ndfip1	are	more	pathogenic	in	vivo.	
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For	Th17	cells,	we	showed	this	by	transferring	Ndfip1-deficient	Th17	cells	into	RAG-
/-	hosts	with	resulting	evidence	of	severe	colitis.	For	Treg	cells,	we	showed	that	the	loss	 of	 Ndfip1	 specifically	 only	 in	 Treg	 cells	 was	 sufficient	 to	 cause	 spontaneous	auto-inflammatory	 disease.	 Therefore,	 by	 repressing	 Th17	 identity,	 Ndfip1	 limits	the	pathogenicity	that	Th17	cells	could	drive	if	they	were	increased	in	number	and	function.	 Simultaneously,	 by	 promoting	 lineage	 stability	 of	 the	 anti-inflammatory	Treg	 cells,	Ndfip1	prevents	 the	 spontaneous	autoinflammatory	disease	 that	would	result	 from	 having	 very	 metabolically	 active,	 IL-4	 producing	 current	 and	 former	Treg	cells.	This	highlights	the	long-proclaimed	paradigm	of	Th17	cells	and	Treg	cells	as	antagonistic	and	suggests	that,	by	repressing	proinflammatory	Th17	identity	and	by	 promoting	 Treg	 stability	 and	 anti-inflammatory	 function,	 Ndfip1	 promotes	 a	general	state	of	anti-inflammation.	
	
FIGURE	4.1	Model	for	how	Ndfip1	regulates	Th17	cells	and	Treg	cells	Ndfip1	 drives	 the	 degradation	 of	 RORγT	 and	 limits	 cytokine	 production	 from	 Th17	 cells.	 This	prevents	Th17-mediated	inflammation.	Ndfip1	also	promotes	lineage	stability	by	preventing	the	loss	of	Foxp3,	and	also	prevents	destabilizing	IL-4	production,	from	Treg	cells.	Together,	these	actions	by	Ndfip1	result	in	protection	from	spontaneous	auto-inflammatory	disease.	
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The	 role	 of	 Ndfip1	 in	 Th17	 cells:	 Unresolved	 questions	 and	 future	
directions		
The	 work	 presented	 here	 supports	 a	 model	 in	 which	 Th17	 differentiation	does	not	require	Ndfip1.	However,	once	differentiated,	Th17	cells	require	Ndfip1	to	limit	 RORγT	 protein	 levels	 in	 response	 to	 TCR	 stimulation,	 to	 limit	 their	proliferation,	 and	 to	 dampen	 proinflammatory	 cytokine	 secretion	 (Fig	 4.2).	 This	work	and	model	however	raise	a	few	unresolved	questions.	
	
FIGURE	4.2	Model	for	how	Ndfip1	functions	in	Th17	cells.		Activation	of	a	naïve	CD4	T	cell	during	Th17	differentiation	results	in	a	production	of	Ndfip1	and	Itch.	Ndfip1	 activates	 Itch	 in	 order	 to	 degrade	 RORγT	 protein	 and	 to	 prevent	 Th17	 cell	 proliferation,	decrease	protein	 levels	of	RORγT	and	 to	prevent	production	and	secretion	of	 cytokines	such	as	 IL-17A,	IFNγ	and	GM-CSF.	This	results	in	decreased	recruitment	of	neutrophils	and	also	prevents	direct	damage	from	these	proinflammatory	cytokines	at	the	mucosal	site	and	prevents	auto-inflammatory	disease.	
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Why	do	Ndfip1-deficient	CD4	T	cells	not	have	 increased	Th17	differentiation	
in	vitro?	It	is	striking	that	under	different	conditions	of	Th17	differentiation,	including	low	TGFβ	 (Fig	 2.10),	 high	 TGFβ	 (Fig	 2.5),	minimal	 Th17-polarizing	 cytokines	 (Fig	2.5),	 excessive	Th17-polarizing	cytokines	 (Fig	2.10),	 and	even	 in	a	TCR-transgenic	model	with	altered	peptide	ligands	(Fig	2.6),	we	see	no	role	for	Ndfip1	in	influencing	the	 differentiation	 of	 Th17	 cells	 from	 naïve	 CD4	 T	 cells.	 This	 is	 unusual	 as	many	other	 factors	 that	 influence	 Th17	 abundance	 in	 vivo	 do	 so	 by	 affecting	 the	differentiation	 of	 these	 cells	 from	naïve	 CD4	 cells.	 RORγT-/-,	 IRF4-/-,	 Batf-/-	 and	 IL-23R-/- mice	 have	 very	 little	 to	 no	 Th17	 cell	 differentiation	 in	 vivo66,77,231,232	 and	overexpression	 of	 these	 factors	 drives	 increased	 Th17	 cell	 differentiation.	Furthermore,	 BATF	 (basic	 leucine	 zipper	 transcription	 factor	 ATF-like)	 can	 form	dimers	with	JunB	(an	Ndfip1-Itch	substrate)	to	drive	transcription	of	IL-17A,	IL-21	and	 IL-22	 and	 Th17	 differentiation.	 Therefore	 given	 that	 loss	 of	 Ndfip1	would	 be	expected	 to	 increase	 both	 the	 levels	 of	 JunB	 protein	 and	 RORγT	 protein,	 it	 is	surprising	net	effect	is	not	aberrantly	increased	Th17	cell	differentiation.	This	may	be	due	to	several	reasons,	I	will	discuss	three	here.	
	 First,	the	timing	of	Ndfip1	and	RORγT	protein	production	in	naïve	CD4	T	cells	undergoing	Th17	differentiation	is	not	addressed	by	my	work.	Ndfip1	is	expressed	in	very	low	levels	in	resting,	naive	CD4	T	cells	and	its	expression	increases	upon	TCR	stimulation.	Therefore	at	the	start	of	Th17	differentiation,	Ndfip1	protein	levels	may	be	 very	 low.	 If	 the	 timing	 of	 Ndfip1	 protein	 and	 RORγT	 protein	 levels	 do	 not	
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coincide,	Ndfip1	may	be	 too	 late	 to	 regulate	 the	 levels	 of	RORγT	needed	 for	Th17	differentiation.	Rorc,	the	gene	that	drives	RORγT	protein	levels,	has	been	shown	to	increase	at	4hrs	after	the	start	of	Th17	differentiation233..	However,	RORγT	protein	levels	 do	 not	 increase	 until	 20hrs	 after	 the	 start	 of	 differentiation233.	 The	 time	course	 of	 Ndfip1	 protein	 during	 Th17	 differentiation	 is	 unknown.	 The	 hypothesis	that	non-overlapping	timing	of	protein	expression	of	Ndfip1	and	RORγT	may	make	Th17	 differentiation	 independent	 of	 Ndfip1	 may	 be	 tested	 in	 vitro.	 First,	 protein	levels	of	RORγT	and	Ndfip1	may	be	determined	during	a	time	course	of	naïve	CD4	T	cell	 stimulation	 and	 differentiation	 in	 Th17	 cells.	 Additionally,	 by	 forced	 over-expression	of	Ndfip1	at	different	time	points	during	Th17	differentiation,	it	may	be	possible	 to	 determine	 whether	 Ndfip1	 can	 regulate	 Th17	 differentiation	 when	protein	abundance	is	timed	appropriately.	Furthermore,	a	system	using	tamoxifen-induced	 knockdown	 of	 Ndfip1	 may	 be	 able	 to	 establish	 whether	 the	 timing	 of	expression	 of	Ndfip1	 and	RORγT	protein	 explains	 the	 lack	 of	Ndfip1	 regulation	 of	Th17	cells	differentiation.	 	
Alternatively,	it	is	possible	that	there	is	an	intrinsic	differentiation	threshold	for	 RORγT	 protein	 levels	 required	 to	 drive	 Th17	 cell	 differentiation.	 This	 would	represent	a	digital	differentiation	or	on-off	 system.	 It	has	been	shown	 that	RORγT	has	 a	 strong	 impact	 on	 a	 very	 small	 number	 of	 Th17	 loci	 during	 Th17	differentiation234	 i.e.	 RORγT	 takes	 advantage	 of	 a	 chromatin	 landscape	 already	established	by	key	transcription	factors	such	as	IRF4,	BATF4	and	STAT3	in	order	to	activate	 and	 repress	 its	 target	 genes.	 Therefore	 it	 is	 possible	 that	 Th17	
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differentiation	 depends	 on	 a	minimal	 amount	 of	 RORγT	 protein.	 Thus,	 in	 Ndfip1-deficient	T	cells,	the	loss	of	the	ability	to	degrade	RORγT	may	mean	there	are	excess	levels	of	RORγT	protein	beyond	the	minimum	amount	needed	to	pass	the	threshold	and	 to	 support	 Th17	 differentiation.	 Therefore,	 this	would	 result	 in	 no	 additional	increase	in	Th17	differentiation	in	Ndfip1-deficient	CD4	T	cells.	This	could	be	tested	
in	 vitro by	 the	over	expression	of	 graded	amounts	of	RORγT	protein	 to	determine	effect	on	Th17	differentiation.	 	 	
	 Lastly,	 it	 is	possible	 that	Ndfip1	does	directly	 affect	differentiation	of	Th17	cells	and	that	the	in	vitro	assays	used	in	our	study	were	not	adequate	to	answer	the	question	 of	 Th17	 differentiation.	 In	 support	 of	 this,	 when	 we	 injected	 Ndfip1-deficient	and	sufficient	naïve	CD4	T	cells	into	RAG-/-	mice	for	seven	weeks,	we	were	able	to	recover	greater	numbers	of	Th17	cells	from	the	mice	that	received	Ndfip1-deficient	naïve	CD4	cells	(Fig.	2.7	and	2.9).	While	this	increase	may	be	explained	by	increased	proliferation	by	these	cells,	it	does	not	rule	out	a	role	for	increased	in	vivo	Th17	 differentiation	 in	 driving	 the	 Th17	 abundance.	 The	 use	 of	 T	 cell	 transgenic	mice	 on	 a	 RAG-/-	 background	 may	 help	 address	 the	 contribution	 of	 both	 in	 vivo	differentiation	 and	 proliferation	 to	 the	 abundance	 of	 Th17	 cells	 seen	 in	 Ndfip1-deficient	animals.	This	may	be	done	by	injecting	antigen	into	the	mice	in	the	context	of	in	vivo	labeling	such	as	BrdU,	and	measuring	Th17	generation	before	the	onset	of	extensive	proliferation	in	vivo	(for	example,	within	the	first	48	hours).		 	
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How	does	Ndfip1	influence	the	RORγT	transcriptional	co-factor	landscape?	The	 pathogenicity	 of	 Th17	 cells	 lacking	 Ndfip1	 suggests	 that	 failure	 to	degrade	RORγT	may	result	in	a	modified	co-factor	landscape	for	Th17	cells,	in	favor	of	 new	 protein-protein	 or	 protein-DNA	 interactions	 that	 favor	 the	 production	 of	proinflammatory	 cytokines	 such	 as	 IL-17A,	 IFNγ,	 GM-CSF	 and	 others.	 In	 spite	 of	recent	 advances,	 the	 normal	 transcription	 factor	 landscape	 required	 for	 Th17	differentiation	 and	 for	 RORγT-mediated	 thymopoiesis	 is	 currently	 not	 well	understood235.	It	is	thought	that	in	order	to	drive	Th17	cell	differentiation,	pioneer	factors	such	as	IRF4	and	BATF	need	to	complex	with	lineage-specifying	factors	such	as	 STAT3,	 as	 well	 as	 other	 factors	 such	 as	 p-300	 and	 HIF1α169.	 Furthermore,	 in	pathogenic	 Th17	 cells,	 exposure	 to	 IL-23	 is	 thought	 to	 drive	 increased	 Blimp1	protein	 levels	 and	 to	 allow	 such	 cells	 to	 express	 genes	 such	 as	 Csf2,	 Il23r	 and	
Il17a169.	
However,	 it	 has	 never	 been	 addressed	 whether	 there	 are	 IL-23R-independent	pathways	that	can	drive	Th17	pathogenicity.	In	Ndfip1-deficient	Th17	cells,	 we	 did	 not	 detect	 increased	 levels	 of	 IL-23R	 gene	 expression	 in	 spite	 of	exposure	to	IL-23.	Therefore	Ndfip1	may	regulate	Th17	pathogenicity	independent	of	IL-23R	levels.	If	this	is	true,	this	represents	a	departure	from	the	way	the	field	has	traditionally	 thought	of	Th17	pathogenicity	and	requires	 further	study.	Regulation	of	RORγT	protein	may	involve	modulating	amount	of	RORγT	available	to	bind	DNA	directly	 as	well	 as	 the	 amount	 available	 to	 bind	 coactivators.	 Perhaps	Ndfip1	 and	Itch	 work	 to	 limit	 RORγT	 levels	 so	 that	 there	 is	 enough	 RORγT	 to	 drive	 Th17	
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differentiation	but	not	excessive	amounts	of	RORγT	that	may	drive	binding	of	RORγT	to	additional	sites	or	coactivators	associated	with	Th17	cell	pathogenicity.	If	this	is	true,	CHIP-seq	(Chromatin	Immunoprecipitation	sequencing)	and	ATAC-seq	(Assay	for	Transposase-Accessible	Chromatin	with	high	 throughput	sequencing)	 analysis	of	 RORγT-binding	 sites	 in	 Ndfip1-deficient	 versus	 sufficient	 Th17	 cells	 would	 be	expected	to	show	that	there	is	a	core	set	of	binding	sites	that	would	be	preserved	in	Ndfip1-deficient	Th17	cells.	However,	we	would	also	expect	to	find	enhanced	RORγT	binding	to	additional	sites	in	Ndfip1-deficient	Th17	cells,	particularly	sites	that	are	associated	with	Th17	pathogenicity	such	as	Ccl5	and	Csf2.	Furthermore,	one	would	predict	 that	 in	 Ndfip1-deficient	 Th17	 cells,	 there	 might	 be	 enhanced	 binding	 of	RORγT	to	coactivators	associated	with	pathogenicity,	such	as	Blimp-1	and	others.		 	
This	 is	 an	 exciting	 area	 for	 future	 work	 that	 will	 provide	 much-needed	insight	 into	 our	 understanding	 of	 how	 ubiquitylation	 affects	 the	 generation	 of	pathogenic	Th17	cells.	Furthermore,	understanding	how	Ndfip1	contributes	to	these	processes	 is	sure	 to	provide	opportunities	 for	 therapeutics	 that	can	 target	specific	aspects	of	Th17	cell	function	in	a	more	precise	manner.	
Does	Ndfip1	influence	other	functions	of	RORγT?	RORγT	is	initially	expressed	in	the	thymus	where	T	cell	factor	(TCF)-1	drives	its	 expression	 in	 CD4+	 CD8+	 double	 positive	 (DP)	 cells.	 The	 expression	 of	 RORγT	enhances	survival	of	 these	DP	cells,	giving	 them	more	 time	 to	undergo	positive	or	negative	 selection236.	 Yet	 the	gene	expression	directed	by	RORγT	 in	 the	 thymus	 is	very	different	 from	the	periphery237	 suggesting	 that	 the	effects	of	Ndfip1	on	Th17	
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cells	in	the	periphery	do	not	predict	an	effect	of	Ndfip1	on		RORγT+	DP	cells	in	the	thymus.	In	our	studies	of	Ndfip1-deficient	animals,	we	have	not	observed	evidence	of	a	cell-intrinsic	defect	in	the	thymus	that	would	indicate	alterations	in	positive	or	negative	selection.	Therefore,	if	Ndfip1	affects	RORγT	expression	in	the	thymus,	this	is	 a	 very	 subtle	 defect.	 However,	 it	 would	 be	 worth	 examining	 in	 finer	 detail	whether	Ndfip1-deficient	 thymocytes	show	any	evidence	of	greater	survival	at	 the	DP	thymocyte	stage.	
RORγT	 is	 also	 important	 for	 the	 development	 of	 Lymphoid	 Tissue	 Inducer	cells	(LTis).	LTis	are	critical	early	colonizers	of	developing	lymph	nodes	and	secrete	lymphotoxin-α1β2	which	 binds	 to	 receptors	 on	 stromal	 cells	 found	 in	 the	 lymph	node.	 This	 results	 in	 the	 upregulation	 of	 factors	 that	 attract	 and	 retain	 other	hematopoietic	 cells	 in	 the	 lymph	 node	 and	 help	 it	 gain	 structure	 and	 form238.	Without	RORγT,	LTis	do	not	develop	and	consequently	peyer’s	patches,	cryopatches	and	peripheral	 lymph	nodes	do	not	 form,	 even	 though	 a	 spleen	 forms.	Given	 that	Itch	E3	ligase	has	been	shown	to	regulate	RORγT	in	type	3	innate	lymphoid	(ILC3)	cells173,	it	is	possible	that	Ndfip1	and	Itch	regulation	of	RORγT	is	not	limited	to	just	Th17	cells	and	ILC3s.	It	is	possible	that	Ndfip1	and	Itch	may	regulate	RORγT	protein	levels	in	LTi	cells	as	well.	It	remains	to	be	explored	whether	LTi	cells	express	Ndfip1	and	 whether	 in	 the	 absence	 of	 Ndfip1,	 an	 increase	 in	 RORγT	 and	 unchecked	 LTi	development	 can	 explain	 the	 increased	 recruitment	 of	 lymphocytes	 into	 the	peripheral	 lymph	 nodes	 and	 the	 resulting	 lymphadenopathy	 in	 Ndfip1-deficient	animals.	 	 	 	 	 	 	 	 	
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	 RORγT-expressing	regulatory	T	cells	have	also	been	described239.	These	are	mostly	peripherally	generated	Treg	cells	that	are	found	in	the	colon	and	in	the	small	intestine	 and	 are	 important	 enforcers	 of	 colonic	 integrity.	 These	 cells	 suppress	spontaneous	Th2	responses	and	regulate	commensal	immune	responses240,241.	Since	Ndfip1	 is	 expressed	 in	 RORγT+	 Th17	 cells	 and	 in	 Foxp3+	 Treg	 cells,	 it	 will	 be	important	 to	 determine	 the	 role	 of	 Ndfip1	 in	 RORγT+	 Foxp3+,	 so-called	 “biTreg”	cells.	 These	 cells	 are	 known	 to	 express	 IRF4	 and	 STAT3	 and	 to	 show	 high	 IL-10	production239.	It	is	possible	that	the	surprising	lack	of	spontaneous	colon	pathology	in	Ndfip1fl/fl	Foxp3-Cre	animals	 is	due	 to	an	 increase	 in	 the	number	or	 function	of	these	RORγT+	Foxp3+	Treg	cells	leading	to	a	tissue-specific	protection	of	the	colon	from	 the	pathology	 seen	 in	other	 sites	 such	 as	 the	 lungs,	 skin	 and	 spleens,	where	these	 cells	 are	 lacking.	 Whether	 this	 hypothesis	 is	 supported	 remains	 to	 be	investigated.		 	 	
How	does	a	trans-membrane	protein	like	Ndfip1	regulate	the	protein	levels	of	
a	nuclear	protein	like	RORγT?	This	 is	 an	 interesting	 question	 not	 addressed	 by	my	 current	work.	 Ndfip1	interacts	 with	 several	 different	 Nedd4	 E3	 ligases	 to	 ubiquitinylate	 a	 variety	 of	protein	 substrates.	 In	 the	 case	 of	 PTEN,	 Ndfip1	 activates	 Nedd4	 and	 Nedd4-2	 E3	ligases	 in	 order	 to	 ubiquitinylate	 cytosolic	 PTEN	 and	 drive	 its	 nuclear	translocation242.	 Of	 particular	 interest,	 Ndfip1	 also	 activates	 the	 Nedd4	 family	 E3	ligase,	 Itch,	 in	order	to	drive	the	ubiquitylation	of	the	transcription	factor,	 JunB,	 in	CD4	 T	 cells	 (as	 previously	 discussed)25,50.	 Intriguingly,	 using	 a	 technique	 called	
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ubiquitin-mediated	 fluorescence	 complementation,	 it	 has	 been	 shown	 that	 non-ubiquitylated	 JunB,	 is	 predominantly	 nuclear	 but	 ubiquitylated	 JunB	 is	 found	localized	 in	 lysosomes243.	 This	 sets	 a	 precedent	 for	 how	 Ndfip1	 and	 Itch	 may	regulate	a	nuclear	receptor	such	as	RORγT.	Interestingly,	the	HECT	E3	ligase,	UBR5,	which	has	also	been	reported	to	degrade	RORγT,	is	found	both	in	the	cytoplasm	and	in	the	nucleus	and	so	may	have	access	to	RORγT	in	both	locations.	Further	work	is	needed	 to	establish	whether	RORγT	 is	 shuttled	between	cytoplasm	and	nucleus	 in	order	 to	gain	access	 to	Ndfip1	and	Itch.	 It	 is	alternatively	possible	 that	 there	 is	an	initial	modification	of	 nuclear	RORγT	 that	may	 allow	 it	 to	 exit	 the	nucleus	 and	be	recognized	and	ubiquitylated	by	Ndfip1	and	Itch	in	the	cytoplasmic	space.	It	remains	to	 be	 explored	whether	 this	 latter	 alternative	 occurs	 and	whether	UBR5	 could	 be	involved	in	such	a	mechanism.	
These	 are	 interesting	 areas	 for	 further	 work	 as	 any	 information	 that	contributes	 to	 our	 understanding	 of	 possible	 off-target	 effects	 of	 an	 Ndfip1	therapeutic	 intervention	 will	 be	 crucial	 in	 tailoring	 therapeutics	 for	 maximal	 on-target	benefits.	
	
The	 role	 of	 Ndfip1	 in	 Treg	 cells:	 unresolved	 questions	 and	 future	
directions	
Our	 work	 in	 Treg	 cells	 has	 revealed	 Ndfip1	 is	 indispensable	 for	 normal	immune	 homeostasis.	We	 show	 that	 Ndfip1	 is	 important	 in	 Treg	 cells	 to	 prevent	
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proliferation	 and	 excessive	 activation	 in	 Treg	 cells	 following	 TCR	 stimulation.	Ndfip1	 limits	 the	 cell-autonomous	 expression	 of	 GITR	 and	 ICOS	 proteins	 on	 the	surface	 of	 Treg	 cells,	 although	 the	 consequence	 of	 this	 regulation	 is	 not	 yet	understood.	Furthermore,	Ndfip1	prevents	IL-4	production	from	activated	WT	Treg	cells,	helping	to	prevent	methylation	of	CNS2	and	protecting	Treg	cells	from	loss	of	Foxp3	 during	 periods	 of	 extensive	 proliferation.	 Finally,	 Ndfip1	 reins	 in	mTORC1	signaling	 in	 order	 to	 prevent	 glycolysis	 and	 proliferation	 that	 would	 fuel	unregulated	growth	of	the	Treg	cells	(Fig	4.3).		Several	questions	that	remain	about	this	current	work	and	the	future	implications	for	other	work	are	discussed	next.	
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FIGURE	4.3	Model	for	how	Ndfip1	functions	in	Treg	cells.		Ndfip1	is	induced	upon	T	cell	stimulation	and	carries	out	two	important	functions:	dampens	signaling	via	mTORC1	to	limit	Treg	cell	proliferation	and	growth,	and	inhibits	IL-4	production	from	Treg	cells.		
Can	dysregulated	mTORC1	signaling	in	Treg	cells	be	beneficial	if	the	resulting	
Treg	cells	do	not	make	IL-4?	We	 propose	 at	 the	 end	 of	 our	 Treg	 study	 that	 Ndfip1	 regulates	 IL-4	production	 and	mTORC1	 signaling	 via	 two	distinct	 pathways.	However,	 to	 further	extend	 this	 hypothesis,	 I	 propose	 that	 the	 excessive	 proliferation	 fueled	 by	 the	mTORC1	 signaling	 may	 be	 sufficient	 to	 drive	 loss	 of	 Foxp3	 independent	 of	 IL-4	signaling	(Fig	4.3).	It	has	been	shown	by	others	that	Treg	proliferation,	even	in	WT	
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Treg	cells,	leads	to	detectable	loss	of	Foxp3	after	several	progressive	rounds	of	cell	division213.	The	CNS2	region	in	the	Foxp3	gene	exists	to	slow	down	this	loss	of	Foxp3	by	 recruiting	 STAT5	 and	 preventing	 methyltransferases	 from	 binding	 and	methylating	the	Foxp3	 locus.	However,	with	Ndfip1-deficiency,	we	see	a	significant	increase	in	the	ability	of	Treg	cells	to	proliferate	and	this	may	set	up	the	Treg	cells	to	lose	Foxp3	in	vivo	in	spite	of	intact	CNS2	function.	Future	work	will	need	to	explore	whether	 in	 vivo	 mTORC1	 inhibition	 -for	 example,	 during	 the	 adoptive	 transfer	experiment-	will	prevent	 loss	of	Foxp3	 in	 the	Ndfip1-deficient	Treg	cells.	This	will	need	 to	 be	 done	 in	 the	 context	 of	 IL-4	 sufficient	 and	 IL-4-deficient	 Treg	 cells.	Furthermore,	 the	 generation	 of	 Ndfip1fl/fl	 Foxp3-Cre	 IL-4KO	 animals	 will	 provide	sufficient	 evidence	 of	 the	 extent	 to	which	mTORC1	 and	 IL-4	 pathways	 in	 Ndfip1-deficient	Treg	cells	may	be	dissociated	from	each	other.			 	 	 		 Of	 note,	 mice	 bearing	 a	 conditional	 knockout	 of	 a	 negative	 regulator	 of	mTORC1	signaling	called	TSC1	have	been	generated.	As	expected,	these	TSC1-/- Treg	animals	have	 increased	mTORC1	signaling	 (pS6K	and	pS6).	Additionally,	however,	they	 have	 increased	 IL-17A	 cytokine	 production.	 This	 is	 particularly	 interesting	because	TSC1-/- T	conventional	or	effector	cells	are	more	likely	to	make	IL-17A	and	to	 differentiate	 into	 Th17	 cells.	 The	 production	 of	 IL-17A	 by	 these	 Tregs	 is	 a	consequence	 of	 increased	 mTORC1	 signaling,	 specifically,	 increased	 S6K1.	 Thus	inhibition	 of	 this	 mTORC1	 substrate	 led	 to	 abrogation	 of	 IL-17A	 production.	Juxtaposing	 this	 data	with	 that	 gathered	 from	 our	Ndfip1fl/fl	 Foxp3-Cre	mice,	 it	 is	surprising	 that	 increased	mTORC1	signaling	 in	our	mice	also	drives	 increased	pS6	and	yet	it	is	IL-4	that	is	intrinsically	produced	by	these	Treg	cells,	and	not	IL-17A.		It	
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is	 not	 understand	 why	 an	 alteration	 in	 mTORC1	 signaling	 leads	 to	 dysregulated	production	of	different	cytokines	–	IL-17A	versus	IL-4	versus	other	cytokines.	This	might	 suggest	 that	 downstream	 of	 mTORC1	 signaling,	 there	 may	 be	 differential	regulation	 of	 substrates	 of	 mTORC1	 according	 to	 other	 effects	 mediated	 by	 the	protein	 that	 has	 been	 knocked	 down.	 In	 Ndfip1fl/fl	 Foxp3-Cre,	 it	 is	 possible	 that	downstream	of	mTORC1	there	 is	a	general	 increase	 in	protein	 translation	and	cell	proliferation	 and	 that	 in	 the	 context	 of	 a	 cell	 that	 also	 has	 dysregulated	 IL-4	production,	 possibly	due	 to	un-degraded	 JunB	or	 an	unknown	 substrate,	 this	may	lead	to	the	expansion	of	IL-4	producing	Treg	cells.	This	hypothesis	argues	(as	others	have	done244)	for	more	research	into	understanding	how	coordination	of	the	actions	of	 mTORC1/mTORC2	 complexes	 directs	 Treg	 metabolism,	 cytokine	 production,	function	and	lineage	stability.		
Therefore,	 in	 short,	 I	 predict	 that	 dysregulated	 mTORC1	 signaling	 in	 Treg	cells	 even	 in	 the	 context	 of	 IL-4	 deficient	mice	will	 still	 lead	 to	 autoinflammatory	disease,	albeit	with	a	delayed	timeline	of	onset	and	progression,	and	perhaps	with	a	different	cytokine	 that	 is	dysregulated,	compared	to	what	 is	observed	 in	Ndfip1fl/fl	Foxp3-Cre	mice.	
What	 is	 the	 significance	 of	 increased	 ICOS	 protein	 levels	 on	 the	 Ndfip1-
deficient	Treg	cells?	ICOS,	 a	 co-stimulatory	 receptor	 and	 a	 CD28	 family	member,	 is	 induced	 on	Tconventional	and	Treg	cells	alike	in	response	to	T	cell	activation245–247.	ICOS	binds	the	ligand	called	B7H2	(also	called	CD275,	B7RP1	or	ICOSL),	which	is	expressed	on	
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B	 cells,	 dendritic	 cells,	 monocytes/macrophages,	 and	 on	 T	 cells.	 It	 is	 found	 in	extremely	 low	 levels	on	naïve	CD4	T	cells	and	 therefore	 its	abundance	on	Ndfip1-deficient	 Treg	 cells	 is	 not	 likely	 to	 be	 the	 cause	 of	 their	 activation.	 Instead,	 ICOS	induction	on	these	Treg	cells	very	likely	occurs	after	the	cells	are	already	activated.	ICOS	 signaling	drives	 proliferation,	 as	well	 as	 cytokine	production,	 from	activated	effector	T	cells245.	ICOS	expression	on	Treg	cells	has	been	correlated	with	increased	suppressive	 function	 and	 protection	 against	 lung	 pathology	 and	 autoimmune	disease248,249.	IL-4	production	 is	particularly	tied	to	 ICOS	expression.	 ICOS-/- CD4	T	cells	are	impaired	in	their	ability	to	differentiate	into	Th2	cells	and	consequently	in	their	ability	to	fight	Th2-biased	lung	pathology.	It	is	thought	that	ICOS-/- CD4	T	cells	are	unable	 to	phosphorylate	 STAT6	and	 increase	 IL-4R	 levels	 in	 response	 to	 IL-4.	Thus	ICOS-/- CD4	T	cells	are	unable	to	respond	to	IL-4	in	order	to	secrete	more	IL-4250.	 Furthermore,	 ICOS	 signaling	 increases	 c-MAF	 expression	 to	 drive	 IL-4	transcription251.	 C-Maf	 has	 also	 been	 shown	 to	 cooperate	 with	 JunB	 protein	 (the	Ndfip1	and	Itch	substrate)	to	drive	IL-4	transcription51,251.	Therefore	ICOS	has	been	tied	to	Treg	suppressive	function	as	well	as	IL-4	production	by	CD4+	T	cells.		 	
Treg	cells	isolated	from	Ndfip1fl/fl	Foxp3-Cre	male	and	female	animals	show	increased	expression	of	ICOS.	After	a	7	day	 in	vitro expansion	using	high	dose	IL-2	(2000U/ml)	 and	 αCD3/αCD28	 activator	 beads,	 Ndfip1-deficient	 Treg	 cells	 have	higher	 expression	 of	 ICOS	 and	 this	 is	 true	 even	 in	 co-culture	 settings	 (Fig	 3.16).	Interestingly,	 in	 a	 4day	 culture	 using	 a	 10fold	 lower	 dose	 of	 IL-2	 (200U/ml)	 and	plate-bound	TCR	stimulation,	Ndfip1-deficient	Treg	cells	do	not	have	the	same	high	
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levels	 of	 ICOS	 (Fig	 3.18).	 This	 may	 be	 consistent	 with	 knowledge	 that	 ICOS	expression	on	Treg	cells	 is	critically	sensitive	to	IL-2	exposure248.	We	show	that	 in	spite	of	high	ICOS	expression	on	Ndfip1-deficient	Treg	cells	in	vivo,	the	mice	get	sick.	Furthermore,	 when	 tested	 in	 an	 in	 vitro suppression	 assay,	 these	 ICOShi	 Ndfip1-deficient	Tregs	cells	were	not	better	suppressors	of	Tconventional	cells.	Therefore	the	 high	 ICOS	 expression	 on	 these	 Treg	 cells	 is	 unlikely	 to	 be	 affecting	 their	suppressive	function.	However,	it	is	possible	that	the	high	ICOS	levels	on	these	Tregs	may	 signal	 through	 c-Maf	 to	 contribute	 to	 IL-4	 production	 by	 these	 Treg	 cells.	Testing	of	this	hypothesis	could	be	done	by	treating	mixed	chimeras	WT/Ndfip1fl/fl	Foxp3-Cre	chimera	animals	with	ICOS	blocking	antibodies	in	order	to	determine	the	effect	 on	 IL-4	production	by	Ndfip1-deficient	Treg	 cells.	An	extension	of	 the	work	presented	 in	 Figure	 3.16	 would	 also	 be	 useful	 here.	 Specifically,	 Ndfip1-deficient	versus	WT	Treg	cells	could	be	treated	in	vitro with	ICOS	blocking	antibodies,	with	or	without	 rapamycin,	 in	 order	 to	 detect	 effect	 on	 IL-4	 production.	 This	would	 help	determine	whether	the	IL-4	production	is	regulated	via	ICOS-c-Maf	signaling	or	via	mTORC1-dependent	pathways	in	Ndfip1-deficient	Treg	cells.	
What	 is	 the	 significance	 of	 increased	 GITR	 protein	 levels	 on	 the	 Ndfip1-
deficient	Treg	cells?	GITR,	also	known	as	Tumor	necrosis	factor	receptor	superfamily	member	18	(TNFRSF18),	 is	 expressed	 on	 activated	 T	 effector	 cells	 and	 on	 Treg	 cells.	 GITR	 is	expressed	 at	 low	 levels	 on	 naïve	 CD4	 T	 cells	 but	 is	 upregulated	 in	 response	 to	activation.	GITR	binds	to	GITR	Ligand,	which	is	constitutively	expressed	by	B	cells,	
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macrophages,	and	dendritic	cells	(particularly	plasmacytoid	dendritic	cells).	Effector	CD4	(activated	CD4+	CD25-)	T	cells	respond	to	GITR	stimulation	by	increasing	the	threshold	for	Treg	suppression	and	thus	becoming	resistant	to	Treg	suppression252.	However,	in	response	to	stimulation	via	GITR,	both	T	effector	cells	and	Foxp3+	Treg	cells	 have	 increased	 proliferation	 and	 expansion	 in	 vivo253.	 The	 effect	 of	 GITR-stimulation	on	Treg	cell	suppressive	 function	 is	still	contested.	Some	studies	show	loss	 of	 suppressive	 function	 of	 GITR-stimulated	 Treg	 cells	 while	 others	 show	 no	effect	on	Treg	suppression.	GITR	stimulation	of	Treg	cells	(defined	as	CD4+	CD25+	cells)	may	lead	to	increased	JNK2	signaling	and	loss	of	suppression254.	In	the	tumor	environment,	 agonistic	 GITR	 signaling	 does	 not	 alter	 frequencies	 of	 Treg	 cells	 or	their	 suppressive	 function,	 instead	 GITR	 stimulation	 may	 promote	 loss	 of	 Foxp3	expression	 in	 vivo,	 leading	 to	 the	 generation	 of	 Foxp3-	 ex-Treg	 cells255.	 However,	agonistic	 GITR	 signaling	 may	 also	 lead	 to	 death	 of	 Treg	 cells	 transferred	 into	 a	lymphopenic	mouse256.	In	short,	the	effect	of	GITR	stimulation	on	Treg	cells,	as	these	and	 other	 studies	 have	 shown,	 is	 contextual.	 To	 avoid	 the	 use	 of	 agonistic	 GITR	antibodies	 in	 studying	 the	 effects	 of	 GITR	 stimulation	 on	 Treg	 cells	 as	 all	 of	 the	existing	studies	have	done,	there	is	the	need	for	the	generation	of	GITRfl/fl	Foxp3-Cre	mice.	 The	 current	 studies,	 however,	 support	 that	 increased	 GITR	 expression	 on	Ndfip1-deficient	 Treg	 cells	 may	 contribute	 to	 their	 expansion	 the	 lymphoreplete	Ndfip1fl/fl	 Foxp3-Cre	 mice,	 and	 possibly	 to	 the	 loss	 of	 Foxp3	 expression	 after	transfer	into	the	lymphopenic	RAG1-/- mice.	However,	if	GITR	stimulation	does	lead	to	the	suppression	of	Treg	cell	activity,	high	GITR	levels	on	the	Ndfip1-deficient	Treg	
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cells	cannot	explain	their	normal	suppression	of	WT	cells	in	the	in	vitro suppression	assay	and	in	the	adoptive	T	cell	transfer	colitis	models	(Figure	3.3).	
Increased	 levels	 of	 GITR	 on	 Ndfip1-deficient	 Treg	 cells	 could	 indicate	 a	failure	 to	 degrade	 GITR	 in	 the	 absence	 of	 Ndfip1.	 While	 the	 protein	 sequence	 of	GITR	does	not	reveal	a	P-P-X-Y	or	L-P-X-Y	or	P-P-L-P	motif	that	would	suggest	that	it	can	 bind	 directly	 to	 the	 WW	 domains	 of	 an	 E3	 ubiquitin	 ligase,	 it	 would	 be	interesting	 to	 explore	 whether	 GITR	 is	 a	 direct	 substrate	 downstream	 of	 Ndfip1	activity	 since	 Ndfip1	 and	 its	 homolog	 Ndfip2	 are	 known	 to	 promote	 the	ubiquitylation	 of	 proteins	 that	 do	 not	 have	 PY	 motifs	 (e.g.	 endophilin)49.	 Future	experiments	could	determine	GITR	protein	levels	in	response	to	TCR	stimulation;	in	response	to	 inhibition	of	protein	translation	with	cycloheximide;	or	 in	response	to	inhibition	 of	 proteasomal/lysosomal	 degradation	 by	 Mg132	 and	 chloroquine	 in	Ndfip1-deficient	versus	WT	Treg	cells.	This	would	provide	clarity	on	whether	GITR	levels	 are	 upregulated	 because	 of	 a	 direct	 failure	 of	 degradation	 or	 because	 of	alterations	 in	 pathways	 that	 drives	 up	 transcription	 and/or	 translation	 of	 GITR.	These	experiments	would	be	beneficial	for	ICOS	as	well.	
Does	Ndfip1	promote	autophagy	in	Treg	cells?	mTORC1	 signaling	 is	 an	 important	 coordinator	 of	 different	 metabolic	 and	cellular	processes	in	a	cell.	During	nutrient-rich	periods	in	the	cell,	sensing	of	amino	acids,	 glucose	 and	 oxygen	 can	 all	 drive	 increased	 mTORC1	 signaling.	 Increased	mTORC1	 signaling	 drives	 increased	 lipid	 synthesis	 (mediated	 by	 mTORC1	substrates	 SREBP1	 and	 PPARγ);	 increased	 mRNA	 translation	 to	 support	 protein	
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translation	 (mediated	 by	 substrates	 S6K	 and	 eIF4E);	 and	 inhibition	 of	macroautophagy	(also	called	autophagy,	mediated	by	substrate	ULK1).	Autophagy	is	a	process	that	is	initiated	in	a	nutrient	starved	cell	and	involves	the	degradation	of	cytoplasmic	 organelles	 in	 the	 lysosome	 in	 order	 to	 generate	nutrients	 and	 energy	that	 can	be	 recycled	 to	 support	 cell	 function.	When	mTORC1	 is	activated	during	a	time	of	nutrient	abundance,	it	carries	out	the	inhibitory	phosphorylation	of	ULK1257,	preventing	ULK	from	undergoing	activating	phosphorylation	at	a	nearby	site.	ULK1	(also	called	Autophagy-related	gene	1,	Atg1)	forms	part	of	the	Atg1	kinase	complex,	which	is	the	earliest	complex	to	assemble	in	the	pre-autophagosomal	structure,	and	is	required	 for	autophagy	 to	occur258.	Therefore	mTORC1	 inhibition	of	ULK1/Atg1	activation	prevents	autophagy	from	occurring	during	a	time	of	nutrient	abundance.	The	increased	mTORC1	signaling	in	Ndfip1-deficient	Treg	cells	would	be	expected	to	signal	 to	 the	cells	 that	 there	 is	nutrient	abundance	and	therefore	no	need	to	carry	out	 autophagy.	 Therefore	 an	 important	 question	 that	 we	 do	 not	 address	 in	 our	current	 work	 is	 what	 is	 the	 consequence	 of	 the	 elevated	 mTORC1	 signaling	 on	autophagy.	 It	was	 recently	 shown	 that	 autophagy	 is	 essential	 for	 the	 functions	 of	Treg	 cells.	 Atg5	 and	 Atg7	 are	 two	 components	 of	 the	 autophagosome	 that	 when	deleted	 specifically	 in	 Foxp3+	 cells	 leads	 to	 abrogation	 of	 autophagy206.	Interestingly,	 deletion	 of	 autophagy	 in	 Treg	 cells	 led	 to	 a	 spontaneous	 auto-inflammatory	disease	in	mice,	marked	by	lymphadenopathy,	increased	activation	of	T	 cells	 and	 increased	 Th1	 and	 Th17	 effector	 subsets	 but	 a	 decrease	 in	 Treg	 total	numbers.	 Further	 work	 revealed	 that	 while	 mTORC1	 can	 inhibit	 autophagy,	autophagy	 is	 also	 important	 for	 restraining	 mTORC1	 activation	 as	 a	 way	 of	
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maintaining	Treg	cell	stability206.	The	results	of	that	study	indicate	that	the	defects	observed	 in	 our	 Ndfip1-deficient	 Treg	 cells	 are	 unlikely	 to	 be	 wholly	 due	 to	inhibition	of	autophagy	in	the	Treg	cells	since	primary	defects	in	autophagy	would	not	 explain	 why	 Ndfip1-deficient	 Treg	 cells	 are	 more	 likely	 to	 proliferate	 and	expand	in	vivo	or	why	it	is	IL-4	cytokine	production	(and	not	IFNγ	or	IL-17A)	that	is	dysregulated	in	Ndfip1-deficient	Treg	cells.	It	is	possible	that	the	elevated	mTORC1	signaling	 in	 Ndfip1-deficient	 Treg	 cells	 inhibits	 autophagy	 in	 those	 cells,	 further	contributing	 to	elevated	mTORC1	signaling.	Future	 studies	 in	Ndfip1fl/fl	 Foxp3-Cre	mice	looking	at	protein	levels	of	autophagy	related	proteins,	as	well	as	microscopy	work	 to	 determine	 whether	 autophagy	 is	 active	 or	 inhibited	 in	 these	 Ndfip1-deficient	Treg	cells	will	be	a	good	place	to	start	to	understand	a	role	 for	Ndfip1	in	promoting	autophagy	in	Treg	cells.	
How	 does	 Ndfip1	 control	 of	 Treg	 cell	 proliferation	 influence	 an	 immune	
response?	The	 initial	 phases	 of	 an	 immune	 response	 are	 characterized	 by	 increased	production	 of	 IL-2	 resulting	 in	 extensive	 proliferation	 of	 proximal	 Treg	 cells	 and	leading	 to	 enhancement	 in	 Treg	 cell	 suppressive	 function259,260.	 This	 is	counterintuitive	since	one	expects	that	during	an	immune	response	Treg	cells	would	be	 quiescent	 and	 allow	 effector	 T	 cells	 to	 eliminate	 the	 pathogen.	 It	 has	 been	proposed	 that	 this	 initial	 expansion	 of	 suppressive	 Treg	 cells	 is	 to	 control	 the	initiated	response	and	to	prevent	immunopathology	as	the	effector	T	cells	respond	to	antigen259.	Based	on	the	data	from	the	adoptive	transfer	of	Tconv	and	Treg	cells	
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into	RAG1-/- animals	 (Figure	3.11),	 I	predict	 that,	physiologically,	 it	 is	at	 this	early	stage	of	an	 immune	response	where	 there	 is	a	simultaneous	 increase	 in	 IL-2	 from	Tconv	cells	and	increased	demand	for	extensive	proliferation	that	Ndfip1-deficient	Treg	cells	would	increase	in	number,	increase	production	of	IL-4,	and	be	especially	susceptible	to	loss	of	Foxp3	protein.	Therefore	in	response	to	a	live	bacterial	or	viral	infection,	 I	 would	 predict	 that	 Ndfip1-deficient	 Treg	 cells	 would	 initially	 very	heavily	expand	and	make	 IL-4.	Then	 I	would	expect	 a	 loss	of	Foxp3	expression	 in	these	cells,	and	the	corresponding	in	vivo	generation	of	IL-4-producing	ex-Treg	cells.	I	would	predict	that	the	resolution	stages	of	the	immune	response	would	be	delayed	due	to	the	presence	of	these	ex-Tregs	instead	of	Treg	cells.	Whether	these	ex-Treg	cells	contribute	to	pathology	due	to	resistance	to	Treg	cell	suppression	or	 in	some	other	manner	has	not	been	fully	explored.	Therefore,	future	studies	might	uncover	an	 additional	 role	 for	 Ndfip1	 in	 Treg	 cells	 at	 the	 initiation	 phases	 of	 an	 immune	response	and	explore	how	this	might	affect	the	generation	of	immune	memory.	
Concluding	thoughts	
Ndfip1-deficient	 Th17	 and	 Treg	 cells	 both	 have	 an	 intrinsic	 tendency	 to	proliferate	 and	 to	 expand	 in	 vivo.	 In	 Treg	 cells,	 this	 in	 vivo	 advantage	 is	 due	 to	increased	mTORC1	signaling.	We	have	not	explored	whether	Ndfip1-deficient	Th17	cells	 also	 have	 increased	mTORC1	 signaling.	 T	 effector	 subsets	 generally	 do	 have	heavy	 dependence	 on	 mTORC1	 signaling	 and	 on	 the	 use	 of	 glycolysis	 to	 fuel	metabolic	demands.	 It	would	be	 intriguing	 to	discover	whether	Ndfip1	suppresses	these	 pathways	 in	 both	 T	 effector	 and	 Treg	 cells	 in	 order	 to	 prevent	 excessive	
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proliferation	in	vivo.		Since	 T	 effector	 cells	 need	 to	 rely	 on	 glycolysis,	 one	 would	expect	that	if	Ndfip1	dampens	glycolysis	in	both	T	effector	and	in	Treg	cells,	it	might	require	 different	 additional	 regulation	 of	 the	 degree	 to	 which	 this	 process	 is	inhibited	in	T	effector	cells	so	these	cells	can	still	predominantly	perform	glycolysis.	 	
In	 both	 Ndfp1-deficient	 Th17	 cells	 and	 Treg	 cells	 there	 is	 an	 increase	 in	secretion	of	proinflammatory	cytokines.	In	Th17	cells,	secretion	of	IL-17A,	IFNγ	and	GM-CSF	is	due	to	a	failure	to	degrade	the	Ndfip1-Itch	substrate,	RORγT.	In	Treg	cells,	the	 substrate	 responsible	 for	 the	 IL-4	 production	 remains	 unclear.	 Failure	 to	degrade	 JunB	 in	Ndfip1-deficient	CD4+	T	cells	drives	 IL-4	production	but	we	have	not	explored	whether	it	is	this	same	substrate	in	Treg	cells,	which	explains	the	IL-4	production.	A	study	in	Itch-deficient	Treg	cells,	which	largely	phenocopy	the	Ndfip1-deficient	 Treg	 cells,	 failed	 to	 find	 evidence	 to	 support	 JunB	 as	 the	 IL-4	 driving	substrate104.	 Therefore,	 it	 warrants	 investigation	 in	 future	 studies	 to	 determine	whether	Ndfip1-deicient	Treg	cells	 secrete	excess	 IL-4	because	of	GITR-c-Maf-IL-4	pathways	or	because	of	JunB-IL-4	pathways.	Elucidating	the	substrate	underpinning	this	 phenomenon	 will	 also	 help	 clarify	 whether	 the	 IL-4	 production	 and	 the	metabolic	 fitness	 are	 two	 independent	 but	 converging	 pathways	 that	 are	 both	downstream	on	Ndfip1	activity.	 	 	
The	 holy	 grail	 of	 studies	 involving	 Ndfip1	 may	 be	 to	 fully	 understand	 the	molecular	mechanisms	through	which	Ndfip1	dampens	T	cell	activation.	Our	work	with	 Th17	 cells	 revealed	 that	 while	 activation	 alone	 does	 not	 explain	 Ndfip1	regulation	of	Th17	cells,	at	least	part	of	the	difference	in	Th17	abundance	between	
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Ndfip1-deficient	and	sufficient	mice	is	explained	by	Ndfip1	regulation	of	activation.	Specifically,	 when	 we	 examined	 IL-17A+	 cells	 gated	 through	 CD4+	 versus	 CD44+	cells,	 we	 found	 that	 after	 accounting	 for	 CD44+	 cells	 (activation),	 there	 was	 a	smaller	 but	 still	 significant	 difference	 between	 Ndfip1-sufficient	 and	 –deficient	 T	cells.	 This	 extra	 difference	 beyond	 activation	 is	 explained	 by	 the	 ability	 of	 the	Ndfip1-deficient	Th17	cells	to	proliferate	and	expand	in	vivo.	Similarly,	in	Treg	cells,	Ndfip1-deficient	eTreg	cells	or	activated	Treg	cells,	but	not	the	quiescent	cTregs,	had	the	 most	 dramatic	 differences	 in	 surface	 marker	 expression	 and	 in	 proliferation.	This	 reinforces	 the	 concept	 that	 since	Ndfip1	 is	 expressed	 after	 activation,	 it	 is	 in	previously	activated	T	cells	 that	we	see	 the	biggest	effects	when	Ndfip1	 is	absent.	Why?	We	know	that	Ndfip1	is	not	just	induced	upon	T	cell	activation,	but	also	works	to	dampen	T	cell	activation	in	a	negative	regulatory	loop.	Ndfip1-deficient	T	cells	fail	to	exit	the	cell	cycle,	preferring	to	stay	in	cycle	and	to	undergo	many	extra	rounds	of	activation	and	division153.	Given	that	Ndfip1’s	only	known	function	is	as	an	activator	of	Nedd4	family	HECT	E3	ligases,	the	role(s)	of	Ndfip1	in	T	cell	activation	would	be	predicted	 to	 somehow	 involve	 ubiquitylation	 of	 specific	 substrates.	 Yet	 the	biochemical	pathways	used	by	Ndfip1	to	dampen	T	cell	activation	and	proliferation	remain	elusive.	Our	lab	is	turning	to	large-scale	mass	spectrometry	proteomic	work	using	 several	 emerging	 ubiquitylation	 tools	 with	 subsequent	 in	 vitro validation	studies	in	order	to	determine	exactly	how	Ndfip1	drives	the	ubiquitylation	of	T	cell	proteins	 to	 limit	 excessive	 activation.	Work	 of	 this	 nature	 is	 crucial	 since	 Ndfip1	regulation	of	T	cell	activation	is	unlikely	to	be	dependent	on	a	single	substrate	alone.	It	 is	 more	 likely	 that	 there	 are	 several	 proteins	 whose	 degradation	 depends	 on	
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Ndfip1	in	order	to	limit	different	pathways	downstream	of	T	cell	activation	as	well	as	influence	other	aspects	of	T	cell	differentiation	and	function,	such	as	proliferation	and	cytokine	production.	Furthermore,	rather	than	limiting	our	investigations	of	the	ubiquitin	E3	 ligases	 involved	to	the	relatively	well-studied	ones	such	as	 Itch,	mass	spectrometry	 data	 will	 have	 the	 added	 advantage	 of	 revealing	 little-known	 E3	ligases	 as	 well	 as	 little-studied	 ubiquitin	 linkages	 that	 are	 dependent	 on	 Ndfip1.	These	 studies	may	 prove	 central	 to	 a	 greater	 and	more	 holistic	 understanding	 of	how	these	CD4	T	cell	subsets	are	regulated.		
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CHAPTER	5:	Materials	and	Methods	
Mice.	
Th17	 work:	Ndfip1-/-,	 Ndfip1fl/fl	 CD4-Cre+,	 IL-4-/- and	 Ndfip1-/- IL-4-/- (DKO)	 mice	have	 been	 generated	 previously25,68,154,155.	 IL-17A	 GFP	mice	were	 purchased	 from	Jackson	 laboratory	 (C57BL/6-Il17atm1Bcgen/J,	 stock#	 018472),	 were	 crossed	 to	 in-house	IL-4-/- (Jackson	 laboratory,	B6.129P2-Il4tm1Cgn/J,	stock	#002253)	or	Ndfip1-/- IL-4-/- (DKO)	mice,	and	bred	for	one	copy	of	the	IL-17A	GFP	gene.	Itch	IL-4	DKO	mice	were	generated	by	crossing	previously	described	Itch-/- animals26	to	in-house	IL-4-/- animals.	 CD45.1	 IL-4-/- mice	 were	 obtained	 by	 crossing	 in-house	 CD45.1	(C57BL6.SJL-Ptprca	 Pepcb/BoyJ)	mice	 to	 in-house	 IL-4-/-	 animals	 for	more	 than	10	generations.	 The	 T	 cell	 transgenic	 B3K506	 mice	 have	 been	 described	previously179,261,	were	obtained	from	the	laboratory	of	Eric	Huseby,	and	crossed	to	Ndfip1-/- RAG1-/- animals.	In	all	experiments	described,	male	and	female	mice	were	appropriately	age	and	sex-matched	in	experiments	and	data	was	pooled.	Primers	for	Ndfip1-/- ,	 CD4-Cre+,	 IL-4-/- ,	 IL-17A	GFP,	RAG1-/- mice	are	available	on	 the	 Jackson	Laboratories	 website	 (https://www.jax.org/).	 CD45.1	 mice	 were	 genotyped	 by	staining	peripheral	 blood	 lymphocytes	 for	 CD45.1	 versus	CD45.2,	while	B3K	mice	were	genotyped	by	staining	peripheral	blood	lymphocytes	for	B220-,	CD4+	Vb8.1+	T	cells.	
Treg	work:	Ndfip1fl/fl	mice	(previously	described155)	were	crossed	to	Foxp3-YFP-Cre	reporter	mice	(Jackson	laboratory,	B6.129(Cg)-Foxp3tm4(YFP/icre)Ayr/J,	stock	#016959),	
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also	referred	to	as	Foxp3-Cre,	and	bred	for	only	one	copy	of	the	Cre	gene	to	generate	Ndfip1fl/fl	 Foxp3-Cre	 male	 mice	 and	 Ndfip1fl/fl	 Foxp3-Cre+/-	 female	 mice.	 Control	mice	were:	Ndfip1+/+	Foxp3-Cre+	male	and	Ndfip1+/+	Foxp3-Cre+/-	female	mice.	We	generated	congenic	CD45.1/CD45.2	control	mice	by	crossing	Ndfip1+/+	Foxp3-Cre+	mice	 to	CD45.1+	mice	 (Jackson	 laboratory).	CD45.1	and	RAG1-/- are	maintained	 in	house.	Animals	were	used	ages	indicated	in	each	figure	legend.	Genotyping	primer	sequences	 for	 Ndfip1	 flox	 alleles	 and	 Foxp3-YFP-Cre	 have	 been	 described	previously155,207	 and	 sequences	 for	 Il-4	 and	 Foxp3	 are	 available	 from	 the	 Jackson	laboratory	website.		
Mice	were	maintained	in	a	barrier	facility	at	the	Children’s	Hospital	of	Philadelphia.	The	Institutional	Care	and	Use	Committee	of	the	Children’s	Hospital	of	Philadelphia	approved	all	procedures.		
Mixed	chimeras.		
Fetal	 liver	 was	 harvested	 from	 embryos	 between	 days	 E13-E17	 old.	 Fetal	 livers	were	crushed	through	a	35um	FACS	tube	with	strainer	cap	and	washed	with	plain	DMEM	 media.	 After	 centrifugation,	 pellets	 were	 resuspended	 in	 90%	 FCS	 10%	DMSO	freezing	media	and	stored	at	-80°C	until	needed.	Bone	marrow	was	harvested	from	 donor	 mice	 by	 flushing	 the	 femurs	 and	 tibias	 with	 a	 22G	 needle	 and	 10ml	syringe	containing	DMEM.	The	flushed	cells	were	strained	though	a	70um	strainer	cap	 and	 5ul	 of	 purified	 anti	 CD4	 (clone	 GK1.5)	 and	 anti	 CD8	 (clone	 53-6.7)	antibodies	were	 added	 to	 5ml	 of	 bone	marrow	 cells	 and	 rotated	 at	 4	 degrees	 for	30mins-1hr.	 Cells	 were	 washed	 with	 extra	 DMEM	 and	 resuspended	 in	 1ml	 of	
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suspension.	1.5ml	of	goat	anti	rat	IgG	magnetic	beads	were	washed	in	a	dynamagnet	and	the	1ml	of	bone	marrow	suspension	was	added	to	the	washed	beads	and	placed	on	a	dynamagnet.	Supernatant	containing	untouched,	T	cell	depleted	bone	marrow	was	 collected,	 washed,	 resuspended	 in	 freezing	 media	 and	 frozen	 at	 -80°C	 until	needed.	 RAG1-/- recipient	 animals	were	 sublethally	 irradiated	with	 400cGy	 18-24	hours	 before	 injection.	 Frozen	 fetal	 liver	 or	 T	 cell-depleted	 bone	 marrow	 was	thawed	and	resuspended	in	sterile	PBS.	The	irradiated	mice	were	reconstituted	with	a	total	of	0.5-	1.0x10^6	total	cells	per	100ul	via	the	intravenous	route	(tail	vein	or	retroorbitally).	Mice	were	allowed	7-10	weeks	for	reconstitution.	No	difference	was	observed	between	fetal	liver-	versus	bone	marrow-reconstituted	animals.		
Histology.	
	Stool	was	removed	from	colons	by	lightly	pressing	out	using	curved	forceps.	1-2mm	sections	 of	 the	 most	 distal	 colon	 were	 taken	 and	 fixed	 in	 10%	 neutral	 buffered	formalin	for	at	least	24h.	Skin	(ear)	and	esophagus	were	dissected	and	fixed	in	10%	neutral	 buffered	 formalin	 for	 at	 least	 24	 h.	 Lung	 were	 obtained	 after	 manual	transcardial	 perfusion	 with	 10ml	 syringes	 containing	 10%	 neutral	 buffered	formalin.	 All	 organs	were	 then	 embedded	 in	 paraffin,	 sectioned	 to	 5µm	 thickness	and	stained	with	Hematoxylin	and	Eosin	(H&E).	Images	were	obtained	using	a	Leica	DM4000B	 upright	 scope	 paired	 with	 a	 Spot	 RT/SE	 Slider	 camera	 (Children’s	Hospital	of	Philadelphia	Pathology	Core).	
Tissue	processing	for	flow	cytometry.		
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After	transcardial	perfusion	of	lungs	and	flushing	colons	with	cold	HBSS	buffer,	they	were	 minced	 with	 DMEM	 (Dulbecco’s	 minimal	 essential	 medium)	 containing	 0.9	mg/ml	of	collagenase	A,	0.8	mg/ml	of	collagenase	1A,	and	20	µg/ml	of	DNase	I	and	rotated	end-over-end	for	1h	at	room	temperature.	FCS	was	added	at	15%	v/v	and	the	 mixture	 was	 filtered	 sequentially	 through	 a	 100um	 and	 40um	 filter	 before	centrifugation.	 Lung	 pellets	 were	 RBC-lysed	 using	 in-house	 ammonium-chloride-potassium	(ACK)	 lysis	buffer,	washed,	 resuspended	 in	 complete	DMEM	media	and	refiltered.	 Spleens	 and	 thymi	 were	 crushed	 with	 the	 back	 end	 of	 a	 1ml	 syringe	through	a	70um	filter	and	into	a	petri	dish	containing	complete	DMEM	media.	Thymi	were	directly	resuspended	in	complete	media	for	staining	while	spleens	were	RBC-lysed	 before	 being	 resuspended	 and	 filtered	 in	 complete	 T	 cell	 media	 for	 flow	cytometry.	 Complete	 T	 cell	 media	 contained	 DMEM,	 10%	 FCS,	 1%	Penicillin/Streptomycin,	 1%	 glutamax	 and	 0.12mM	 beta-mercaptoethanol.	 Tissue	homogenates	 were	 stimulated	 with	 PMA	 (30ng/ml),	 Ionomycin	 (1uM)	 and	 Golgi	plug	 inhibitor	 (1:1000,	 BD	 Biosciences)	 for	 4hrs	 at	 37	 degrees	 in	 a	 5%	 CO2	incubator.	 Surface	 and	 intracellular	 staining	were	 performed	 for	 surface	 antigens	and	 cytokines,	 respectively,	 before	 flow	 cytometric	 analysis.	 For	 flow	 cytometry	panels	where	only	surface	proteins	were	required,	no	PMA/Ionomycin	stimulation	was	performed.	In	expanded	Treg	cell	cultures,	cells	from	the	7-day	expansion	were	restimulated	with	mouse	T	cell	 activator	beads	 (Gibco,	11456D)	at	a	1:1	 cell:bead	ratio	 for	 4	 hours.	 Samples	were	 immediately	 fixed	 at	 a	 final	 concentration	 of	 2%	PFA,	permeabilized	in	90%	methanol,	and	then	stained	for	pS6	and	surface	markers	together	in	Fc	block.	
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Flow	cytometry.		
Freshly	prepared	or	PMA/Ionomycin-stimulated	tissue	homogenates	in	FACs	tubes	were	washed	once	with	PBS	and	stained	at	1:60	with	10ul	 live	dead	blue	viability	stain	 for	5mins	on	 ice,	 stained	 for	 an	additional	5mins	with	50ul	Fc	block	at	1:25	(anti-CD16/32,	 clone	 2.4G2)	 and	 then	 for	 20mins	 on	 ice	with	 50ul	 of	 cell	 surface	stains.	 Cells	 were	 then	 fixed	 overnight	 (~16	 hours)	 with	 the	 foxp3	 ebioscience	fix/perm	kit	and	stained	for	intracellular	proteins	for	45mins	on	ice.	Flow	cytometry	data	were	acquired	on	an	LSR	Fortessa	and	analyzed	using	Flowjo	software	 (Tree	Star).	 Events	 analyzed	 were	 viability	 dye-negative	 cells;	 FSC-A	 by	 FSC-H	 singlet	cells;	SSC-H	by	SSC-W	singlet	cells;	and	FSC	A	by	SSC	A	lymphocytes.		
Antibodies	 for	 Th17	 work:	 αCD4	 (ebioscience,	 GK1.5);	 αIL-17A	 (ebioscience,	eBio17B7,),	 αCD3	 (Biolegend,	 17A2);	 αCD44	 (Biolegend,	 IM7);	 αTNFα	 (BD,	 MP6-XT22),	 αCD25	 (ebioscience,	 PC61.5);	 αCD45.2	 (Biolegend,	 104);	 αCD45.1	(Biolegend,	 A20),	 αLy6G	 (BD,	 1A8),	 αLy6C	 (Biolegend,	 HK1.4);	 αKi67	 (Biolegend,	16A8);	αGM-CSF	(Biolegend,	MP1-22E9);	αRORγT	(ebioscience,	B2D);	αSiglec	F	(BD,	E502440);	αCD11b	(Biolegend,	M1/70)	and	αIL-10	(ebioscience,	JES5-16E3).		
Additional	 antibodies	 for	 Treg	 work:	 αGITR	 (YGITR765),	 αICOS	 (C398.4A),	 αPD-1	(RMP1-30),	αYFP/GFP	(Life	technologies,A-21311),	αIFNγ	(BD	biosciences,	XMG1.2)	and	 αKi67	 (BD	 biosciences,	 B56),	 Biotinylated	 αphospho-S6	 (Cell	 Signaling	Technologies,	 D57.2.2E),	 αCD25	 (eBioscience	 PC61.5),	 αCD62L	 (eBioscience,MEL-14),	 αIL-4	 (ebioscience,	 11B11),	 αIL-10	 (ebioscience,	 JES5-16E3),	 αFoxp3-biotin	
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(ebioscience,	 FJK-16s).	 Biotinylated	 αFoxp3	 and	 αpS6	 were	 detected	 with	fluorophore-conjugated	streptavidin	(S32354	Invitrogen).		
ELISA.		
Th17	work:	5	days	after	differentiation,	Th1	or	Th17	cells	were	harvested,	re-plated	at	 1x10^6/ml	 in	 50U/ml	 IL-2	 and	 expanded	 for	 72h,	 splitting	 cells	 daily.	 After	 3	days,	cells	were	resuspended	at	1x10^6	cells/ml	and	0.5x10^6	of	these	Th1	or	Th17	cells	were	restimulated	via	plate-bound	5ug/ml	anti-CD3/CD28	for	0.5,	2,	4,	6,	11	or	24hrs	in	48	well	plates.	Supernatants	were	collected	and	kept	frozen	at	-80°C	until	needed.	ELISAs	were	 carried	 in	out	 triplicate	and	according	 to	 the	manufacturer’s	protocols	 for	 IL-17A	 (ebioscience,	88-7371),	 IFNγ	 (ebioscience,	88-7314)	and	GM-CSF	(ebioscience,	88-7334).		
Treg	 work:	 Serum	 was	 isolated	 from	 8-16	 week	 old	 male	 Ndfip1	 sufficient	 and	deficient	Foxp3-Cre+	mice.	The	concentrations	of	Ig	subclasses	in	mouse	sera	were	determined	 using	 isotype-specific	 antibodies	 with	 a	 sandwich	 ELISA	 protocol.	Monoclonal	anti-mouse	IgA-HRP,	IgM-HRP,	IgG1-HRP,	IgG2C-HRP	and	IgE-HRP	were	purchased	 from	South	Biotech.	Flat-bottom,	96-well	plate	 (Nunc)	was	 coated	with	capture	antibody	overnight.	Plates	were	blocked	with	10%	FCS	in	PBS	buffer	for	2	hours	 and	 incubated	 with	 sample	 serum	 for	 2	 hours	 at	 room	 temperature,	 and	detected	with	HRP-conjugated	Ig	subclass	antibody	for	1	hour	at	room	temperature.	Plates	were	developed	with	TMB	substrate	solution	(eBioscience).		
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Absorbance	(450nm)	for	the	ELISA	samples	was	read	using	a	Synergy	HT	Microplate	Reader.	
qPCR.		
Th17	work:	 Cultured	 cells	were	 harvested	with	 sterile	 PBS,	 resuspended	 in	 trizol	reagent	and	frozen	at	-80	C	until	needed.	RNA	was	extracted	using	the	RNeasy	Mini	Kit	(Qiagen).	Isolated	RNA	was	converted	to	cDNA	using	the	High	Capacity	RNA-to-cDNA	 kit	 (Applied	 Biosystems,	 #4387406).	 qPCR	 plates	 were	 set	 up	 using	 the	Taqman	Gene	expression	master	mix	(Applied	Biosystems,	#4369514)	and	primers	for	Ndfip1117,	Actin	(4352933E),	Ccl5	(Mm01302427_m1),	Csf2	(Mm01290062_m1),	
Rorc	 (Mm01261022_m1),	Tbx21	 (Mm00450960_m1),	Tnf	 (Mm00443258_m1),	 Ifng	(Mm01168134_m1),	 Blimp1/Prdm1(Mm00476128_m1),	 all	 from	 Applied	Biosystems.	 Each	 qPCR	 sample	 was	 run	 in	 triplicate	 on	 a	 7500	 Real-Time	 PCR	system	(Applied	Biosytems)	using	8-10ng/ul	of	cDNA.		
Treg	work:	 10ng	of	 cDNA	was	added	 to	TaqMan	Gene	Expression	Master	Mix	and	TaqMan	 Gene	 Expression	 primer/probe	 mix	 specific	 for	 Ndfip1	 (Applied	Biosystems)	 for	 a	 final	 reaction	 volume	 of	 20µl.	 qPCR	 was	 performed	 using	 an	Applied	 Biosystems	 7500	 Real-Time	 PCR	 system.	 Each	 sample	 was	 assayed	 in	triplicate	 along	 with	 the	 endogenous	 control	 (actin).	 ACTB	 primer/probe	(4352933E)	was	obtained	from	Applied	Biosystems.	
Relative	mRNA	expression	was	calculated	as	2^dCt,	where	dCt	represents	threshold	cycle	(Ct)	of	actin	beta	minus	Ct	of	gene	of	interest.		
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Statistical	Analysis.	
	All	 statistical	 analyses	 were	 performed	 using	 Graphpad	 prism	 software	 with	 p	values	 less	 than	 or	 equal	 to	 0.05	 considered	 statistically	 significant.	 In	 mixed	chimera	experiments	and	in	co-transfer	experiments,	p	values	were	calculated	via	a	paired	 t	 test.	 In	 ex	 vivo	 flow	 cytometric	 analysis,	 p	 values	 were	 calculated	 by	unpaired	 ttest	 or	 ANOVA,	 as	 appropriate.	 In	 time	 course	 ELISA	 experiments,	 p	values	were	calculated	by	2-way	ANOVA.	The	heatmap	was	generated	in	prism	7.	All	data	 are	 shown	 as	 average	 +/-	 SEM,	 with	 a	 cutoff	 of	 p<0.05	 for	 statistical	significance:	*	p<0.05,	**	p<0.01,	***p<0.001,	****p<0.0001.	
Th17-specific	protocols:	
	In	vitro Th17	cell	differentiation	protocols.		Single	cell	suspensions	of	spleen	and	lymph	nodes	were	sorted	on	a	Moflo	Astrios	for	 naïve	 CD4+	 cells	 (CD8-	 CD44-	 CD62L+	 CD25-).	 0.5x10^6	 naïve	 cells	 were	cultured	 for	 5	 days	 in	 Th17	 polarizing	 media	 containing	 TGF-β	 (PeproTech),	20ng/ml	IL-6	(R&D	Systems),	20ng/ml	IL-1β	(PeproTech)	and	50ng/ml	IL-23	(R&D	Systems).	In	the	experiments	shown	in	Figure	2.5a	and	b,	5ng/ml	of	TGFβ	was	used;	all	 other	 experiments	 used	 0.5ng/ml.	 For	 Th1	 polarizing	 conditions,	 50U/ml	(~10ng/ml)	rhIL-2	and	20ng/ml	IL-12	was	added	to	the	media.	In	both	cases,	cells	were	 cultured	 on	 plates	 coated	with	 500ul	 of	 5ug/ml	 anti-CD3	 (clone	 145-2C11)	and	 5ug/ml	 anti-CD28	 (clone	 37.51)	 antibodies.	 After	 harvest,	 cells	 were	restimulated	 with	 PMA	 (30ng/ml),	 Ionomycin	 (1uM)	 and	 Golgi	 plug	 inhibitor	(1:1000)	for	4h	before	intracellular	cytokine	staining.	
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Th17	differentiation	of	B3k	Trangenic	(Tg)	T	cells.		CD4+	T	cells	were	isolated	from	7-12	week	old	RAG1-/- B3K	Tg	or	Ndfip1-/- RAG1-/- B3K	 Tg	 animals	 and	 incubated	 for	 5	 days	 in	 Th17-polarizing	 media:	 and	 in	 the	presence	 of	 20ug/ml	 anti-IL-4.	 Each	 well	 also	 contained	 10x10^5	 congenically	marked	(CD45.1)	APCs	pulsed	for	2	hours	with	10ug/ml	of	peptide	(p3K,	p-1K	or	p-1A).	 On	 day	 5,	 cells	 were	 harvested	 and	 restimulated	 with	 PMA	 (30ng/ml),	Ionomycin	 (1uM)	 and	 Golgi	 plug	 inhibitor	 (1:1000)	 for	 4hrs	 before	 intracellular	cytokine	staining.		
Western	blotting.		Naïve	CD4+	T	 cells	were	differentiated	 into	Th17	 cells	 for	 5	days	using	0.5ng/ml	TGFβ,	 20ng/ml	 IL-6,	 20ng/ml	 IL-1β,	 50ng/ml	 IL-23	 and	 plate	 bound	 5ug/ml	αCD3/CD28.	 On	 day	 5,	 Th17	 cells	 were	 harvested	 and	 resuspended	 at	 1-2x10^6	cells/ml	and	restimulated	with	plate	bound	5ug/ml	αCD3/CD28	for	0.5hrs	or	4hrs	+/-	 10ug/ml	 final	 concentration	 of	 cycloheximide.	 Harvested	 cells	 were	 washed	with	PBS	and	 lysed	by	 incubating	pellets	with	1%	Nonidet	P-40	 lysis	buffer	on	 ice	for	20mins,	followed	by	spinning	at	4degrees	at	15	000	rpm	for	10mins	and	saving	the	lysate.	The	lysis	buffer	contained	1%	Nonidet	P-40,	50	mM	Tris-HCl	(pH	8),	150	mM	 NaCl,	 5mM	 NaF,	 1mM	 Na	 Orthovanadate	 and	 complete	 protease	 inhibitors	(Roche).	4x	SDS	sample	buffer	was	added	to	 lysate	 to	a	1x	dilution	and	this	 lysate	was	boiled	for	10mins	at	95	degrees	prior	to	loading	on	an	SDS	PAGE	gel	(Criterion	pre-cast	 gels,	 Biorad).	 After	 transfer	 to	 a	 PVDF	 membrane,	 membranes	 were	blocked	 for	 1hour	with	 odyssey	 blocking	 buffer	 and	probed	with	 anti-RORγT	 and	
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anti-GAPDH	antibodies.	RORγ	 (H-190)	rabbit	polyclonal	 from	Santa	Cruz	was	used	at	 1:1000	 and	 GAPDH	 (mab374)	 mouse	 monoclonal	 from	 Millipore	 was	 used	 at	1:5000.	Membranes	were	probed	using	anti-rabbit	or	anti-mouse	 IR800	and	A680	secondary	antibodies	and	imaged	on	an	odyssey	imager.	Data	was	quantified	using	the	Image	Studio	Lite	software.	
Adoptive	Th17	transfer	experiments.		WT	or	Ndfip1-deficient	naïve	CD4+	T	 cells	were	 sorted	 from	 IL-17A	GFP	 reporter	mice	(Ndfip1-/- IL-4-/- IL-17A-GFP	versus	IL-4-/- IL-17A	GFP)	and	differentiated	into	Th17	 cells	 using	 0.5ng/ml	 TGFβ,	 20ng/ml	 IL-6,	 20ng/ml	 IL-1β,	 50ng/ml	 IL-23,	20ug/ml	 anti-IL-2,	 and	 plate	 bound	 5ug/ml	 antiCD3/antiCD28	 for	 4-5	 days.	 Pure	Th17	cells	were	sorted	as	CD4+	(IL-17A)-GFP+	cells	and	2x10^5	of	these	cells	were	introduced	via	intraperitoneal	injection	(IP)	into	each	recipient	RAG-/- host.	After	5-7	weeks,	animals	were	analyzed	in	experiments.	
Treg	specific	protocols:	
T	cell	isolation.		YFP+	 CD4+	 Treg	 cells	 were	 isolated	 by	 cell	 sorting	 from	 spleen	 and	 lymph	 node	enriched	 for	 CD4+	 T	 cells	 by	 negative	 selection	 using	 rat	 αmouse	 CD8α	 (2.43;	Biolegend)	and	rat	αmouse	I-A/I-E	(M5/114.15.2;	Biolegend).	Cell	suspensions	were	incubated	 with	 antibodies	 in	 complete	 DMEM	 for	 30	 minutes	 with	 end-over-end	rotation	 at	 4C,	washed	 and	 incubated	with	 Biomag	 goat	 αrat	 IgG	magnetic	 beads	(Qiagen)	for	10	minutes	with	end-over-end	rotation	at	room	temperature;	unbound	
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cells	were	collected	using	a	Dynal	magnet	(Invitrogen).	Enriched	CD4+	T	cells	were	then	 stained	 with	 antibodies	 against	 CD4,	 CD44,	 and	 CD62L.	 Naïve	 CD4+	 T	 cells	were	isolated	from	single	cell	suspensions	of	spleen	and	lymph	nodes	stained	with	antibodies	against	CD4,	CD44,	CD8α,	CD25	and	CD62L.	Cells	were	 filtered	 through	35uM	 filter	 cap	 polystyrene	 FACS	 tube	 (BD	 Biosciences),	 and	 sorted	 under	 high	speed	 on	 a	 MoFlow	 Astrios	 (Beckman	 Coulter)	 or	 a	 FACs	 Aria	 (BD	 Biosciences).	Total	Treg	cells	were	sorted	as	CD4+YFP+,	cTreg	cells	as	CD4+YFP+CD62LhighCD44-,	eTreg	 cells	 as	 CD4+YFP+CD62LlowCD44+.	 Naïve	 cells	 were	 identified	 as	CD4+CD62LhighCD44-CD25-.		
Bisulfite	sequencing.		Sodium	 bisulfite	 conversion	 followed	 by	 PCR	 amplification	 and	 sequencing	 of	individual	clones	was	used	to	determine	the	extent	of	CpG	DNA	methylation	at	the	CNS2	and	promoter	regions	of	the	Foxp3	gene.	CD4+YFP+CD62LlowCD44+eTreg	cells	were	sorted	from	YFP+	WT	and	Ndfip1fl/fl	Foxp3-Cre+	mice.	Naïve	CD4+	T	cells	were	sorted	 from	 WT	 mice.	 DNA	 was	 extracted	 using	 the	 Quiagen	 DNeasy	 blood	 and	tissue	kit.	Approximately	1	µg	of	DNA	purified	 from	CD4+	Treg	 cells	was	bisulfite	converted	as	previously	described262.	The	DNA	was	desalted	using	the	Wizard	DNA	clean-up	 system	 (Promega),	 desulfonated	with	 0.3	M	NaOH,	 neutralized	with	 3	M	ammonium	 acetate,	 and	 precipitated	with	 100%	 ethanol.	 The	 CNS2	 region	 of	 the	
Foxp3	gene	was	PCR	amplified	using	the	following	primers:	Foxp3	Intron	Forward1	5’-GGGTTTTGGGATATTAATATATATAGTAAG-3’,	 Foxp3	 Intron	 Reverse1	 5’-CCACTATATTAACTTAACCCATATAACTAA-3’,	 Foxp3	 Intron	 Forward2	 5’-
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TTGAGTTTTTGTTATTATAGTATTTGAAGAT-3’,	 Foxp3	 Intron	 Reverse2	 5’-ACTAAAAACCTAAAAAACTAAACTAACCAA-3’.	 The	 promoter	 region	 was	 amplified	with	 the	 following	 primers:	 Foxp3	 Promoter	 Forward1	 5’-GTTTGGAGTAGAAGGAAGTTTTTGGAGAT-3’,	 Foxp3	 Promoter	 Reverse1	 5’-TATCTAAAAACCAACTACTCCACCTATCTA-3’,	 Foxp3	 Promoter	 Forward2	 5’-GGTTGTTTTTTATTTATATGGTAGGT-3’,	 Foxp3	 Promoter	 Reverse2	 5’-CCAAAATCCTTACCTAAAATAACTA-3’.	 Following	nested	PCR,	 bands	 of	 appropriate	sizes	 were	 gel	 purified	 and	 cloned	 into	 pGEM-T	 Easy	 vector	 (Promega).	 Single	colonies	 were	miniprepped	with	 the	 QIAprep	 spin	miniprep	 DNA	 purification	 kit	(Qiagen)	 and	 sequenced	 with	 SP6	 primer.	 Only	 sequences	 derived	 from	 fully	converted	alleles	were	used	for	methylation	analysis.		
	In	vitro cell	culture.	
	For	 the	 in	 vitro Treg	 cell	 suppression	 assay,	 sorted	 naïve	 CD45.1+	CD4+CD62LhighCD44-CD25-	 T	 cells	 were	 stained	 with	 2.5uM	 CFSE,	 mixed	 with	sorted	 YFP+CD4+CD45.2+	 Treg	 cells	 with	 at	 varying	 Treg	 to	 Tconv	 ratios,	 and	cultured	with	irradiated	CD45.2+	splenocytes	(1X105),	1ug/mL	soluble	αCD3	(145-2C11;	Biolegend),	and	50U/ml	 IL-2	 for	4	days.	For	expanded	Treg	cultures,	sorted	YFP+CD4+	 total	 Treg	 cells	 or	 CD4+YFP+CD62LhighCD44-	 cTreg	 cells,	 were	resuspended	at	1x10^6	cells/mL	in	media	containing	2000U/ml	IL-2	and	stimulated	at	 a	 1:3	 (cell:bead)	 ratio	 with	 mouse	 αCD3/αCD28	 T	 cell	 activator	 Dynabeads	(Gibco,	 11456D).	 After	 48	 hours,	 cultures	 were	 counted	 and	 split	 daily	 with	 IL-2	media.	 Cells	 were	 assayed	 by	 flow	 cytometry	 after	 6	 or	 7	 days	 in	 cultures.	 For	
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analysis	of	RNA,	expanded	Treg	cells	were	restimulated	on	day	seven	of	culture	at	a	1:1	ratio	with	αCD3/CD28	beads	for	the	 indicated	periods.	Supernatant	was	saved	for	ELISA	and	cells	were	harvested	for	qPCR.	For	co-cultures,	sorted	WT	and	Ndfip-1	deficient	Treg	cells	were	mixed	in	a	1:1	ratio	before	being	plated.	All	cultured	cells,	unless	 otherwise	 noted,	 were	 cultured	 at	 10%	 CO2	 in	 DMEM	 (Mediatech)	supplemented	 with	 10%	 fetal	 calf	 serum	 (Atlanta	 Biologicals),	 1%	 pen/strep	(Invitrogen),	1%	Glutamax	(Invitrogen),	1%	MEM-NEAA	(Invitrogen),	20mM	HEPES	(Invitrogen),	 1mM	 Sodium	 Pyruvate,	 and	 0.12mM	 betamercaptoethanol	 (Sigma)	supplemented	with	recombinant	human	IL-2	(obtained	through	the	AIDS	Research	and	Reference	Reagent	Program,	Division	of	AIDS,	National	Institute	of	Allergy	and	Infectious	Diseases,	National	Institutes	of	Health).		
Metabolic	function	assays.		YFP+CD44-CD62L+	Treg	cells	(cTreg	cells)	or	YFP+CD4+	Treg	cells	(total	Treg	cells)	were	 sorted	 from	 7-12	 week	 old,	 age-matched	 male	 and	 female,	 congenically	marked	CD45.1	WT	or	CD45.2	Ndfip1fl/fl	Foxp3-Cre+	(cKO)	mice.	After	sorting,	 the	WT	 or	 cKO	 Treg	 cells	 were	 expanded	 with	 a	 1:3	 (cell:bead)	 ratio	 with	 mouse	αCD3/α	CD28	beads	for	7	days.	On	day	7,	cells	were	harvested	and	resuspended	at	5x10^6	cells/ml	in	appropriate	Seahorse	media.	40ul	of	cells	were	added	to	140ul	of	appropriate	 seahorse	 media	 or	 140ul	 of	 Seahorse	 media	 containing	 fresh	 mouse	αCD3/α	CD28	beads	at	a	1:1	(cell:	bead)	ratio.	Cells	were	plated	in	XF96	cell	culture	microplates	that	were	precoated	with	25ul	of	Cell	 tak	reagent	overnight	according	to	 manufacturer’s	 instructions	 (Corning,	 354240).	 For	 examining	 glycolysis,	 the	
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glyo-stress	 test	kit	 (Seahorse	bioscience)	was	used	with	additions	of	 the	 following	reagents	 to	 cells	 in	 glucose-free	 Seahorse	media:	 10mM	 glucose,	 2uM	 oligomycin	and	50mM	2-DG.	To	determine	 the	rate	of	glycolysis,	Treg	cells	were	 incubated	 in	glucose-free	 medium	 and	 the	 increased	 ECAR	 response	 upon	 stimulation	 of	glycolysis	 by	 glucose	 and	 oligomycin	 was	 determined.	 Oligomycin	 inhibits	mitochondrial	 ATP	 synthase	 (complex	V)	 forcing	 glycolysis	 to	 compensate	 for	 the	lack	of	ATP	production	 in	oxidative	phosphorylation.	Finally,	2-Dexoglucose	(2DG)	was	added	to	inhibit	glycolysis.	Glycolysis	was	calculated	as	the	difference	between	the	ECAR	after	addition	of	glucose	and	 the	baseline	ECAR.	Glycolytic	 capacity	was	calculated	as	the	difference	between	the	ECAR	after	addition	of	oligomycin	and	the	baseline	 ECAR.	 For	 examining	mitochondrial	 function,	 a	 mito-stress	 kit	 was	 used	with	additions	of	the	following	reagents	to	cells	in	appropriate	Seahorse	media:	2uM	Oligomycin,	 1.5uM	 fluoro-carbonyl	 cyanide	 phenylhydrazone	 (FCCP,	 an	 uncoupler	of	respiration	and	oxidative	ATP	synthesis),	and	pre-mixed	100nM	rotenone	+	1uM	antimycin	 A	 solution	 (Electron	 Transport	 Chain	 complex	 I	 and	 III	 inhibitors).	Maximum	respiratory	capacity	was	calculated	as	the	difference	between	the	Oxygen	Consumption	 Rate	 (OCR)	 after	 addition	 of	 FCCP	 and	 the	 OCR	 after	 addition	 of	rotenone/Antimycin	A.	Spare	respiratory	capacity	was	calculated	as	 the	difference	between	maximal	 (post	 FCCP)	 and	 basal	 respiration.	 Plates	were	 run	 on	 an	 XF96	Seahorse	assay	instrument,	using	settings	that	have	previously	been	described263.	
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Treg	cell	transfer	colitis.		Naïve	CD4+	T	cells	from	CD45.1+	WT	mice	and	CD4+YFP+	Treg	cells	from	CD45.2+	Ndfip1fl/fl	 Foxp3-Cre+	 and	 Ndfip1+/+	 Foxp3-Cre+	mice	 were	 isolated	 from	 spleens	and	lymph	nodes.	Cells	were	resuspended	in	sterile	PBS	and	congenic	naïve	T	cells	were	 mixed	 at	 a	 5:1	 ratio	 with	 YFP+	 Treg	 cells.	 A	 total	 of	 0.36x10^6	 cells	 were	injected	intraperitoneally	into	6-8	week	old	RAG1-/- mice.	In	the	transfer	experiment	involving	 Treg	 cells	without	 T	 conventional	 cells,	 a	 total	 of	 0.06x10^6	 YFP+	Treg	cells	 from	CD45.2+	Ndfip1fl/fl	 Foxp3-Cre+	and	CD45.2+	Ndfip1+/+	Foxp3-Cre+	mice	were	 used.	 Mice	 were	 weighed	 weekly.	 Recipients	 of	 both	 genotypes	 were	 co-housed.	 At	 sacrifice,	 mice	 were	 weighed,	 spleens	 were	 weighed,	 and	 spleens	 and	lung	were	processed	for	 flow	cytometry	as	described	above.	A	fraction	of	the	total	lung/spleen	 single	 cell	 suspensions	 were	 stained	 with	 antibodies	 against	 CD4,	CD45.1	 and	 CD45.2,	 and	 sorted	 using	 a	 Moflow	 Astrios	 as	 described	 above	 for	analysis	of	Ndfip1	mRNA	 in	cells	 from	Ndfip1fl/fl	Foxp3-Cre+	and	Ndfip1+/+	Foxp3-Cre+	donor	Treg	 cells.	 Sorted	 cells	were	 CD4+CD45.2+CD45.1-YFP+	 (current	 Treg	cells)	 or	 CD4+CD45.2+CD45.1-YFP-	 (former	 Treg	 cells)	 or	 CD4+CD45.2-CD45.1+YFP-	(T	conventional	cells).	Cells	were	stimulated	for	5hrs	with	plate-bound	5ug/ml	 αCD3/CD28	 at	 3x10^5	 cells/mL	 and	 harvested	 in	 trizol	 for	 qPCR.	 The	remaining	fractions	of	total	lung/spleen	single	cell	suspensions	were	either	stained	directly	 for	 flow	 cytometry	 or	 stimulated	 for	 4	 hrs	 with	 PMA/ionomycin	 in	 the	presence	of	Brefeldin	A	to	analyzed	cytokine	production	by	flow	cytometry.	
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Preparation	of	 lysates	 for	whole	cell	proteome	analysis.	 [CHOP	protein	core,	
Claire	O’Leary,	Guoping	Deng]	
	Ndfip1	 sufficient	 and	 deficient	 cTreg	 cells	 and	 eTreg	 cells	 were	 isolated	 and	 lysed	using	a	lysis	buffer	containing	100mM	Tris-HCl,	pH	8.0,	0.15M	NaCl,	5mM	EDTA,	1%	NP-40,	0.5%	Triton-X	100,	protease	inhibitor	cocktail	(Roche,	11697498001),	5mM	of	1,10-phenyanthroline	(o-PA),	5mM	N-Ethymaleimide	(NEM)	and	0.1mM	PR-619.	10ul	of	lysis	buffer	was	used	for	every	10x10^6	cells.	Protein	was	quantified	by	BCA	(Pierce,	23227).	~15ug	of	lysate	was	mixed	1:1	with	4x	Laemmli	sample	buffer	for	whole	proteome	analysis.	Samples	were	boiled	and	run	~2cm	past	the	stacking	gel	in	 10%	 Criterion	 pre-cast	 Tris-HCL	 gels	 (Biorad).	 Gels	 were	 fixed	 overnight	 and	stained	 briefly	 with	 Coomassie	 blue.	 Each	 lane	 of	 the	 Coomassie-stained	 gel	 was	divided	 into	 8-10	 2mm	 x	 9mm	 ‘pixels,’	 each	 cut	 into	 1	mm3	 cubes264.	 They	were	destained	with	50%	Methanol/1.25%	Acetic	Acid,	reduced	with	5mM	dithiothreitol	(Thermo),	 and	alkylated	with	40mM	 iodoacetamide	 (Sigma).	Gel	pieces	were	 then	washed	 with	 20mM	 ammonium	 bicarbonate	 (Sigma)	 and	 dehydrated	 with	acetonitrile	(Fisher).	Trypsin	(5ng/uL	in	20mM	ammonium	bicarbonate,	Promega)	was	added	to	the	gel	pieces	and	proteolysis	was	allowed	to	proceed	overnight	at	37	ºC.	Peptides	were	extracted	with	0.3%	triflouroacetic	acid	 (J.T.Baker),	 followed	by	50%	acetonitrile.	Extracts	were	combined	and	the	volume	was	reduced	by	vacuum	centrifugation.		
138	
Mass	Spectrometry.	[CHOP	protein	core]	Tryptic	 digests	were	 analyzed	by	 LC-MS/MS	on	 a	 hybrid	 LTQ	Orbitrap	Elite	mass	spectrometer	 coupled	 with	 a	 Dionex	 Ultimate	 3000	 (Thermofisher	 Scientific	 San	Jose,	CA).	Peptides	were	separated	by	reverse	phase	(RP)-HPLC	on	a	nanocapillary	column,	75μm	id	×	30	cm	Reprosil-pur	1.9uM	(Dr.	Maisch,	Germany).	Mobile	phase	A	 consisted	 of	 0.1%	 formic	 acid	 (Thermo)	 and	mobile	 phase	 B	 of	 0.1%	 formic	 in	acetonitrile.	 Peptides	were	 eluted	 into	 the	mass	 spectrometer	 at	 300nL/min	with	each	RP-LC	run	comprising	a	90	minute	gradient	 from	3	to	45	%	B	 in	90	minutes.	The	 mass	 spectrometer	 was	 set	 to	 repetitively	 scan	 m/z	 from	 300	 to	 1800	 (R	 =	240,000	 for	 LTQ-Orbitrap	 Elite)	 followed	 by	 data-dependent	MS/MS	 scans	 on	 the	twenty	most	abundant	ions,	with	a	minimum	signal	of	1500,	dynamic	exclusion	with	a	repeat	count	of	1,	repeat	duration	of	30s,	exclusion	size	of	5000	and	duration	of	60s,	 isolation	 width	 of	 2.0,	 normalized	 collision	 energy	 of	 33,	 and	 waveform	injection	and	dynamic	exclusion	enabled.	FTMS	full	scan	AGC	target	value	was	1e6,	while	MSn	AGC	was	1e4,	respectively.	FTMS	full	scan	maximum	fill	time	was	10ms,	while	 ion	 trap	MSn	 fill	 time	was	 100ms;	microscans	were	 set	 at	 one.	 FT	 preview	mode;	 charge	 state	 screening,	 and	 monoisotopic	 precursor	 selection	 were	 all	enabled	with	rejection	of	unassigned	and	1+	charge	states.	
Proteomic	data	analysis.	[Claire	O’Leary,	Joe	Dybas]		Proteomic	 data	were	 analyzed	 using	Maxquant	 version	 1.5.0.30	 searching	 against	the	Uniprot	complete	mouse	reference	proteome,	including	isoforms,	(updated	Sept	19,	 2013)	 and	 common	 laboratory	 contaminants.	 A	minimum	peptide	 length	 of	 6	
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amino	acids	and	a	peptide	and	protein	 false	discovery	of	1%	was	 required.	The	3	biologic	 replicates	 for	 Ndfip1	 sufficient	 and	 deficient	 eTreg	 cells	 and	 cTreg	 cells	were	analyzed	together,	with	match	between	runs	and	requantify	turned	on.	Label	free	quantification	via	intensity	based	absolute	quantification	(iBAQ)	was	calculated	in	MaxQuant.	Quantification	data	was	normalized	by	the	mean	quantification	value	of	 identified	 proteins	 in	 each	 replicate	 and	 log2	 transformed.	 Comparisons	 of	protein	 hits	 from	WT	 or	Ndfip1-deficient	 eTreg	 or	 cTreg	 cells	were	 calculated	 by	log2	 fold	 changes	 and	 evaluated	 for	 significance	 using	 a	 one-sample	 t-test.	 Area	proportional	 Venn	 diagrams	 were	 generated	 with	 eulerAPE	 version	 3.0	(http://www.eulerdiagrams.org/eulerAPE/)265.	 The	 gene-ontology	 analysis	 and	corresponding	 network	 diagram	 was	 generated	 with	 the	 BiNGO	 application266	 in	Cytoscape267	 The	 differentially	 regulated	 proteins	 identified	 in	 WT	 vs	 cKO	 eTreg	comparisons	 were	 compared	 against	 the	 Mus	 Musculus	 GO	 Biological	 Process	annotation	using	a	hypergeometric	significance	test	with	Benjamini-Hochberg	FDR	correction.	A	threshold	of	adjusted	p-value	of	<0.01	was	required	for	enrichment.	
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